The evolving genetic and pathophysiological spectrum of migraine by Vries, B. de




Boukje de Vries 
The evolving genetic and pathophysiological spectrum of migraine
PhD thesis, Leiden University, 20 januari, 2011
ISBN: 978-94-90371-61-6
© Boukje de Vries
Except (parts of): 
Chapter 2: John Wiley & Sons, Inc.
Chapter 3: American Academy of Neurology Enterprises, Inc.
Chapter 4: American Medical Association
Chapter 5: BMJ Publishing Group Ltd.
Chapter 5 and 6: Nature Publishing Group 
No part of this thesis may be reproduced in any form, by print, photocopy, digital file, internet, or any 
other means without written permission of the copyright owner.
Printed by: Off Page
Cover Design: A. Portier  




de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. P.F. van der Heijden
volgens besluit van het College voor Promoties










Prof. dr. M.D. Ferrari
Prof. dr. R.R. Frants
Co-promotor:
Dr. A.M.J.M. van den Maagdenberg
Overige leden:
Prof. dr. G.J.B. van Ommen
Prof. dr. R.A. Roos
Prof. dr. C.M. van Duijn (Erasmus MC, Rotterdam)
Prof. dr. A. Palotie (Sanger Institute, Cambridge, United Kingdom; University of Helsinki, Finland)
The studies presented in this thesis were performed at the Department of Human Genetics of the 
Leiden University Medical Center (LUMC). This work was supported by grants of the Netherlands 
Organisation for Scientific Research (NWO) (VICI 918.56.602); the EU sixth framework programme 
(FP6) “EUROHEAD” (grant LSHM-CT-2004-504837); and the Centre for Medical Systems Biology 
within the framework of the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for 
Scientific Research (NWO).
Financial support for the publication of this thesis has been provided by the J.E. Jurriaanse 
Stichting, Nederlandse Hoofdpijn Vereniging, Menarini Farma Nederland and Allergan.
5
Chapter 1 General Introduction  .............................................................................................................................................................. 7
Chapter 2 Genetic and functional analysis of FHM gene mutations ............................................................................ 29
  2.1  CACNA1A mutation linking hemiplegic migraine and alternating 
   hemiplegia of childhood ................................................................................................................................................................................. 31  
   Cephalalgia 2008 28:887-891
  2.2   Familial hemiplegic migraine is associated with febrile seizures 
in an FHM2 family with a novel de novo ATP1A2 mutation ..................................................................... 39
Epilepsia 2009 50:2503-2504
  2.3   The novel p.L1649Q mutation in the SCN1A epilepsy gene is associated 
with familial hemiplegic migraine: genetic and functional studies  .......................................... 45
  Human mutation 2007 28:522
Chapter 3  Systematic analysis of three FHM genes in 39 sporadic patients 
  with hemiplegic migraine ............................................................................................................................................................................. 57
  Neurology 2007 4:2170-2176
Chapter 4 Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake ...... 73
  Archives of Neurology 2009 66:97-101
Chapter 5  Mutations in TREX1 play a role in disorders comorbid with migraine ...................................... 85
      5.1   C-terminal truncations in human 3’-5’ DNA exonuclease TREX1 cause 
autosomal dominant retinal vasculopathy with cerebral leukodystrophy ......................... 87
Nature Genetics 2007 39:1068-1070
      5.2  TREX1 gene variant in neuropsychiatric systemic lupus erythematosus ...........................103
   Annals of the Rheumatic Diseases 2010 69:1886-1887
Chapter 6 Genome-wide association studies in migraine ...........................................................................................................109
      6.1   Genome-wide association study of migraine implicates a common 
susceptibility variant on 8q22.1 ......................................................................................................................................................111
  Nature Genetics 2010 467:52-58
      6.2   Genome-wide association study for migraine in a Dutch genetic isolate 
and meta-analysis with other population-based cohorts .........................................................................137
  In preparation
Chapter 7  RNA expression profiles of familial hemiplegic migraine type 1 mouse 
models with relevance to migraine-associated cerebellar ataxia ..................................................161
  In preparation 
Chapter 8 General Discussion .................................................................................................................................................................................................179
Summary ......................................................................................................................................................................................................................................................................208
Nederlandse samenvatting ...........................................................................................................................................................................................................211









& scope of the thesis
8
1.1. Migraine
Migraine is an episodic neurovascular disorder that is characterized by attacks of severe, unilateral, 
pulsatile headache that is often accompanied by nausea, vomiting, photo- and/or phonophobia. 
Typical migraine attacks last a few hours to several days.1 Migraine can start at any age, but the 
age at onset usually is before the age of 50 years. The peak age at onset is between 10 to 12 years 
of age for males and between age 14 to 16 for females.2 Migraine is a very common disease that 
is more prevalent in women than in men. The one-year overall prevalence of migraine in Western 
countries is around 11%; with 6-8% in men and 15-18% in women.3-6 The median attack frequency 
is 1.5 per month. Approximately ten percent of migraineurs have weekly attacks.6 The World Health 
Organisation (WHO) rates severe migraine among the most disabling chronic disorders.7
1.2. Migraine with and without aura
Migraine can be subdivided in migraine without aura (MO) and migraine with aura (MA), based 
on the absence or presence of an aura phase preceding the headache phase (Table 1). About one-
third of the migraine patients experience an aura. The aura phase generally lasts 20-60 minutes 
and includes mostly visual symptoms, but symptoms can also be sensory or speech related.8 
Currently no reliable biological markers are available for the diagnosis of migraine. Therefore, the 
diagnosis depends on the patient’s symptom description, using the Diagnostic and Classification 
Criteria of the International Headache Society.1 Patients are characterised by the recurrence of 
their migraine attacks (Table 1).1 To classify as an MO patient, the patient needs to have had at 
least five MO attacks. An MA patient has had at least two MA attacks. Current treatment options 
for migraine are far from optimal and effective in only about half of the patients.9
Table 1. International headache criteria for migraine without and migraine with aura 1
Migraine without aura
A. At least five attacks fulfilling criteria B-D
B. Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)
C. Headache has at least two of the following characteristics:
 1. Unilateral location
 2. Pulsating quality
 3. Moderate or severe pain intensity
 4. Aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs)
D. During headache at least one of the following;
 1. Nausea and/or vomiting
 2. Photophobia and phonophobia




A. At least two attacks fulfilling criteria B-D
B. Aura consisting of at least one of the following, but no motor weakness:
 1.  Fully reversible visual symptoms including positive features (e.g., flickering lights, spots, 
or lines) and/or negative features (i.e., loss of vision)
 2.  Fully reversible sensory symptoms including positive features (i.e., pins and needles) and/
or negative features (i.e. numbness)
 3. Fully reversible dysphasic speech disturbance
D.   Headache fulfilling criteria B-D for migraine without aura begins during the aura or follows 
aura within 60 minutes
E.  Not attributed to another disorder
1.3. Migraine is a genetic disorder
Migraine has a strong genetic component. Many patients have first-degree relatives who also 
suffer from migraine.10 Population-based family studies showed that the familial risk of migraine 
is increased.11,12 First-degree relatives of probands with MO have an almost 2-fold increased risk to 
also suffer from this disorder, but had only 1.4 times the risk of MA, compared with the general 
population. Instead, first-degree relatives of probands with MA had a nearly 4-fold increased 
risk for MA, but no increased risk for MO.11 Studies of mono- and dizygotic twin pairs are the 
classical method to investigate the relative importance of genetic and environmental factors. 
Migraine concordance rates are between 1.5 and 2 times higher in monozygotic twins than in 
dizygotic twins for both MO and MA13,14, indicating that genetic factors are important in migraine 
susceptibility. A large population-based twin study comprising of some thirty thousand twin 
pairs revealed that genetic and environmental factors had an almost equally large contribution.15 
Shared environmental factors seemed to play a minor role as shown by studies comparing twins 
that were raised together or apart.16,17 
1.4. Hemiplegic migraine
An often-used approach to find genes for complex genetic disorders is to study monogenic 
subtypes of these disorders. A monogenetic subtype of migraine with aura exists and is called 
familial hemiplegic migraine (FHM). FHM is characterized by transient hemiparesis during the 
aura phase (Table 2)1, which may last from several minutes to several hours or even days. FHM 
patients have at least one additional first-degree family member that has identical hemiplegic 
migraine attacks.1 FHM can be associated with additional neurological features, including 
cerebellar dysfunction, epilepsy and mental retardation.18-20
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A sporadic form of hemiplegic migraine does exist and is called sporadic hemiplegic migraine 
(SHM). These patients do not have affected family members.1 The estimated population prevalence 
for SHM is similar to that of FHM; approximately 0.01%. The clinical symptoms of SHM patients 
are identical to those of FHM.21 It is unknown whether FHM and SHM share biological pathways 
and genetic factors.
Table 2. International Headache Society Criteria for Familial Hemiplegic Migraine1
Familial hemiplegic migraine
A. At least two attacks fulfilling criteria B and C
B. Aura consisting of fully reversible motor weakness and at least one of the following;
 1.  Fully reversible visual symptoms including positive features (e.g., flickering lights, spots, 
or lines) and/or negative features (i.e., loss of vision)
 2.  Fully reversible sensory symptoms including positive features (i.e. pins and needles) and/
or negative features (i.e., numbness)
 3. Fully reversible dysphasic speech disturbance
C. At least two of the following:
 1.  At least one aura symptoms develops gradually over ≥ 5 minutes, and/or different aura 
symptoms occur in succession over ≥ 5 minutes
 2. Each symptom lasts ≥ 5 and ≤ 24 hours
 3.  Headache fulfilling criteria B-D for migraine without aura begins during the aura or follows 
aura within 60 minutes
D. At least on first-or second-degree relative has had attacks fulfilling these criteria A-E
E. Not attributed to another disorder
1.5. Hemiplegic migraine as a model for common migraine 
A considerable proportion of the FHM and SHM patients also has attacks of common migraine 
with or without aura, not associated with hemiparesis.22,18,23 Furthermore, the main clinical 
symptoms of the headache and aura phase are similar in HM and common migraine.24 Therefore, 
FHM is believed to be part of the migraine spectrum and is considered a suitable model to study 
the pathophysiology of common migraine. Thus, genes and pathways involved in HM can be 
considered candidate genes and pathways for the common forms of migraine.
1.6. Hemiplegic migraine genes
So far, three genes have been identified in families with FHM. The first FHM gene identified is 
CACNA1A (FHM1) that is located on chromosome 19p13.25 CACNA1A encodes the α1 subunit of 
neuronal CaV2.1 (P/Q-type) voltage-gated calcium channels that are widely expressed throughout 
the central nervous system (CNS)26 and the neuromuscular junction.27 FHM1 mutations are 
General Introduction 1
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associated with a broad spectrum of clinical features besides hemiplegic migraine.18 Cerebellar 
ataxia28-31 and epilepsy, both during severe FHM attacks32 or independent of FHM attacks33,34, are 
not uncommon. FHM1 mutations are also identified in some sporadic patients with hemiplegic 
migraine.35 
Mutations in the CACNA1A gene can also cause episodic ataxia type-2 (EA2)25 and spinocerebellar 
ataxia type-6 (SCA6).36 EA2 is characterized by recurrent episodes of ataxia often associated 
with vertigo and migrainous headache and can be triggered by exercise, fatigue, and stress.37 
Whereas FHM1 is mainly caused by missense mutations, EA2 is mostly caused by nonsense, 
frameshift, splice site, and sometimes missense mutations.38 SCA6 resulting in late onset ataxia 
is characterized by atrophy of cerebellar Purkinje cells. SCA6 is a polyglutamine disorder caused 
by small extensions of a CAG repeat that is located in the 3’-end of the CACNA1A gene.
The second FHM gene, ATP1A2 (FHM2), is located on chromosome 1q23.39 It encodes the α2 subunit 
of sodium-potassium pumps. Most of the ATP1A2 mutations are associated with pure FHM without 
additional clinical symptoms.39-42 However, over the years, a number of FHM2 mutations have been 
reported that are associated with FHM and cerebellar problems43, childhood convulsions (BFIC)19, and 
epilepsy.41 Interestingly, certain ATP1A2 mutations were shown to be associated with non-hemiplegic 
migraine phenotypes, such as basilar migraine44 and even common migraine.45 A specific ATP1A2 
mutation was identified in a family with atypical alternating hemiplegia of childhood (AHC)46,47, a rare 
brain disorder that is characterized by hemiplegia, quadriplegia and other paroxysmal phenomena, 
including choreoathetotic movements and nystagmus. Age at onset in AHC is typically before 18 
months (but later in the AHC family with the ATP1A2 mutation) and symptom cessation often occurs 
after falling asleep.48 
The most recently identified FHM gene is the SCN1A (FHM3) gene, which is located on chromosome 
2q2449 and encodes the α1 subunit of neuronal voltage-gated NaV1.1 sodium channels. SCN1A is 
a well-known epilepsy gene with over 150 truncating and missense mutations that are associated 
with childhood epilepsy (i.e., severe myoclonic epilepsy of infancy (SMEI) or generalized epilepsy 
with febrile seizures (GEFS+)).50,51 The fact that not all FHM families are linked to one of the three 
known FHM loci implies that there are additional FHM genes to be identified.
1.7. Monogenic and complex disorders in which migraine is prevalent
Over the past years, several biological pathways have been suggested to play a role in migraine 
pathophysiology. Most prevailing hypotheses suggest that migraine has a vascular, a neuronal 
or inflammatory origin. Interestingly, migraine patients have an increased risk (comorbidity) for 
several diseases in which these pathways also play a role.  
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Vascular pathway  
A vascular component in the etiology of migraine has been debated for many years52,53 and 
several vascular disorders show an increased prevalence of migraine. A clear example of a 
monogenetic vascular disorder in which migraine can be considered part of the clinical spectrum 
is the autosomal dominant disorder Cerebral Autosomal Dominant Arteriopathy with Subcortical 
Infarcts and Leukoencephalopathy (CADASIL).54 CADASIL is caused by mutations in the NOTCH3 
gene, which encodes the Notch3 receptor that plays a key role in vascular smooth muscle cell 
function in small arteries and arterioles of the brain.55 Up to one-third of CADASIL patients suffer 
from migraine with aura, where migraine often is the presenting clinical symptom.56 Another 
example of a vascular monogenic disorder in which migraine is highly prevalent is Hereditary 
Vascular Retinopathy (HVR).57 HVR is primarily characterized by progressive blindness due to 
vascular retinopathy and can be associated with a wide range of systemic and cerebral symptoms, 
including cerebral infarcts and white matter hyperintensities, vascular dementia, liver and kidney 
dysfunction, Raynaud’s phenomenon, and migraine. Two additional North American families with 
similar symptoms were reported58,59, which like the Dutch HVR family were linked to the same 
3p21.1-p21.3 region.60 A family-based genetic association analysis between the 3p21 locus and 
migraine and Raynaud’s phenomenon showed that the HVR locus gives a higher susceptibility 
for migraine and Raynaud’s phenomenon in the Dutch HVR family.61 Furthermore, also non-
genetic vasculopathies, such as ischemic stroke and ischemic heart disease can be comorbid with 
migraine.62,63 
Neuronal pathway
Especially genetic studies in monogenic FHM showed evidence for involvement of neuronal 
hyperexitability pathways in migraine.64,65 Two other common brain disorders in which neuronal 
hyperexcitability pathways seem to play a role are epilepsy and depression. The shared neuronal 
hyperexcitability pathway, may well explain why both epilepsy and depression are bi-directionally 
comorbid with migraine.66,67 The association between migraine and epilepsy is particularly evident 
for FHM. Epilepsy often observed in carriers of FHM gene mutations, and as mentioned earlier, 
the FHM3 SCN1A gene is also a well-known epilepsy gene. Moreover, six percent of patients with 
common migraine have epilepsy68 and patients with epilepsy have a 2.4 times increased risk to 
also suffer from migraine.69 Migraineurs also have increased risk for major depression; population-
based odds ratios (ORs) range from 2.0 to 5.8, with strongest associations for MA.70 Patients with 
depression have a 2.8-3.4 times increased risk for migraine.71 The bi-directional comorbidity for 
these disorders suggests that epilepsy and depression have, at least in part, a shared etiology 
with migraine. This is strengthened by the fact that anti-epileptic and antidepressant drugs are 




During the headache phase of a migraine attack several vasoactive neuropeptides are released in 
the brain. It is hypothesized that these neuropeptides can cause neurogenic inflammation.73,74 
An example of an inflammatory disorder in which migraine is prevalent is systemic lupus 
erythematosus (SLE). SLE is a relapse-remitting autoimmune disorder that may affect multiple 
organs including the brain. About 40% of SLE patients have migraine, mostly migraine with 
aura.75 Studying the genetics and molecular pathways of the disorders that are comorbid with 
migraine may provide valuable insights in molecular mechanisms involved in migraine.
1.8. Migraine mechanisms
Although it was previously thought that migraine either had a vascular or a neurogenic origin, 
the current view is that migraine has a neurovascular origin (for review see Goadsby 2007).76 
Headache is not merely the consequence of painful vasodilatation, but is due to the activation 
of the trigeminovascular system (TGVS) that consists of meningeal and superficial cortical blood 
vessels that are innervated by the trigeminal nerve. The TGVS projects to the trigeminal nucleus 
caudalis in the brainstem, which transfers abnormal pain signals to higher order central nervous 
system centers giving rise to the headache. It is now well accepted that the migraine aura is not 
due to reactive vasoconstriction, but is neurally derived and most likely caused by the human 
equivalent of the cortical spreading depression (CSD) of Leao.77,78 In experimental animals, CSD is 
characterized by a short-lasting, intense wave of neuronal and glial cell depolarization that starts 
in the occipital (visual) cortex and spreads slowly to frontal regions of the cortex at a rate of 
approximately 2-5 mm/min and that is accompanied by massive fluxes of ions (Ca2+, Na+, and K+) 
followed by a longer-lasting inhibition of spontaneous and evoked neuronal activity (for review 
see Somjen 2002).79 The electrophysiological changes are associated with changes in cerebral blood 
flow (CBF). There is a considerable body of clinical evidence that CSD is the likely basis of the 
migraine aura. Visual aura symptoms in humans80-82 typically spread from the centre of the visual 
field to the periphery with a propagation rate comparable to CSD evoked in experimental animals. 
Positive (e.g. scintillations, paraesthesia’s) and negative (e.g. scotomata, paresis) phenomena of 
the migraine aura can be explained by the initial transient hyperexcitation front of CSD followed 
by neuronal depression. Most importantly, however, functional neuroimaging studies in humans 
using blood-oxygen level dependent (BOLD) signals have convincingly demonstrated that CBF 
changes that occur during a migraine aura are very similar to those observed in experimental 
animals during CSD.83 
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Animal studies have shown that CSD can activate the TGVS, and thus might trigger headache 
mechanisms.84 However, the connection between CSD and headache in patients remains an 
open question.85,86 For instance, it would not explain how the headache phase is triggered in 
the majority of migraine patients that never experience an aura. Also, the fact that ketamine 
treatment can reduce aura symptoms but fails to prevent the headache87 would argue against 
a key role of CSD in triggering the headache. Although one can hypothesize that spreading 
depression may occur in these patients in clinically silent subcortical areas of the brain without 
propagating to the visual cortex6,88, this has never been demonstrated. 
1.9. Functional consequences of FHM mutations
Functional effects of FHM1 mutations on CaV2.1 Ca
2+ channels
Electrophysiological methods have been used to study the effect of FHM1 mutations on calcium 
channel functioning. Multiple aspects of the calcium channel are of importance for its function: 
expression of the channel, localization on the cell membrane, conductance of the channel, 
voltage-dependence of opening, closing and reopening, and duration of the open state. For 
electrophysiological studies of FHM1 mutations, heterologous expression systems (without 
endogeneous expression of CaV2.1-α1A) were transfected with recombinant CaV2.1 channel 
components. Calcium channel parameters were measured using whole cell or single channel 
electrophysiology to assess the consequence of FHM1 mutations on the cellular level (i.e., the 
combined effect of all CaV2.1 channels at the plasma membrane) or on the single channel, 
respectively (for review see Pietrobon 2007). At the single channel level, FHM1 mutations open at 
more negative voltages and have an enhanced channel open probability, compared to wild-type 
channels.90-92 This gain-of-function consequence FHM1 mutations results in increased neuronal 
Ca2+ influx, which would predict increased neurotransmission. At the whole cell level, however, 
neurons from CaV2.1-α1A knockout mice93,94 that were transfected with either wild-type or mutant 
CaV2.1-α1A cDNA constructs, all seem to indicate a loss-of-function effect of FHM1 mutations.90-92,96 
Hippocampal neurons derived from CaV2.1-α1A knockout mice, that were transfected with wild-
type or mutant CaV2.1-α1A cDNA constructs revealed a reduced neurotransmitter release and a 
decreased contribution of P/Q-type channels controlling neurotransmitter release.95,96
Functional effects of FHM2 mutations on Na,K ATPases
The functional consequences of ATP1A2 mutations have been investigated by using various in 
vitro assays. The cell survival assay is a frequently used functional test that gives an indication 
of disease causality of ATP1A2 mutations. Na+,K+-ATPase activity is necessary for cell survival. 
In the cell survival assay, endogenous sodium potassium pumps are inactivated by application 
of the drug ouabain to HeLa cells that express either wild-type or mutant α2 Na+,K+- ATPase 
cDNAs that are made insensitive to ouabain.97 The assay tests whether transfected wild-type 
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or mutant α2 Na+,K+- ATPase cDNAs are able to rescue cell survival. Several ATP1A2 mutations 
are tested using this cell survival assay and many showed mutations that have an effect on 
cell survival. For a few ATP1A2 mutations, Segall and colleagues studied additional parameters, 
such as catalytic turnover, extracellular K+ affinity and Na+,K+ ATPase kinetics.98,99 These studies 
showed that certain mutations, such as FHM2 mutation T345A, that were fully functional in the 
cell survival assay, could show an effect on other parameters.
Functional effects of FHM3 mutations on sodium channels
Similar to functional studies for FHM1 mutations, electrophysiological methods were used to determine 
the functional effect of the first FHM3 mutation. FHM3 mutation p.Gln1489Lys was cloned into the 
highly homologous heart-specific SCN5A cDNA due to apparent cloning difficulties with the brain-
specific SCN1A cDNA. Wild-type or mutant SCN5A cDNA was transfected into human tsA201 cells.49 
Electrophysiological measurements (whole cell recordings) revealed a 2-4-fold accelerated recovery 
from fast inactivation for mutant NaV1.5 sodium channels compared to wild-type
49, indicating 
increased firing capacity of the mutant neuron.
1.10. Common pathway and increased neurotransmission
The three FHM genes fit in a common neuronal pathway. Mutations in all three FHM genes affect 
the transport of ions and lead to increased levels of glutamate and K+ ions in the synaptic cleft. 
This may lead to an increased susceptibility for CSD.79 Increased susceptibility for CSD could well 
explain the aura phase of migraine attacks.  Another gene that would perfectly fit this neuronal 
pathway is the SLC1A3 gene, encoding EAAT1 the excitatory amino acid transporter type 1. 
EAAT1 is involved in glutamate removal from the synaptic cleft.100,101 Mutations in EAAT1 could, 
like the known FHM mutations, affect the glutamate levels in the synaptic cleft.
Several additional observations point at a potentially pivotal role of enhanced brain glutamate 
levels in the triggering of migraine attacks. For instance, (i) glutamate receptor antagonists may 
have acute anti-migraine activity102; (ii) noxious dural stimulation, as an experimental animal 
model for acute migraine, increases glutamate release from trigeminal ganglion neurons103; (iii) 
plasma104 and cerebrospinal fluid105 levels of glutamate are increased in migraineurs with and 
without aura in between attacks, further rising during attacks. 
1.11. Migraine mouse models
Natural mouse mutants
Different natural mouse mutants with mutations in the Cacna1a gene exist, such as Tottering, 
Leaner, Rolling Nagoya and Rocker.106-109 Missense Cacna1a mutations are present in the Tottering, 
Rolling Nagoya and Rocker mutants (i.e., P601L, R1262G and T1310K, respectively).106,110,111 
16
The Leaner mutant has a rather complex Cacna1a mutation leading to exon skipping and the 
inclusion of intronic sequences in the aberrantly spliced Cacna1a gene.112 These natural mouse 
mutants all exhibit some degree of ataxia, and except for Rocker, several seizure types are also 
present. Furthermore, dyskinesia and dystonia are part of the phenotype of Tottering and Leaner, 
respectively.113,107
Transgenic mouse models
Cacna1a-deficient knock-out mice (α1A-/-) that do not express CaV2.1 Ca2+ channels initially appear 
healthy. However, at approximately 10 days after birth, these mice develop a rapidly progressive 
neurological deficit with specific characteristics of ataxia and dystonia, and after 3-4 weeks 
after birth they die.93,94 These knock-out mice are perhaps not very useful to study migraine for 
several reasons: i) whereas neurotransmission in the NMJ in heterozygous seems unaffected114, 
the homozygous mice have a lethal phenotype very different from migraine, ii) the knockout 
mutation is a loss-of-function mutation, unlike FHM1 mutations that are considered gain-of-
function mutations.89 Therefore, it seems more appropriate to study migraine pathophysiology 
using knock-in migraine mouse models that carry human pathogenic FHM1 mutations. 
Two transgenic knock-in (KI) mouse models harbouring either the R192Q or the S218L FHM1 
mutation were generated by introducing the respective mutation into the orthologous Cacna1a 
gene by homologous recombination.115,116 These mutations were previously identified in FHM1 
patients.25,117 Whereas the R192Q mutation causes a relatively mild form of FHM, the S218L 
mutation is associated with a more severe form of FHM with additional neurological features (i.e., 
cerebellar ataxia, epilepsy and brain edema after mild head trauma). Interestingly, S218L KI mice 
show a complex phenotype that is very similar to that observed in S218L patients, whereas R192Q 
KI mice show no overt phenotype. These migraine mice models are considered valuable models to 




1.12. Scope and outline of the thesis
Identification and characterization of migraine susceptibility genes and pathways that are involved 
in the disease mechanisms are very important for understanding the pathophysiology of migraine. 
It may also give new insights that can be useful for drug development and treatment of migraine. 
Studies in this thesis focus on genetic factors and molecular pathways involved in FHM, SHM, other 
monogenic diseases in which migraine is prevalent, as well as the common forms of migraine. As HM 
is considered a suitable model for the common forms of migraine, the identification of mutations in 
FHM genes and investigating their functional consequences is also relevant to increase insights in the 
genetic and molecular background of the common forms of migraine. At the start of the thesis, three 
FHM genes had been identified: CACNA1A, ATP1A2 and SCN1A. 
In Chapter 2, several mutations in the three known FHM genes are presented with a functional 
characterisation using cellular assays or electrophysiological studies in cell systems. The 
mutations are associated with a broad spectrum of clinical symptoms, ranging from FHM and 
epilepsy to atypical AHC. 
In Chapter 3, the involvement of the FHM genes in 39 sporadic patients with HM is studied. 
Although SHM patients are clinical indistinguishable from FHM patients, it has not been 
extensively studied whether FHM genes may play a major role in this form of hemplegic migraine. 
The mutation scan resulted in the identification of several novel DNA variants. For all variants, 
functional studies were performed. 
Chapter 4 describes the involvement of the excitatory amino acid transporter EAAT1 in EA2 
patients that were negative for mutations in the CACNA1A gene. EAAT1 fits the same cortical 
glutamate-related pathway of the three known FHM gene products. Previously, a mutation in this 
gene had been identified in a patient with a particularly severe clinical phenotype that included 
episodic ataxia and hemiplegic attacks. A novel EAAT1 mutation is identified in a EA2 patient 
and associated clinical and functional characteristics are described.
Previously, a Dutch family with a vascular monogenic disorder; Hereditary Vascular Retinopathy 
(HVR), was together with two additional North American families with similar symptoms linked 
to chromosome 3p21. In Chapter 5.1, the TREX1 gene is identified as the causative gene in 
these three families. Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL) is the novel 
name for this vascular disorder with autosomal dominant inheritance, that is characterized by 
progressive blindness due to vascular retinopathy that can be associated with a wide range 
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of clinical symptoms, including migraine. TREX1 mutations are also identified in several 
other vascular and immune-related disorders, including Systemic Lupus Erythomatosis (SLE). 
Chapter 5.2 describes the first TREX1 mutation in a patient with neuropsychiatric SLE (NPSLE).
The rapid development of high-throughput genotyping during the last years made genome-
wide association studies (GWAS) a feasible and attractive method to identify genetic factors for 
genetically complex disorders, such as migraine. Large clinic-based migraine cohorts from various 
European headache clinics (Chapter 6.1) and population-based cohorts from the Dutch Icelandic 
(DICE) consortium (Chapter 6.2) were used for these GWA studies. The most significantly 
associated SNP in the clinic-based migraine GWAS was tested in several independent MA and 
MO replication cohorts encompassing a total amount of over 3,000 migraine patients. For the 
population-based study first a GWAS was performed in a large genetically isolated population 
from the south of the Netherlands (ERF) that was followed by meta-analysis of GWAS data from 
five additional cohorts.
The identification of FHM genes gave the opportunity to generate transgenic mouse models. Two 
Cacna1a knock-in migraine mouse models with specific FHM1 mutations (i.e. S218L and R192Q) 
were generated. These knock-in mice are considered useful tools to study migraine. In Chapter 
7, we study the RNA expression profiles of cerebellum and occipital cortex of FHM1 knock-in 
mice under basal (i.e. un-triggered) conditions, to investigate whether and to which extent 
neurobiological differences in these migraine mice were regulated at the gene expression level. 
Chapter 8 provides a general discussion of the thesis, reviewing the results and discussing future 
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Familial hemiplegic migraine (FHM) and alternating hemiplegia of childhood (AHC) are severe 
neurological disorders that share clinical features. Therefore, FHM genes are candidates for AHC. 
We performed mutation analysis in the CACNA1A gene in a monozygotic twin pair with clinical 
features overlapping with both AHC and FHM and identified a novel de novo CACNA1A mutation. 
We provide the first evidence that a CACNA1A mutation can cause atypical AHC, indicating an 
overlap of molecular mechanisms causing AHC and FHM. These results also suggest that CACNA1A 
mutation scanning is indicated in patients with a severe neurological phenotype that includes 
paroxysmal (alternating) hemiplegia.  
Introduction
Alternating hemiplegia of childhood (AHC) and familial hemiplegic migraine (FHM) are clinically 
very similar disorders.1,2 AHC is typically characterized by episodes of alternating hemiplegia or 
quadriplegia and progressive neurological features beginning before the age of 18 months.1 FHM 
is a rare subtype of migraine with aura associated with hemiparesis and in some cases ataxia, 
mental retardation, movement disorders or other neurological abnormalities.3 For FHM, three 
genes have been identified: CACNA1A, ATP1A2 and SCN1A, which all play a role in ion transport.4-6
Except for one Greek family with atypical AHC and an ATP1A2 mutation, no genes have been 
identified for AHC.7,8 Here we describe a monozygotic twin pair suffering from a complex phenotype 
of early-onset ataxia, alternating hemiplegia, epilepsy, migraine-like attacks and mental retardation, 
which clinically overlaps with both AHC and FHM. We identified a novel de novo CACNA1A mutation 
in both patients, confirming a genetic overlap between AHC and FHM. 
Subjects and methods 
Subjects
Standardized criteria were used for the diagnosis of FHM3 and AHC.1 All subjects gave informed 
consent. This study was approved by the local ethics committee of the University of Greifswald. 
Genetic analysis
Genomic DNA was isolated from peripheral leucocytes using a standard salting out extraction method.9 
The 47 coding exons and adjacent sequences of the CACNA1A gene were scanned for mutations by 
direct sequencing. In brief, all exons were amplified by polymerase chain reaction, using genomic 
DNA as a template. Direct sequencing was done by Cycle Sequencing (Prism Big Dye Terminators Cycle 
Sequencing kit; Applied Biosystems, Foster City, CA, USA) using the dideoxy termination method 
and an ABI3700 automated sequencer (Applied Biosystems). One hundred healthy controls were 
screened by direct sequencing. Detailed information is available from the authors upon request.
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Results
The monozygotic German twin brothers, now aged 17 years, were spontaneously born at term 
after an uneventful pregnancy. Their complex clinical features are summarized in the Table 1. 
One twin brother (patient I in Table 1) was severely affected and had a delayed psychomotor 
development. He is still not able to walk without support and is not able to speak. Between the 
ages of 2 and 7 years he suffered from generalized atonic seizures up to three times daily, often 
followed by unconsciousness lasting from seconds to several hours. Subsequently, he developed 
mental and psychomotor regression with ataxic and athetotic limb movements. At age 11 years, 
when he was hospitalized because of severe constipation and abdominal pain, episodes of abrupt 
stops in movement, tachycardia and swallowing automatisms were observed. Ictal EEG recordings 
showed mainly occipitotemporal bilateral synchronic sharp–slow wave activity (not shown). At 
the age of 12 years he experienced a period of alternating hemiplegia, starting on the left side 
and accompanied by fever. Cerebral magnetic resonance imaging (MRI) showed ictal right cortical 
swelling (Fig. 1). After 12 days the left-sided symptoms resolved, but there after right-sided 
weakness occurred, which lasted for days. EEG revealed slow wave activity over the left hemisphere 
(data not shown). As he is still not able to express himself, the presence and severity of migraine 
symptoms (headache, phonophobia, photophobia, nausea) are difficult to assess. At present, he 
is tetraspastic with athetotic and ataxic movements, and has intermittent convergent strabismus. 
 Table 1 Clinical features of monozygotic twins compared with alternating hemiplegia of childhood (AHC) and familial hemiplegic 
migraine (FHM)
 AHC  FHM1  Patient I  Patient II
Onset of (alternating) 
hemiplegic attacks  0–18 months*  > 2 years to adolescence†  12 years  10 years
Hemidystonic spells  +  -  -  -
Quadriplegia  +  -  +  -
Choreoathetosis  +  -  +  -
Ataxia  +  +  +  +
Nystagmus  +  + -  -
Strabismus  +  -  +  +
Mental retardation  +  -  +  +
Autonomic symptoms  +  +  +  +
Positive effect of sleep  +  -  -  -
Epilepsy  +  +  +  +
Aura symptoms  -  +  NA  +
Migrainous headache  -  +  NA  +
 (+) or (-) indicates presence or absence of a symptom, respectively. NA indicates not applicable due to inability of verbal expression 
of the patient. *Typically alternating hemiplegia. †Typically non-alternating hemiplegia.
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The other twin brother (patient II in Table 1) was delivered shortly after his twin brother. Early 
infant psychomotor development was delayed. At the age of 1.5 years he was able to speak single 
words. Between the ages of 3 and 8 years he suffered twice a year from atonic episodes accompanied 
by loss of consciousness for 1 h, followed by ataxia. Ictal EEGs showed no signs of epilepsy (data 
not shown). 
 Figure 2 Single photon emission computed tomography scan shows 
ictal left-sided hypoperfusion contralateral to the hemiparesis in the 
parietofrontal (severe) and temporal (mild) cortex of patient II.
 Figure 1 Fluid-attenuated inversion recovery (FLAIR) image 
shows ictal diffuse cortical swelling of the right hemisphere 
of patient I.
Since the age of 10 years he has experienced several episodes of right- or left-sided hemiplegia, 
and one episode with alternating hemiplegia for several days. One of the hemiplegic episodes was 
accompanied by reduced consciousness and fever and lasted several weeks. Cerebral single photon 
emission computed tomography showed ictal left-sided hypoperfusion in the parieto-fronto-
temporal cortex (Fig. 2). At the age of 12 years, treatment with flunarizine was started, with 
doubtful effect. During hemiplegic attacks he complained of frontal throbbing headache with 
nausea, sometimes accompanied by phonophobia. Ophthalmic examination shows a strabismus. 
Except for the twin pair, no other family members suffer from attacks of hemiplegia, epilepsy or 
migraine. Monozygosity of the twins was confirmed and false paternity was excluded by genetic, 
multimarker analysis (data not shown). Extensive metabolic screening in both twins revealed no 
abnormalities. Cerebral MRI, showing diffuse ictal swelling in patient I (see above), was without 
severe abnormalities in either of the twins, and did not revealcerebellar atrophy.  
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Direct sequencing of all 47 exons of the CACNA1A gene revealed a heterozygous 5361 G>T 
substitution (Genbank Ac. no. X99897) in exon 33 in both twins. This point mutation resulted in 
an amino acid change from a valine to a phenylalanine at position 1696. The mutation is located 
within the transmembrane segment S5 of the fourth domain, which together with segment S6 
forms the inner part of the pore of the Cav2.1-ɑ1 subunit. The parents did not carry the mutation, 
indicating that V1696F is a de novo mutation. Screening of 100 subjects from the general Dutch 
population with no history of migraine or epilepsy was performed by sequence analysis of exon 
33 and was negative.
Discussion
We have identified a novel de novo CACNA1A V1696F mutation in two monozygotic twin brothers 
with complex clinical features in part fulfilling the criteria of both AHC1 and FHM3 (Table 1). 
The presence of hemiplgia and other aura symptoms aswell as migrainous headache are in 
favour of FHM. Episodes of alternating hemiplegia, developmental delay, mental retardation, 
choreoathetotic movements, strabismus and chronic ataxia are supportive of AHC. The severity 
of the phenotype, interictal symptoms and the relatively young age at onset of these patients 
are, in particular, very rare for FHM1 and more common in AHC. As no positive effect of sleep 
was observed and the age at onset was after 18 months, we name this overlap syndrome ‘atypical 
AHC’. Although both monozygotic twin brothers are genetically identical, their clinical symptoms 
and attack frequency vary in severity, with patient I being more severely affected. 
Several lines of evidence indicate that V1696F is the disease-causing mutation in this family. 
Val1696 is highly conserved across multiple calcium channel homologues and across species (data 
not shown). The mutation was not identified in a large number of control chromosomes. The 
mutation occurred de novo, thus strengthening the evidence that it is the V1696F mutation that 
caused the disease. In a French FHM family another mutation affecting the same residue Val1696 
(V1696I) caused hemiplegic migraine without cerebellar signs.10 Finally, electrophysiological 
analysis of mutant Cav2.1-ɑ1 containing Iso1696 has revealed that loss of the valine residue is 
associated with altered channel kinetics compatible with a phenotype of an increased Ca2+ 
influx.11 Notably, change of Val1696 to a phenylalanine (V1696F) or an isoleucine (V1696I) causes 
phenotypes of different severity. Two out of three V1696I mutation carriers had hemiplegic 
migraine without cerebellar signs or other severe neurological features.10 Both V1696F mutation 
carriers, however, had a very severe phenotype of atypical AHC. Apparently, substitution of the 
valine residue for a bulky phenylalanine in the transmembrane domain has a more dramatic 
effect on channel functioning. 
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Previously, sporadic patients with typical AHC have been scanned for mutations in the CACNA1A 
(FHM1), ATP1A2 (FHM2) and SLC1A3 genes, but no mutations were found.12-14 Now, we present 
the first CACNA1A mutation in patients with atypical AHC. Previously an ATP1A2 mutation was 
identified in a Greek family with atypical AHC, with a similar overlapping FHM/AHC phenotype.7,8 
Of note, both CACNA1A and ATP1A2 are involved in ion transport, and mutations in these genes 
are predicted to increase concentrations of K+ and glutamate in the synaptic cleft as a result of 
either increased neurotransmitter release (CACNA1A mutations) or impaired removal of K+ and 
neurotransmitter (ATP1A2 mutations).15,16 Elucidating the molecular basis in this German family 
with complex clinical features strengthens the evidence for a common pathogenesis of FHM and 
AHC. Our results suggest that in severely affected paroxysmal (alternating) hemiplegic patients 
with mental retardation and an age at onset of alternating episodes beyond 18 months, CACNA1A 
mutation scanning is indicated. 
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Febrile seizures are the most common form of convulsions between the age of 6 months and 5 
years1, but genetic factors have not been identified. Here we investigated the molecular basis 
of febrile seizures in a small family with co-occurring hemiplegic migraine2 and febrile seizures 
(Fig. 1). Intermittent ataxia and diffuse encephalopathic episodes are also present in this family. 
Results
Using direct sequencing (see Vanmolkot et al., 2003)3, we identified a novel de novo heterozygous 
2563 G>A substitution in exon 18 resulting in an amino acid change from a glycine to an arginine 
at position 855 in the ATP1A2 FHM2 gene4 that encodes the ɑ2 subunit of Na+, K+-ATPase pumps. 
Only, the proband (III-1), the affected mother (II-2), and affected brother (III-2) carry this 
ATP1A2 mutation. Gly855 is evolutionary conserved (Fig. 2A), and the mutation was not identi-
fied in 300 control chromosomes. An ouabain challenge assay (see Vanmolkot et al., 2006)5 for the 
mutant p.Gly855Arg construct, unlike wildtype, showed complete loss of cell survival, indicating 
that the mutation has functional consequences at the protein level (Fig. 2B).
Figure 1 Pedigree of the FHM2 family. The arrow indicates the proband. Squares indicate male subjects and circles indicate female 
subjects. To indicate clinical diagnosis; with lower‐half‐filled symbols represent FHM and double‐lined symbols represent febrile 
seizures. Individuals heterozygous for the ATP1A2 mutation are indicated by G855R. Wild‐type (WT) indicates that the individual 
does not have the mutation.
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Figure 2 Genetic and functional data on mutant p.Gly855Arg. (A) Alignment of amino acid sequences of several vertebrate sodium‐
potassium ATPase a‐subunits; Gly855 is represented as a black box. (B) Upper panel shows Western blot analysis of transfected HeLa 
cells. Lower panel shows graphic representation of ouabain cell survival assay. Bars represent cell survival after 5 days of ouabain 
treatment [error bars indicate standard error of the mean(SEM)].
Clinical descriptions
This now 13-year-old proband (III-1) (Fig. 1) experienced, from the age of 9 months to 3 years, 
five complex febrile seizures and one simple febrile seizure. The complex seizures either lasted 
more than 15 min or started focally. There were also episodes of several seizures occurring 
sequentially. From the age of 7 months to 5 years, he also experienced several nonfebrile seizures, 
which typically had a focal onset and were secondary generalized. These seizures usually lasted 
up to 5 min, but sometimes were prolonged (up to 40 min), and at times occurred in clusters. 
Seizures stopped at age 5. From age 2.5, he experienced headache attacks accompanied by tran-
sient hemiparesis as well as frequent unprovoked episodes of ataxia lasting a few minutes to 
days. In addition, he had episodes of rapidly progressive drowsiness down to Glasgow Coma scale 
(GCS) 6–7, without any focal neurologic deficits or epilepsy. The patient has ongoing behavioral 
problems and mild learning difficulties. His now 3-year-old half-brother (III-2) had one complex 
(focal) febrile seizure lasting 15 minutes when he was 7 months old. Since the age of 21 months 
he had episodes of hemiplegia, and recurrent encephalopathic episodes often preceded by head-
ache and hemiplegia, and one episode of unsteadiness after minor head injury. The mother (II-2), 
now age 31 years, had two simple febrile seizures at age 2 and also had attacks of hemiplegic 
migraine. The father of the proband (II-1) and the father (II-3) of his halfbrother and their 
grandparents (I-1 and I-2) never had hemiplegic migraine, ataxia, or seizures.
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Conclusion
We feel that the ATP1A2 p.Gly855Arg mutation is the causal mutation in this family for a number 
of reasons: (1) FHM and febrile convulsions were present only in the three mutation carriers 
and not in non–mutation carriers; (2) the mutation was not identified in a panel of 150 healthy 
control individuals, and (3) functional studies revealed that the mutant has a deleterious effect 
on cell survival. Febrile seizures are reported in only some mutation carriers of three FHM2 fami-
lies.3,6,7 Future identification of additional families with co-occurring hemiplegic migraine and 
febrile seizures may shed light on the association between ATP1A2 gene mutations and febrile 
seizures. We, therefore, recommend genetic analysis of the ATP1A2 gene in patients with febrile 
seizures.
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Familial hemiplegic migraine (FHM) is a severe subtype of migraine with hemiparesis during 
attacks. We scanned 10 families with FHM without mutations in the CACNA1A (FHM1) and 
ATP1A2 (FHM2) genes. We identified the novel p.L1649Q mutation (c.4946T>A) in Nav1.1 sodium 
channel gene SCN1A (FHM3) in a North American kindred with FHM without associated ataxia 
or epilepsy. Functional analysis of the mutation, introduced in the highly homologous human 
SCN5A, revealed markedly slowed inactivation and a two-fold faster recovery from fast inac-
tivation predicting enhanced neuronal excitation. Our findings establish the role of neuronal 
Nav1.1 sodium channels in FHM and reinforce the involvement of ion channel dysfunction in the 
pathogenesis of this episodic brain disorder.
Introduction
Familial hemiplegic migraine (FHM) is a rare monogenic form of migraine with hemiparesis during 
aura. Mutations in three genes for FHM have been identified, in the CACNA1A calcium channel 
gene (MIM# 601011) for FHM1 (MIM# 141500)1, the ATP1A2 Na,K-ATPase gene (MIM# 182340) 
for FHM2 (MIM# 602481)2 and, recently, the p.Q1489K mutation (c.4465C>A; p.Gln1489Lys) 
in the SCN1A sodium channel gene (MIM# 182389) for FHM3 (MIM# 609634)3. All three gene 
products are intimately involved in the modulation of ion fluxes across neuronal and glial cell 
membranes, suggesting that FHM, and possibly also common types of migraine, are cerebral 
ionopathies.4 The p.Q1489K SCN1A mutation is remarkable as it represents the first among 
more than 150 mutations in this gene that is not associated with either severe myoclonic 
epilepsy of infancy (SMEI, MIM# 607208) or generalized epilepsy with febrile seizures (GEFS+, 
MIM# 604233).5,6 The mutation spectrum in SMEI differs from that in GEFS+ as the majority of 
SM EI mutations occurred de novo. Approximately half of the SMEI mutations are nonsense or 
frameshift mutations resulting in protein truncation and consequent loss-of-function. Almost 
40% of SMEI mutations are missense mutations, with functional consequences that range from 
complete loss-of-function, gain-of-function to minimal functional effects.7 The milder GEFS+ 
phenotype is associated with missense mutations only, showing either loss- or gain of-function 
effects.8,9 Functional studies of the p.Q1498K mutation expressed and analyzed in the highly 
homologous human SCN5A revealed a more rapid recovery from fast inactivation (Dichgans et al., 
2005). A limitation in that study was that the mutation was found in three families of common 
ancestry leaving the possibility of an isolated finding rather than a prominent FHM gene. In 
order to firmly establish the SCN1A gene as a gene for FHM3, independent confirmation in other 
families is necessary. 
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Here we performed mutation scanning in the SCN1A gene in 10 FHM families that were negative 
for mutations in the CACNA1A and ATP1A2 genes. We identified the novel SCN1A p.L1649Q 
mutation (c.4946T>A) in a large kindred with pure FHM without epilepsy and show that this 
mutation severely interferes with voltage-gated sodium channel functioning.
Subjects and methods
Patients
We investigated 10 families with pure FHM (without associated epilepsy or ataxia) and without 
mutations in the CACNA1A (FHM1) and ATP1A2 (FHM2) genes. Two to seven affected members 
were available per family. Diagnoses were made according to the IHS criteria.10 All subjects gave 
written informed consent. Detailed information on the clinical characteristics of the SCN1A 
mutation carriers is shown in Table 1. Clinical diagnosis was made blinded for the genetic data.
Genetic analysis
Genomic DNA was isolated from peripheral blood using a standard salting out extraction method.11 
All 26 exons of SCN1A were amplified by polymerase chain reaction (PCR), and primer details are 
available from the authors upon request. For several exons, primers were improved compared to 
our original paper3, for instance the alternatively spliced exon 5N, reported by Tate et al.12 is now 
included in the scan. All PCR products were analyzed for mutations by direct sequencing. DNA 
numbering for SCN1A is based on cDNA reference sequence AB093548.1. Nucleotide numbering 
uses the A of the ATG translation initiation codon as nucleotide +1. Mutation nomenclature 
follows guidelines of the Human Genome Variation Society (http://www.hgvs.org/mutnomen/).
Mutagenesis, Cell Culture, and Electrophysiology
As in the first study, we used the closely related SCN5A cDNA because of known difficulties in 
stability of recombinant bacteria with SCN1A cDNA.3 p.L1636Q, which corresponds to p.L1649Q in 
SCN1A was introduced by site-directed mutagenesis into full-length human SCN5A cDNA subcloned 
in pCDNA3.1 (QuikChange XL Kit, Stratagene, La Jolla, CA, USA). SCN5A-L1636Q and SCN5A-WT 
cDNA constructs were transfected into human tsA201 cells using the calcium phosphate method 
and were each coexpressed with accessory human sodium channel subunit β1 (ratio of cDNA 2:1) 
and CD8 cDNA. Before recording, DMEM medium was exchanged with bath solution and anti-
CD8 coated microbeads (Dynabeads M-450 CD8, Oxoid, Basingstoke, UK) were added to the cell 
suspension. The bath solution contained (in mM): 110 Naglutamate, 35 NaCl, 4 KCl, 1 MgCl2, 1.8 
CaCl2, 10 mM HEPES (pH 7.3). Macroscopic sodium currents were recorded using the whole-cell 
configuration of the patch clamp technique, filtered at 10 kHz by a low-pass Bessel filter, and 
acquired by a patch clamp L/M-EPC7 amplifier (List Medical Electronics, Darmstadt, Germany) 
interfaced with a National Instruments interface (PCI-6052E) and a custom acquisition program 
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(GePulse). Temperature was controlled (20 ± 0.5 °C) with a Peltier device. Patch pipettes were 
pulled from aluminium silicate glass (Hilgenberg Gmbh, Malsfed, Germany) and fire polished 
with a microforge. Electrode resistance was 1.5-2.0 MΩ with a pipette solution containing (in 
mM): 110 CsGlu, 30 NaCl, 2 MgCl2, 5 Cs-EGTA, 10 mM HEPES (pH 7.3). Access resistance was 
between 2 and 5 MΩ, and the cell capacitance was between 5 and 15 pF, as measured by the 
compensating circuit of the amplifier. Data from cells with a current amplitude of 0.5-1.5 nA 
were used for the analysis of the voltage-dependent parameters. Thus, the series resistance error 
was less than 4 mV. The holding-potential was –120 mV and steady state activation, steady-state 
inactivation, time constants of inactivation (e.g. time constants τfast and τslow), and recovery from 
inactivation were measured using protocols, as described before.3 Data analysis was performed 
using the program Ana (available at http://www.ge.cnr.it/ICB/conti_moran_pusch/programs-
pusch/software-mik.htm), and Sigma Plot (SPSS Inc., Chicago, IL, USA).
Results
Clinical genetic analysis of FHM families
Mutation scanning of the SCN1A gene in the probands of the 10 families revealed one mutation in 
a North American family of Caucasian descent (Fig. 1A). Clinical details of mutation carriers from 
this family are shown in Table 1. The proband (III-4), aged 51 years, has hemiplegic migraine 
attacks since the age of 10 with a frequency that varies from twice a month to once a year. The 
attacks always start with blurred vision with dark spots, followed within minutes by spreading 
hemiparasthesia and hemiparesis with dysarthria and dysphasia. After 20-30 minutes, this is 
followed by a hemicranial throbbing headache, which is always located on the side opposite to 
the hemiparesis and is accompanied by nausea, vomiting, photo- and phonopobia. Six additional 
family members suffer from typicial hemiplegic migraine attacks as well, with an age of onset 
varying from 11 to 24 years. We classified individual IV-3 also as affected, despite the fact that 
he only has had one attack of FHM so far. We feel that because of his young age (22) subsequent 
attacks are still likely to occur. Besides hemiplegic attacks, individual III-2 suffers from migraine 
with and without aura and individual IV-3 suffers from migraine without aura. No cerebellar signs 
or epilepsy symptoms were reported in this family. 
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Mutation analysis in the proband revealed a heterozygous point mutation in exon 26 (c.4946T>A; 
p.L1649Q), resulting in an amino acid substitution of glutamine for leucine. The mutation 
co-segregated completely with the hemiplegic migraine phenotype in this family and was not 
found in a panel of 400 control chromosomes. Sequence alignments indicated high conservation 
of Leucine1649 among several vertebrate sodium channel α1 subunits (Fig. 1B). Mutation p.L1649Q 
is located in the S4/D4 domain that is implicated in voltage sensing of fast inactivation (Fig. 1C-D).











H   S    V   A
    Hemiplegic attacks 
Duration





II-1 12 +   +   +   + 1-6 h 2/week 24-48 h Both sides Throbbing +/+/+/+
II-2 11 +   +   +   + 10-60 min 4-5/year 4-72 h Unilateral Nagging +/+/+/-
III-2* 21 +   +   +   + 1-14 h 3-4/year 2 days Both sides Pulsating +/+/+/+
IV-2 15 +   +   +   + 10-60 min 2/year 4-72 h Both sides Throbbing +/+/+/+
III-4 10 +   +   +   + >60 min 2/month- 24 h Unilateral Throbbing +/+/+/+
1/year
III-5 24 +   +   +   + 15 min 5/life 3 h Both sides Pounding -/-/-/-
IV-3** 19 +   +   +   + 45 min 1 till present 1.5 h Unilateral Throbbing +/+/+/+
H: hemiparesis or hemiplegia; S: sensory disturbance; V: visual disturbance; A: aphasia; +: symptom consistently present in all or 
most attacks; -: symptom never present; *Patient III-2 also suffers from migraine with and without aura attacks. **Patient IV-3 
also suffers from migraine without aura attacks.
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Figure 1. A: Pedigree of the FHM3 p.L1649Q family. The arrow indicates the proband. Symbols present: FHM: black lower 
half; MA (migraine with aura): right upper square; MO (migraine without aura): left upper square; WT: wild-type; p.L1649Q 
heterozygous carrier of the pathogenic SCN1A mutation. Patient IV-3 (aged 22, gray lower half) had one typical (fulfilling 
the IHS criteria) hemiplegic migraine attack until present. B: Alignment of the amino acid sequence from several vertebrate 
sodium channel α subunits, showing complete conservation of the mutated amino acid Leucine1649. C: Topology of SCN1A, 
encoding the α1-subunit of a neuronal Nav1.1 sodium channel. The subunit consists of 4 repeat domains (D1-D4), which 
contain 6 transmembrane domains (S1-S6). The location of the novel mutation p.L1649Q in the voltage sensor domain S4/
D4 is depicted, as well as the previously identified p.Q1489K FHM3 mutation. D: Over 150 mutations have been identified for 
severe myoclonic epilepsy in infancy (SMEI) or generalized epilepsy with febrile seizures plus (GEFS+). For clarity, only SMEI 
and GEFS+ mutations are shown that are located in the (A) inactivation gate and (B) S4/D4 voltage sensor domain where 
FHM3 mutations were identified (all mutations are based on SCN1A cDNA reference sequence: AB093548.1). For review papers 
with all SCN1A epilepsy mutations see Meisler et al. (2005)5 and Mulley et al. (2005)6.
Functional Consequences of the FHM3 Mutation
TsA201cells expressing construct SCN5A-L1636Q, which is equivalent to mutation p.L1649Q 
in SCN1A showed typical voltage-dependent sodium inward currents, similar to cells trans-
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fected with construct SCN5A-WT (Fig. 2A), and with similar current density (Table 2). Mutant 
channels activated with the same voltage dependence as WT channels (Table 2). However, the 
time course of inactivation was slower for the mutant (Fig. 2A). Quantitative analysis of the 
inactivation time-course revealed that, at all tested voltages (-50 mV to 30 mV), both time con-
stants of the double exponential fits (τfast and τslow) were two- to four-fold larger for the mutant 
compared to wild-type (Fig. 2B-C). The contribution of the fast component relative to the slow 
component (also expressed as the ratio Cfast/Cslow) of inactivation was reduced (Fig. 2D). Both ef-
fects lead to an overall slower fast inactivation of mutant channels (Fig. 2A). On the other hand, 
slow inactivation was unaffected (Table 2). The voltage dependence of steady state fast inactiva-
tion was shifted by ~ 10 mV towards more positive voltages and recovery from fast inactivation, 
measured after a 500 ms conditioning pulse to –10 mV, was 150% faster in the mutant than in 
the wild-type channels. Altogether, these functional analyses show that this mutation severely 
interferes with the fast inactivation process.
Figure 2. Electrophysiological properties of wild-type and mutant sodium channels. A: Macroscopic sodium currents were recorded 
using the whole-cell configuration of the patch clamp technique. Depicted are current traces recorded at -10 mV showing slowed 
inactivation of mutant channels. B-D: Time constants of inactivation (taufast and tauslow) and their respective contributions (Cfast and 
Cslow) were obtained from a bi-exponential fit to the decaying current phase as described earlier fast slow fast slow (Dichgans et al., 
2005). B: fast time constant of inactivation (tauslow). C: slow time constant of inactivation (tauslow). D: ratio of the contribution of 
the fast and the slow component of inactivation (Cfast/Cslow). At -50 mV and -40 mV the fast component was negligible. Mean values 
± SEM are given for SCN5A-WT (filled circles; n=6) and mutant SCN5A-L1636Q (filled squares; n=6). Values marked with asterisks are 
significantly different between wild-type and mutant (* p<0.05; ** p<0.01) with Student’s unpaired t-test.
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Table 2. Activation and Inactivation Parameters for Wild-type and Mutant Sodium Channels
Parameters SCN5A-WT  SCN5A-L1636Q
Current density (nA/pF)  0.24 ± 0.04 (30)  0.21 ± 0.03 (28)
Steady-state activation
Voltage of half maximal activation (Va, mV)  -44.2 ± 5.1 (7)  -41.4 ± 1.5 (6)
Slope factor (ka)  6.1 ± 1.8  6.0 ± 1.5
Reversal potential (Vrev, Mv)  45.6 ± 5.2  41.7 ± 7.0
Steady-state fast inactivation
Voltage of half maximal inactivation (Vfi, mV)  -77.4 ± 3.1 (8)  -67.8 ± 2.7 (5) **
Slope factor (kfi)  7.2 ± 1.4  7.5 ± 1.1
Steady-state slow inactivation
Voltage of half maximal slow inactivation (Vsi, mV)  -99.1 ± 10.2 (3)  -92.8 ± 0.7 (3)
Slope factor (ksi)  12.6 ± 3.3  13.0 ± 2.1
Recovery from inactivation (-120 mV)
Fast time constant (τfast) (ms)  7.1 ± 1.6 (4)  4.6 ± 1.0 (5) *
Slow time constant (τslow) (ms)  322 ± 200  108 ± 48
Onset of slow inactivation
Fast time constant (τfast) (s)  3.8 ± 1.4 (9)  5.1 ± 0.9 (4)
Slow time constant (τslow) (s)  302 ± 105  217 ± 98
Data are mean ± SD. Numbers in brackets indicate number of experiments. Values marked with asterisks are significantly different 
between wild-type and mutant (* p<0.05; ** p<0.01) with Student’s unpaired t-test.
Discussion
We here firmly establish that certain mutations in the SCN1A epilepsy gene may cause FHM. 
First, the p.L1649Q SCN1A mutation completely co-segregated with a pure FHM phenotype 
(without epilepsy) in our family (Fig. 1A) and was not found in the control panel. Second, 
Leucine1649 is highly conserved among several vertebrate sodium channel α1 subunits (Fig. 1B). 
Third, the mutation is located in the S4 segment of domain 4 that acts as a voltage sensor and is 
known to play an important role in channel gating (Fig. 1C-D).13,14 Finally, our functional studies 
of the mutation introduced in the highly homologous human SCN5A revealed clear functional 
effects: i) an overall slower inactivation of sodium channels; ii) a depolarizing shift by ~ 10 mV 
in the voltage dependence of the steady state inactivation; and iii) an accelerated recovery from 
fast inactivation (Table 2). Most likely, the p.L1636Q SCN5A mutation directly interferes with 
the inactivation process, as do other mutations in the S4/D4 domain14, even though we cannot 
fully exclude a contribution of an altered interaction with the β1 subunit.15 Although this study 
convincingly showed causality for p.L1649Q in FHM3, in future studies, these findings should be 
confirmed in SCN1A, or even better in a knockin mouse model. 
FHM3 SCN1A mutation 2.3
53
The previously identified FHM3 mutation p.Q1489K3 was also introduced in the highly homologous 
SCN5A cDNA, which allows comparison of the functional consequences of both FHM3 mutations. 
This mutation is located in the cytoplasmic linker between domains III and IV (Fig. 1C-D) and 
revealed a two-fold to four-fold accelerated recovery from fast inactivation.3 Thus, both the 
p.Q1489K and the p.L1649Q mutation lead to impaired fast inactivation and predict enhanced 
neuronal excitation. This fits very well with our current understanding of the pathogenesis 
of FHM.16,4 The CACNA1A gene encodes neuronal Cav2.1 calcium channels that modulate the 
release of neurotransmitters. FHM1 CACNA1A mutations were shown to cause gain-of-function 
effects in cellular models17,18 and in a knockin mouse model.19 In the transgenic model, FHM1 
mutations increase the release of glutamate and other neurotransmitters (A. Tottene, A. van den 
Maagdenberg, and D. Pietrobon, unpublished observations) and reduce the threshold for cortical 
spreading depression (CSD).19 CSD has been convincingly shown to be the underlying mechanism 
for the migraine aura20 and, based on animal experiments, may also be responsible for triggering 
the headache phase of migraine attacks by activating the trigeminovascular system.21 The ATP1A2 
gene encodes a Na,K-ATPase in glial cells. FHM2 ATP1A2 mutations were shown to have altered 
kinetics or loss-of-function effects in cellular studies, predicting reduced re-uptake of both K+ 
and glutamate from the synaptic cleft into glial cells.2,22 Voltage-gated sodium channels are 
involved in the generation and propagation of action potentials in excitable tissues. FHM3 SCN1A 
mutations changed Nav1.1 channel inactivation kinetics, predicting enhanced neuronal excita-
tion leading to increased release of neurotransmitters, including glutamate. The common overall 
effect of FHM mutations in all three FHM genes seems to be an increase of the concentration of 
K+ and glutamate in the synaptic cleft. This should translate into an enhanced propensity for CSD 
and may thus be responsible for triggering FHM, and possibly “normal” migraine attacks.
Migraine and epilepsy are comorbid disorders and seem to have some overlapping mechanisms 
related to dysfunction of ion transportation.23 It is remarkable that the vast majority of SCN1A 
mutations are associated with severe forms of epilepsy, whilst the p.Q1489K and p.L1649Q muta-
tions cause pure FHM. The p.L1649Q FHM3 mutation is even adjacent to two “epilepsy” mutations 
that affect Arginine1648, the p.R1648C mutation causing SMEI24 and p.R1648H causing GEFS+.25 
Both mutations have been examined in several expression systems with different outcomes all 
affecting channel inactivation.5 From these and our studies it is evident that the voltage sensor 
in domain 4 (S4/D4) is pivotal to the fast inactivation of sodium channels but that there is no 
simple correlation between clinical phenotype and biophysical changes induced by SCN1A 
mutations. Dedicated functional studies comparing epilepsy and migraine mutations in the same 
gene may further the insight into both episodic brain disorders.
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Background: Familial (FHM) and sporadic (SHM) hemiplegic migraine are severe subtypes of 
migraine associated with transient hemiparesis. For FHM, three genes have been identified 
encoding subunits of a calcium channel (CACNA1A), a sodium–potassium pump (ATP1A2), and 
a sodium channel (SCN1A). Their role in SHM is unknown. Establishing a genetic basis for SHM 
may further the understanding of its pathophysiology and relationship with common types of 
migraine. It will also facilitate the often difficult differential diagnosis from other causes of 
transient hemiparesis. 
Methods: We systematically scanned 39 well-characterized patients with SHM without associated 
neurologic features for mutations in the three FHM genes. Functional assays were performed for 
all new sequence variants.
Results: Sequence variants were identified in seven SHM patients: one CACNA1A mutation, five 
ATP1A2 mutations, and one SCN1A polymorphism. All six mutations caused functional changes in 
cellular assays. One SHM patient later changed to FHM because another family member developed 
FHM attacks.
Conclusion: We show that FHM genes are involved in at least a proportion of SHM patients 
without associated neurologic symptoms. Screening of ATP1A2 offers the highest likelihood of 
success. Because FHM gene mutations were also found in family members with “nonhemiplegic” 
typical migraine with and without aura, our findings reinforce the hypothesis that FHM, SHM, 
and “normal” migraine are part of a disease spectrum with shared pathogenetic mechanisms.
Introduction
Hemiplegic migraine is a rare, often severe subtype of migraine with aura in which attacks are 
associated with hemiparesis.1 Otherwise, the aura and headache symptoms are identical to those 
of common types of migraine.2 Hemiplegic migraine may run in families (familial hemiplegic 
migraine [FHM]) or may be sporadic (SHM).1 Clinically, FHM and SHM attacks are indistinguishable, 
and the majority of patients also have common attacks of migraine with or without aura, not 
associated with hemiparesis.3 
Thus far, three genes for FHM have been identified. The CACNA1A gene (FHM1)4 encoding the 
pore-forming subunit Cav2.1 of neuronal P/Q-type calcium channels, the ATP1A2 gene (FHM2)
5 
encoding the α2 subunit of sodium–potassium pumps, and the SCN1A gene (FHM3)6 encoding the 
α1 subunit of neuronal sodium channels. 
Although clinically indistinguishable,3 it is unknown whether and to what extent SHM and FHM 
are pathophysiologically related and whether and to what extent FHM genes are also involved 
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in SHM. Previous studies identified mutations in the CACNA1A gene in SHM patients.7-11 Most of 
these patients showed cerebellar signs, suggesting an involvement of the CACNA1A gene in SHM 
with associated cerebellar and other neurologic signs or symptoms, such as cerebral edema and 
coma after minor head trauma. In contrast, the role of the FHM genes in “pure” SHM without 
associated neurologic symptoms is less clear. One CACNA1A mutation (R583Q)8 and one ATP1A2 
mutation (R383H)12 were reported in such patients. 
Investigating the involvement of FHM genes in sporadic patients with hemiplegic migraine is im-
portant because it may further the insight into the pathophysiology of SHM and the relationship 
with other types of migraine. Moreover, understanding and establishing the genetic basis of SHM 
may help clinicians in diagnostic and therapeutic decision making. Many patients are initially 
misdiagnosed and mistreated. We therefore set out to search systematically for mutations in the 
known FHM genes in a large set of 39 clinically well-characterized patients with “pure” SHM, who 
had no interictal neurologic symptoms.
Methods 
Patients 
Sporadic hemiplegic migraine was diagnosed according to the criteria of the International Head-
ache Society (IHS).1 Patients with interictal neurologic symptoms, in particular ataxia, were ex-
cluded because these patients have a high a priori probability of carrying a CACNA1A mutation.7-11 
All available family members were directly interviewed, and their headache was diagnosed ac-
cording to the IHS criteria. In addition to newly recruited SHM patients, we included 25 of the 
27 patients from our previous study in which only the FHM1 CACNA1A gene was investigated.8 
Two patients from that study were excluded because of associated symptoms; one had ataxia 
and carried the T666M mutation, the other patient had childhood epilepsy and did not carry a 
CACNA1A mutation. Approval was obtained by local ethical committees in accordance with 
national legislation; all patients gave informed consent. 
Mutation scanning 
Genomic DNA was isolated from peripheral leukocytes using a standard salting out extraction 
method. The CACNA1A, ATP1A2, and SCN1A genes were screened for mutations by sequencing.6,8,13 
In brief, all exons and flanking intronic regions were amplified by PCR, using genomic DNA as a 
template. Direct sequencing was performed with Cycle Sequencing (Prism Big Dye Terminators 
Cycle Sequencing kit, Applied Biosystems, Foster City, CA) using the dideoxy termination method 
and an ABI3700 automated sequencer (Applied Biosystems). For each exonic variant identified, 
150 healthy controls were screened, by restriction enzyme analysis or direct sequencing. Detailed 
information is available from the authors on request. 
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Functional analysis. 
Functional analysis of mutations in the CaV2.1-α1 calcium channel subunit was not performed 
because the single CACNA1A mutation found in this study was thoroughly investigated before.14 
Functional analysis of ATP1A2 variants was performed by survival assays. Human Na,K–adenosine 
triphosphatase (ATPase) α2-subunit complementary DNA (cDNA) was subcloned into a modi-
fied pCDNA3.1 vector.15 To distinguish endogenous Na,K-ATPase activity from that of transfected 
Na,K-ATPase, we used a cDNA construct encoding ouabain-resistant wildtype (ATP1A2-WT).15,16 
Mutations E120A, E492K, P786L, R834X, and R908Q were introduced in the ouabain-resistant 
wild-type α2-subunit construct by site-directed mutagenesis (Quikchange, Stratagene, La Jolla, 
CA). HeLa cells (5 x 105) were transfected with plasmid DNA of either ATP1A2-WT or ATP1A2-
mutant (ATP1A2-E120A, ATP1A2-E492K, ATP1A2-P789L, ATP1A2-R834X, ATP1A2-R908Q) using 
Lipofectamine 2000 Transfection Reagent (Invitrogen, Carlsbad, CA). Two days after transfec-
tion, two-thirds of the cells were harvested for immunoblotting, and the α2-subunit protein 
was detected using the specific polyclonal antibody HERED.15,16 The remaining one-third of the 
cells was seeded on 10-cm petri dishes, and subsequently 1 μM ouabain was added to the culture 
medium. After 5 days of ouabain challenge, colonies were stained with 1% methylene blue in 70% 
methanol, scanned, and analyzed with Image Pro Plus (MediaCybernetics, Silver Spring, MD). 
Each transfection was performed 7 to 15 times. In case of partial survival, statistical significance 
was tested using Student t-test (p < 0.05). 
For functional analysis of the SCN1A variant, we used the closely related SCN5A cDNA, because 
of the known stability problems of recombinant bacteria with SCN1A cDNA.6,17 R1914G, which 
corresponds to SCN1A R1928G, was introduced by site-directed mutagenesis into full-length 
human SCN5A cDNA subcloned in pCDNA3.1 (QuikChange XL Kit, Stratagene). SCN5A-R1914G 
and SCN5A-WT cDNAs were transfected into human tsA201 cells and were each coexpressed 
with accessory human sodium channel subunit β1.6 Macroscopic sodium currents were recorded 
using the whole-cell configuration of the patch clamp technique.6 Steady state activation, steady 
state inactivation, time constants of inactivation (e.g., time constants τfh and τsh), and recovery 
from inactivation (e.g., τfast and τslow time constants) were measured using protocols, as described 
before.6




Thirty-nine patients with “pure” SHM were included; 37 originated from Western Europe (mostly 
The Netherlands or Germany) and 2 came from the United States (table 1). As expected,3,18 some 
of the patients exhibited basilar-type migraine symptoms during the attacks, but they were all 
free of interictal signs or symptoms. Age at onset of hemiplegic attacks ranged from 4 to 42 
years. The number of attacks varied from 2 per lifetime to more than 200 per year. Likewise, 
duration of hemiparesis was variable, from several minutes to 1 week. Four patients reported loss 
of consciousness during attacks; 2 patients reported triggering of attacks by minor head trauma. 
In 1 patient, the initial diagnosis was later changed to FHM, when a family member developed 
hemiplegic migraine attacks. Notwithstanding, this patient was kept in the SHM group because 
he fulfilled the inclusion criteria of SHM at the time of clinical presentation. In approximately 
70% of the families of our 39 SHM patients, attacks of common nonhemiplegic migraine with 
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Genetic and functional findings. 
Sequencing of all exons and flanking intronic sequences in the 39 index cases revealed seven 
different sequence variants which were present in seven probands (table 2 and figure 1): one in 
CACNA1A, five in ATP1A2, and one the SCN1A gene. None of the sequence variants was present in 
150 healthy controls (data not shown). 
Table 2 DNA variants identified in pure SHM patients
Gene  Amino acid change  Nucleotide change  Abnormality in functional test
CACNA1A  R583Q  nt2021GA  Electrophysiologic consequence
ATP1A2  E120A  nt463AC  Partial cell survival
ATP1A2  E492K  nt1578GA  Partial cell survival
ATP1A2  P786L  nt2604CT  No cell survival
ATP1A2  R834X  nt2461CT  No cell survival
ATP1A2  R908Q  nt2827GA  No cell survival
SCN1A  R1928G  nt5782CG  No electrophysiologic consequence
SHM: sporadic hemiplegic migraine.
Figure 1 Pedigrees of sporadic hemiplegic migraine cases with a mutation in one of the familial hemiplegic migraine genes 
(CACNA1A, ATP1A2, and SCN1A). The following symbols are used to indicate the diagnosis: filled lower half = familial hemiplegic 
migraine; right upper quadrant = migraine with aura; left upper quadrant = migraine without aura. Circle = female; square = male. 
Arrows indicate probands. Individuals homozygous for the wild-type allele are indicated by WT; individuals heterozygous for a DNA 
variant are indicated by the respective variant. Fam = family.
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CACNA1A
The single variant in the CACNA1A gene (R583Q) has been reported as part of our earlier study.8 
R583Q was present in the index case and his unaffected mother, who had migraine with aura but 
no hemiplegic attacks indicating incomplete penetrance. R583Q has previously been identified in 
families with FHM and shown to affect Cav2.1 Ca
2+ channel gating in functional studies.14 Thus, 
R583Q can be considered causative in our case. 
ATP1A2
The five DNA variants in ATP1A2 included four missense variants (E120A, E492K, P786L, R908Q) 
and one nonsense mutation (R834X). P786, R908, and R834 are completely conserved across 
multiple homologs and orthologs, whereas E120 and E492 are less well conserved (figure 2). The 
P786L mutation was not present in the proband’s parents. False paternity was excluded in this 
case. Thus, P786L represents a de novo mutation. E120A, E492K, and R834X were all present in 
one or more relatives who had no hemiplegic attacks, thus suggesting incomplete penetrance. 
R908Q was not present in the proband’s mother, but DNA from additional family members was 
not available (figure 1). 
Figure 2 Alignments of novel ATP1A2 and SCN1A DNA variants identified in SHM patients Conservation of mutated amino acids 
(highlighted in gray) is depicted in boxes. Dashed lines indicate conserved amino acids. Proteins were obtained from GenBank. 
Human: P50993 (ATP1A2), P05023 (ATP1A1), P13637 (ATP1A3), Q13733 (ATP1A4); Rat: P06686 (ATP1A2), P06685 (ATP1A1), 
P06687 (ATP1A3), Q64541 (ATP1A4); Chicken: P24797 (ATP1A2), P09572 (ATP1A1). Human: P35498 (SCN1A), Q99250 (SCN2A2), 
Q9NY46 (SCN3A): P35499 (SCN4A), Q14524 (SCN5A), Q01118 (SCN7A), Q9UQD0 (SCN8A), Q15858 (SCN9A), Q9Y5Y9 (SCN10A), 
Q9UI33 (SCN11A).
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 Figure 3 Ouabain survival assay of novel ATP1A2 DNA variants identified in sporadic hemiplegic migraine patients
(A and B) Western blot analysis of HeLa cells transfected with wild-type (WT) or mutant ATP1A2 complementary DNA (cDNA). 
(C and D) Ouabain sensitivity of cells transfected with either wild-type or mutant ATP1A2 cDNA. Bars represent cell survival after 5 
days of ouabain treatment (error bars  SEM). * Partial survival is significantly lower than for WT (p0.05). Mutants P786L, R834X, 
and R908Q gave no survival. Ctrl  control.
Functional consequences of all five ATP1A2 variants were investigated using survival assays in 
HeLa cells as previously reported for FHM2 mutations.5,16 The survival assays test for the ability of 
mutant protein to compensate for the loss of endogenous Na,K pump function, as achieved by 
ouabain treatment (figure 3, C and D). Because of an altered ouabain binding site, the transfected 
wild-type (ATP1A2-WT) and mutant (ATP1A2-E120A, ATP1A2-E492K, ATP1A2-P786L, ATP1A2-R834X, 
ATP1A2-R908Q) Na,K-ATPase α2 subunits are ouabain insensitive. Western blot analysis showed that 
the constructs were expressed at comparable levels (figure 3, A and B). In the survival assay, cells 
expressing the wild-type construct survived ouabain treatment. In contrast, ATP1A2 mutants gave no 
(ATP1A2-P786L, ATP1A2-R834X, ATP1A2- R908Q) or partial (ATP1A2-E120A [p = 0.03], ATP1A2-E492K 
[p = 0.002]) cell survival, indicating a clear functional consequence for all mutants (figure 3, C and D). 
SCN1A. 
DNA variant R1928G in the SCN1A gene was present in the index case and five additional family 
members, two of whom had nonhemiplegic migraine. R1914G (which is equivalent to SCN1A-R1928G) 
was introduced to highly homologous human SCN5A (SCN5A-R1914G) and functionally tested for its 
biophysical properties by patch clamp experiments in transiently transfected human tsA201 cells.6 
Cells expressing the SCN5A-R1914G showed no significant difference in current density, steady state 
activation, steady state inactivation, and recovery from inactivation when compared with wild-type 
(table 3). These results indicate that the variant may be a DNA variant without a biologically 
significant effect on Nav1.1 channel functioning. 
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Table 3. Activation and inactivation parameters for wild-type and mutant sodium channel subunit
 SCN5A/WT  SCN5A/R1914G
Currrent density (nA/pF)  0.24 ± 0.04 (30)  0.14 ± 0.09 (15)
Steady state activation
Voltage of half maximal activation (Va, mV)  -44.2 ± 5.1 (7)  -40.4 ± 3.7 (5)
Slope factor (ka)  6.1 ± 1.8  6.2 ± 0.78
Reversal potential (Vrev, mV)  45.6 ± 5.2  35.4 ± 3.2
Steady-state inactivation
Voltage of half maximal fast inactivation (Vfi, mV)  -77.4 ± 3.1 (8)  -76.5 ± 5.9 (5)
Slope factor (kfi)  7.2 ± 1.4  8.1 ± 1.5
Recovery from inactivation (-120 mV)
Fast time constant (τrf) (ms)  7.1 ± 1.7 (4)  0.6 ± 2.1 (4)
Slow time constant (τrs) (ms)  323 ± 200  310 ± 144
Electrophysiology was performed for wild-type SCN5A-WT and mutant SCN5A-R1914G, equivalent to SCN1A R1928G, in transiently 
transfected tsA201 cells. Values are mean ± SD. In brackets the number of recorded cells is given.
Discussion 
We screened 39 patients with “pure” SHM without ataxia or other additional neurologic features 
for mutations in the three known FHM genes. In 7 patients, we found a sequence variant (table 
2). None was found in 300 control chromosomes. Six of these showed obvious functional changes 
and can be considered causal mutations. These results indicate that genes for FHM are involved 
in at least a proportion of patients with “pure” SHM. Our findings have important pathogenetic, 
clinical, and diagnostic implications. 
With our findings, a sensible approach to genetic testing in SHM has become available to confirm 
the often difficult and clinically important diagnosis of SHM.19 Because SHM patients with de 
novo mutations may represent the founder of a new family with highly disabling FHM, genetic 
confirmation of the diagnosis may have consequences for genetic counseling. When genetic 
testing is considered in a patient with “pure” SHM, the ATP1A2 gene should be screened first. 
We found an ATP1A2 sequence variant in five of the seven SHM cases with a confirmed sequence 
variant corresponding to 13% of the overall SHM sample. This is a strikingly higher prevalence 
compared with a previous study of the ATP1A2 gene that included patients with SHM but pro-
vided no specific clinical details.12 
Our findings are in line with earlier smaller studies showing that the yield of CACNA1A mutations 
in SHM patients is low in the absence of ataxia.20,21 In contrast, CACNA1A mutations were found in 
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50% of SHM patients with associated cerebellar signs.7,9 The present study is the first to evaluate 
the role of the recently identified FHM3 gene6 in SHM. The likelihood of finding SCN1A mutations 
in “pure” SHM, however, seems very low. 
Most ATP1A2 mutations in this study were also found in asymptomatic relatives and in relatives 
with nonhemiplegic migraine. They thus showed reduced penetrance, as has also been noticed 
for ATP1A2 mutations associated with FHM2.22-24 This might explain why mutations in the ATP1A2 
gene are relatively common among sporadic patients. In contrast, all SCN1A mutations previously 
identified in FHM families showed complete penetrance.6,17 This might relate to the low yield of 
mutations in this gene in our sample of sporadic cases. 
Although we found FHM gene mutations in 18% of our patients with pure SHM, we did not 
find mutations in the majority of our patients. It is likely that when additional genes for FHM 
are discovered, greater proportions of patients with SHM will prove to have mutations in FHM 
genes. Until then, a diagnosis of SHM remains based on the exclusion of other causes of recur-
rent hemiparesis, careful physical examination, detailed personal and family history, and regular 
follow-up. In one patient (with ATP1A2 mutation R834X; Family 5: figure 1), we had to change 
the initial diagnosis of SHM to FHM when an additional family member developed hemiplegic 
migraine attacks several years after our initial investigation. A diagnosis of pure SHM is likely 
when transient hemiparesis occurs in the course of a typical attack of migraine with aura, when 
there are no interictal abnormalities, and when “normal” attacks of migraine with or without 
aura are present in first-degree relatives.25 Approximately 70% of pure SHM cases and 60% of the 
mutation carriers had first-degree relatives with common types of migraine. 
Our findings provide genetic evidence that FHM genes are also involved in SHM and thus extend 
and reinforce the growing clinical, epidemiologic, genetic, and pathophysiologic evidence that 
FHM and SHM share neurobiological mechanisms.26 Moreover, because the majority of hemiplegic 
migraine patients also have “normal” attacks of migraine without hemiparesis, both diseases can 
be considered extremes of the pathogenetic migraine spectrum with shared common pathways 
with “normal” migraine with and without aura.26-29 
We identified five sequence variants in ATP1A2 (figure 1; Families 2-6). All conferred reduced 
survival in cellular assays (figure 3) and therefore are likely to be causative mutations. P786L 
occurred de novo and could thus be the founder of a new FHM family. R908Q was found in a 
patient whose mother did not carry the mutation. Because DNA from the father was not avail-
able, it could not be established whether the mutation had occurred de novo. E120A and E492K 
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showed partially reduced survival (figure 3D). Both mutations were identified in other family 
members who were unaffected or had nonhemiplegic migraine with aura. The single CACNA1A 
mutation (R583Q) we found was previously shown to affect CaV2.1 Ca
2+ currents in cellular models 
by changing channel gating.14 The mutation was inherited from the mother, who has attacks of 
nonhemiplegic migraine with aura. The R1928G DNA variant that was identified in the SCN1A 
gene did not reveal significant effects on channel properties as investigated by electrophysiologic 
recordings. Also, this variant poorly segregates with the migraine phenotype. It was present in 
five nonhemiplegic family members; only one of them has migraine with aura, and another has 
migraine without aura. R1928G may therefore be a rare sequence variant without functional 
consequences. 
Screening of FHM genes in sporadic patients with hemiplegic migraine may help to establish 
the diagnosis, enable counseling, and prevent unnecessary diagnostic and therapeutic trial 
with potentially harmful drugs. Scanning of the FHM2 ATP1A2 gene seems to offer the highest 
likelihood of success. Because FHM mutations were also found in SHM and common types of 
migraine with or without aura, our findings reinforce the growing evidence that FHM, SHM, 
basilar-type migraine, and “normal” migraine are part of a disease spectrum with at least some 
shared pathogenetic pathways. Unraveling these pathways may help to identify novel migraine 
prophylactic drugs. 
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Abstract
Background: Episodic ataxia (EA) is variably associated with additional neurologic symptoms. At 
least 4 genes have been implicated. Recently, a mutation in the SLC1A3 gene encoding the glu-
tamate transporter EAAT1 was identified in a patient with severe episodic and progressive ataxia, 
seizures, alternating hemiplegia, and migraine headache. The mutant EAAT1 showed severely 
reduced uptake of glutamate. The syndrome was designated EA6 and shares overlapping clinical 
features with EA2, which is caused by mutations in CACNA1A.
Objective: To test the role of the SLC1A3 gene in EA. 
Design: Genetic and functional studies. We analyzed the coding region of the SLC1A3 gene by 
direct sequencing.
Setting: Academic research.
Patients: DNA samples from 20 patients with EA (with or without interictal nystagmus) negative 
for CACNA1A mutations were analyzed.
Main Outcome Measures: We identified 1 novel EAAT1 mutation in a family with EA and studied 
the functional consequences of this mutation using glutamate uptake assay.
Results: We identified a missense C186S mutation that segregated with EA in 3 family members. 
The mutant EAAT1 showed a modest but significant reduction of glutamate uptake.
Conclusions: We broadened the clinical spectrum associated with SLC1A3 mutations to include 
milder manifestations of EA without seizures or alternating hemiplegia. The severity of EA6 
symptoms appears to be correlated with the extent of glutamate transporter dysfunction.
Introduction
Episodic ataxias (EAs) are rare genetic disorders characterized by recurrent episodes of cerebellar 
ataxia variably associated with additional neurologic features. Different subtypes of EA are defined 
on the basis of genetic loci and clinical manifestations.1 
The most common and best characterized subtypes of EA are EA1 and EA2. EA1 is caused by mis-
sense mutations in the KCNA1 gene encoding a subunit of neuronal KV1.1 K
+ channels.2 EA1 usually 
presents with short-lasting attacks that often are triggered by exertion, stress, or startle. Patients 
show persistent interictal motor unit activity (myokymia). EA2 is caused by mutations in the 
CACNA1A gene encoding the pore-forming subunit of neuronal CaV2.1 Ca
2+ channels.3 Mostly, non-
sense, frameshift, splice site, and missense mutations have been described, resulting in either a 
complete loss4 or partial impairment5,6 of CaV2.1 channel function. The episodes in EA2 last longer 
than in EA1, up to several hours,7 and are often associated with vertigo and migrainous headache 
and can be triggered by exercise, fatigue, and stress.8 Acetazolamide may prevent attacks.9 Between 
attacks, nystagmus usually occurs. Many patients have interictal ataxia in addition to the attacks. The 
EA3, EA4, and EA5 subtypes are rarer and less well-defined disorders compared with EA1 and EA2.1 
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The EA6 subtype was identified in a 10- year-old patient with a severe phenotype of episodic 
and progressive ataxia, seizures, alternating hemiplegia, and migraine headache.10 A heterozygous 
de novo P290R missense mutation was identified in the SLC1A3 gene by use of a candidate gene 
approach. SLC1A3 encodes the glial excitatory amino acid transporter EAAT1, which is involved in 
glutamate removal from the synaptic cleft.11,12 Functional analysis of the mutant EAAT1 protein 
showed marked reduction of glutamate uptake in vitro.10 In the present study, we performed a 
mutation analysis of the SLC1A3 gene (OM/M 600111) in 20 patients with EA2-like symptoms but 
without CACNA1A mutations. In 1 family, we found an EAAT1 mutation that segregated with the 
disease in 3 patients. Functional studies revealed a moderate impairment of glutamate reuptake.
Methods
Patients
We investigated 20 patients who were referred for molecular confirmation of EA2 in whom no muta-
tions were found in the CACNA1A gene. These patients showed typical EA2-like symptoms, including 
interictal nystagmus but no myokymia, attacks of mild ataxia with a duration of several hours, and 
a positive response to acetazolamide. Except for 2 patients from the United States, all patients came 
from Europe, mostly the Netherlands. Family members of the proband with the SLC1A3 mutation 
(Figure 1) underwent neurologic examination by experienced neurologists (S.L.M.B. and A.H.S). All 
patients gave informed consent, and the study was approved by the local review board.
Figure 1. Pedigree of the episodic ataxia family with the EAAT1 C186S mutation. Episodic ataxia is indicated by a filled black square 




Genomic DNA was isolated from peripheral leukocytes using a standard salting out extraction 
method.13 All exons and flanking intronic regions of the SLC1A3 gene were amplified by polymerase 
chain reaction (PCR), using genomic DNA as a template. Direct sequencing was performed by cycle 
sequencing (Prism Big Dye Terminators Cycle Sequencing kit; Applied Biosystems, Foster City, 
California) using the dideoxy termination method and an ABI3700 automated sequencer (Applied 
Biosystems). Two hundred healthy controls were screened for the mutation by PCR analysis of 
exon 5 and subsequent restriction digestion of PCR products with restriction enzyme AluI.
Functional studies
Functional studies10 on glutamate uptake of wild-type and mutant EAAT1 were performed as 
described previously. In brief, full-length wild-type complementary DNA (EAAT1-WT) was cloned 
into a mammalian expression vector pcDNA3.1 (Invitrogen; Carlsbad, California). The mutant 
construct (EAAT1-186S) was generated by performing sitedirected mutagenesis (QuikChange; 
Stratagene; La Jolla, California). For functional analyses of the SLC1A3 C186S mutation, 2 μg 
of wild-type (EAAT1-WT) or mutant (EAAT1-186S) EAAT1 complementary DNA constructs were 
transfected into COS7 cells. One day after transfection, the cells were dissociated and plated onto 
60-mm-diameter tissue culture dishes. The cells were incubated with 1.5 mL of 1μM L-glutamic 
acid containing 1 μCi/mL of L-[3,4-3H]-glutamic acid for 2 minutes at room temperature. A total 
of 4 independent and masked experiments were performed, each in triplicate.
Results
Genetic studies and clinical features associated with EAAT1 mutation
Mutation analysis of the SLC1A3 gene in 20 patients revealed in 1 patient a heterozygous c.556 
T>A substitution (SLC1A3 reference sequence; GenBank NM004172) that changed a cysteine to a 
serine at position 186 (C186S) of the EAAT1 protein (Figure 2A and 2B). The mutation was absent 
in 200 Dutch control individuals. C186S was identified in the proband (III-3), clinically affected 
family members II-3 and III-4, and 1 asymptomatic family member (III-2) (Figure 1).
Clinical information of the affected family members is summarized in the Table. The proband (III-
3) is a 35-year-old man who has had episodes of ataxia since early childhood. Attacks gradually 
changed over time. Initially, vertigo, nausea, and vomiting were the most bothersome symptoms. 
Later in life, truncal and gait ataxia during the attacks became more prominent. Attacks are 
often associated with nausea, vomiting, photophobia, phonophobia, vertigo, diplopia, slurred 
speech, and blurred vision. No headache was reported. Typically, attacks were provoked by 
emotional stress, fatigue, or consuming alcohol or caffeine. Attack duration was usually 
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between 2 and 3 hours. Currently, his average attack frequency is once a month. Interictal 
neurologic examination revealed a horizontal gaze-evoked nystagmus without gait or truncal 
ataxia. Interictal electroencephalographic recording revealed no epileptic activity, and magnetic 
resonance imaging revealed no abnormalities (data not shown).
Figure 2 EAAT1 C186S mutation. A, Schematic representation of the EAAT1 protein and the location of the mutated Cys186 amino 
acid in transmembrane segment 4B (indicated by a black dot) (the structure is adapted from Yernool et al14). B, Conservation of 
the mutated residue Cys186 highlighted in gray. The protein sequences were obtained from GenBank (homo sapiens, NP_004163; 
Bos taurus, NP_46411; Mus musculus, NP_683740; Rattus norvegicus, NP_062098; salamander, O57321; Danio rerio, NP_997805; 
Drosophila melanogaster, NP_477428; human EAAT2, AY066021; human EAAT3, NP_004161; human EAAT4, NM_005062; human 
EAAT5, NP_006662). C, Glutamate uptake assay in COS7 cells expressing mutant EAAT1-186S (mean [SEM], 88.2[5.5]) or wild-type 
EAAT1-186C (mean [SEM], 107.8[6.9]). The results are the mean (SEM) of the 4 experiments, each in triplicate. The values are 
picomoles of glutamate transported per milligram of protein per minute of incubation. Asterisk indicates significant reduction of 
glutamate uptake compared with wild type (P=0.029). Error bars indicate SEM. HP indicates helical hairpin.
His mother (II-3) and sister (III-4) were also diagnosed as having EA. The 56-year-old mother (II-
3) has had episodes of ataxia similar to those of the proband since elementary school. Her attacks 
are also associated with vertigo, nausea, vomiting, photophobia, phonophobia, and slurred 
speech. The attacks were not associated with headache. She now has approximately 10 attacks 
per year, which may last for several hours and can be triggered by stress. The 28-year-old sister 
(III-4) has had episodes of ataxia since the age of 14 years. Associated symptoms include vertigo, 
nausea, vomiting, and mild photophobia. Sometimes, the day after an attack, she experiences 
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bilateral headache not associated with nausea, vomiting, phonophobia, or photophobia. Reported 
triggers are exercise, fatigue, and stress. Currently, she has on average 6 attacks a year. Typically, 
attacks last several hours. Acetazolamide significantly reduced the frequency of attacks in all 3 
affected family members. 
His 40-year-old cousin (III-2) is an asymptomatic carrier of the C186S EAAT1 mutation. He 
experienced 4 attacks of migraine without aura and has tensiontype headache, but does not 
exhibit signs or symptoms related to ataxia. Individuals I-1, I-2, and II-2 were considered healthy 
based on limited heteroanamnestic information. His grandfather had died at the age of 98 years. 
His grandmother had complained about dizziness, but no neurologic examination was performed 
during her lifetime. No relevant clinical information is available for individual II-2, who died of 
an unrelated cause. Non–mutation carrier III-1 is asymptomatic.
Table. Summary of Clinical Features of Patients With Episodic Ataxia Carrying the EAAT1 C186S Mutation
Clinical Feature  Mother (II-3)  Proband (III-3)  Sister (III-4)
Age at examination, y  56 35 28
Age at onset, y  <10  3 14
Ataxia  +  +  +
Vertigo  +  +  +
Diplopia/visual blurring  -/-   +/+   -/-
Nausea/vomiting  +/+  +/+  +/+
Photophobia/phonophobia  +/+  +/+  +/-
Attack duration  Hours  Hours  Hours
Attack frequency  ~10 y  1-2 mo  ~6 y
Triggers  Emotional stress  Emotional stress,   Emotional stress,
  fatigue, alcohol,  fatigue, exercise
  caffeine
Response to acetazolamide  +  +  + 
Interictal gaze-evoked 
nystagmus  −  +  −
Headache  −  −  +
Abbreviations: +, presence; −, absence.
Functional study of EAAT1 mutation C186S
To investigate the functional consequences of the EAAT1 C186S mutation, radioactive glutamate 
uptake assays were performed in COS7 cells. The low level of endogenous glutamate uptake 
activity has long established the COS7 cells as being well suited for functional studies of 
glutamate transporters.15 We measured glutamate uptake in COS7 cells transfected with the 
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wild-type (EAAT1-186C) or the mutant construct (EAAT1-186S). An 18% reduction in glutamate 
uptake was observed in cells expressing the mutant (mean [SEM], 88.2[5.5]) compared with the 
wild-type (mean [SEM], 107.8[6.9]) EAAT1, measured in picomoles per milligram of total protein 
per minute of incubation (P=0.029; Figure 2C).
Comment
We scanned the SLC1A3 gene for mutations in 20 patients with EA2-like symptoms without 
CACNA1A mutations because of overlapping clinical features between EA2 and EA6. We found a 
novel nucleotide change c.556TA in the SLC1A3 gene, resulting in EAAT1 mutation C186S, in a 
family with EA and interictal nystagmus but without migraine, seizures, cerebellar atrophy, or 
alternating hemiplegia.
Our genetic and functional data suggest that mutation C186S is pathogenic. First, the mutation 
C186S segregated with all 3 symptomatic family members but was not identified in a large 
panel of controls. The asymptomatic mutation carrier (III-2) had migraine without aura, but 
given the relatively high prevalence of migraine it is unlikely that these attacks are caused 
by the EAAT1 mutation. Therefore, he likely represents a nonpenetrant case of EA. Second, 
Cys186 is highly conserved among species (Figure 2B). Our functional studies revealed a reduced 
glutamate reuptake for the mutant EAAT1 (Figure 2C). Cys186 resides in transmembrane segment 
4B (Figure 2A) on the outer perimeter of the human EAAT1 transporter protein that is implicated 
in intersubunit contact.15 The 4B-4C loop was recently shown to undergo substrate-dependent 
conformational changes and has been hypothesized to be important in stabilizing the trimeric 
structure of the transporter and coordinating the cooperativity for sodium binding.16
Clinical severity of EA6 appears to be well correlated with glutamate reuptake capability of mutant 
EAAT1. The P290R mutation leads to a complete loss of glutamate reuptake and is associated 
with a severe EA phenotype with months-long attacks, seizures, and alternating hemiplegia.10 
In contrast, the C186S mutation has a mild effect on glutamate reuptake and is correlated with 
a milder EA phenotype. Although it is hard to predict from cellular studies how a mild increase 
in extracellular glutamate will affect cerebellar functioning in patients, it is well known that 
ion and neurotransmitter pathways are complex and tightly regulated. Subtle changes in these 
pathways have been associated with clinical manifestations.17,18 
Since we found a mutation in only 1 of 20 patients with CACNA1A-negative EA2-like symptoms, 
other genes must be involved. Likely candidate genes are components of ion and neurotransmitter 
pathways involved in the regulation of cerebellar neuronal excitability.
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Autosomal dominant retinal vasculopathy with cerebral leukodystrophy is a microvascular 
endotheliopathy with middle-age onset. In nine families, we identified heterozygous C-terminal 
frameshift mutations in TREX1, which encodes a 3’-5’ exonuclease. These truncated proteins 
retain exonuclease activity but lose normal perinuclear localization. These data have implications 
for the maintenance of vascular integrity in the degenerative cerebral microangiopathies leading 
to stroke and dementias. 
We have previously described three families sharing common features of retinal and cerebral 
dysfunction. Visual loss, stroke and dementia begin in middle age, and death occurs in most families 
5 to 10 years later. These diseases map to 3p21.1–p21.3 (ref. 1) and are called cerebroretinal 
vasculopathy (CRV)2, hereditary vascular retinopathy (HVR)3,4 and hereditary endotheliopathy, 
retinopathy, nephropathy and stroke (HERNS)5. We now designate these illnesses as autosomal 
dominant retinal vasculopathy with cerebral leukodystrophy (RVCL) (OMIM 192315). The neuro-
vascular syndrome features a progressive loss of visual acuity secondary to retinal vasculopathy, 
in combination with a more variable neurological picture1–7. In a subset of affected individuals, 
systemic vascular involvement is evidenced by Raynaud’s phenomenon and mild liver (micronodular 
cirrhosis)2,5 and kidney (glomerular) dysfunction5. 
This retinal vasculopathy is characterized by telangiectasias, microaneurysms and retinal 
capillary obliteration starting in the macula. Diseased cerebral white matter has prominent 
small infarcts that often coalesce to pseudotumors. Neuroimaging studies demonstrate contrast- 
enhancing lesions in the white matter of the cerebrum and cerebellum. Histopathology shows 
ischemic necrosis with minimal inflammation and small blood vessels occluded with fibrin5. 
The white matter lesions resemble post-radiation vascular damage2. Ultrastructural studies of 
capillaries show a distinctive, multilamellar subendothelial basement membrane5. 
By combining haplotypes in the three RVCL families, we narrowed the disease gene to a 3-cM 
region between markers D3S1578 and D3S3564 that encompassed ~10 Mb, containing over 120 
candidate genes1. We then sequenced the full coding region and intron-exon boundaries of 33 
candidate genes within this region (Supplementary Table 1).
Here we report the identification of mutations in TREX1 (NM_033627), encoding DNA-specific 
3’ to 5’ exonuclease DNase III. In the CRV2 and HVR3,4 pedigrees, a heterozygous 1-bp insertion 
(3688_3689insG) leads to V235fs and a consequent premature stop. In HERNS5, a heterozygous 
4-bp insertion (3727_3730dupGTCA) results in a frameshift at T249 (Fig. 1a,b). 
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Figure 1 Diagram of TREX1 protein. a) TREX1 has three exonuclease domains. Mutations in italics are associated with AGS13, 
and those in boldface at the C terminus are associated with RVCL. b) Comparison of the amino acid sequence of the C terminus of 
wild-type (WT) TREX1 with RVCL associated mutations. The abnormal sequence introduced by the frameshifts is depicted in gray.
Next, we examined six families with putative RVCL (Supplementary Table 2)2,6,7. In each, we 
identified frameshift mutations affecting the C terminus of TREX1. In three, the alteration was 
V235fs, the same as that in the CRV and HVR pedigrees. Haplotype analysis suggests that they are 
not related (data not shown). We did not detect any of the mutations in panels of chromosomes 
matched by ancestry or location (Supplementary Methods). In the CRV and HERNS families, all 
affected individuals over the age of 60 (but none of the unaffected individuals over the age of 60) 
carried a TREX1 mutation (100% penetrance). In the HVR3,4 family, 10 of the 11 mutation carriers 
over 60 years of age have retinopathy.
TREX1 (DNase III) is a DNA-specific 3’ to 5’ exonuclease ubiquitously expressed in mammalian 
cells8–10. It is thought to function as a homodimer, with a preference for single-stranded DNA and 
mispaired 3’ termini8. TREX1 is a part of the SET complex11 that normally resides in the cytoplasm 
but translocates to the nucleus in response to oxidative DNA damage12.
Recently, homozygous mutations in TREX1 have been reported to cause Aicardi-Goutiere 
syndrome (AGS)13. AGS is a rare, familial, early-onset progressive encephalopathy featuring basal 
ganglia calcifications and cerebrospinal fluid lymphocytosis, mimicking congenital viral encepha-
litis14. Notably, mutations associated with AGS disrupt the enzymatic sites in TREX1. This loss of 
exonuclease function13 (Fig. 1) is hypothesized to cause the accumulation of altered DNA that 
triggers a destructive autoimmune response13. No phenotype was reported for the heterozygous 
carriers of these mutations; however, a heterozygous mutation in TREX1 causing familial chilblain 
lupus has been reported recently15.
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The distinctive clinical course and pathology of RVCL compared with AGS suggests separate 
disease mechanisms. The frameshift mutations observed in RVCL are downstream of the regions 
encoding the catalytic domains, whereas in AGS, homozygous mutations occur that alter exo-
nuclease function. The heterozygous mutations observed in RVCL did not impair the enzymatic 
activity of TREX1 (Fig. 2a), in comparison with the R114H substitution in AGS13.
To investigate how the RVCL TREX1 proteins differ from the wild-type, we performed expression 
studies using confocal microscopy on cells transfected with TREX1 tagged with a fluorescent 
protein (Fig. 2b and Supplementary Fig. 1). The wild-type TREX1 labeled with fluorescent pro-
tein (FP-TREX1) localized to the perinuclear region. In contrast, the TREX1 proteins FP-V235fs 
and FP-T249fs were diffusely distributed in the cytoplasm and the nucleus, as was the case for 
the fluorescent protein alone (Fig. 2b and Supplementary Videos 1–4 online). Protein blotting 
confirmed that the expressed proteins were of the correct size (Fig. 2c). These results suggest 
a perinuclear targeting signal within the C terminus of TREX1. Consequently, we generated a 
construct containing the C-terminal 106 amino acid residues of TREX1 (FP-C-106). This protein 
showed a perinuclear localization pattern identical to that of the wild-type TREX1 protein (Fig. 
2b). The TREX1 protein containing amino acid change R114H, found in AGS, also had the same 
pattern as the wild-type protein. In contrast, the protein with the alteration closest to the 
C terminus of TREX1, FP-287fs, was diffusely distributed, like the other two truncated proteins 
(data not shown).
Figure 2 Functional consequences of RVCL associated TREX1 mutations. a) Assessment of 3’-5’ exonuclease activity using equiva-
lent amounts of purified recombinant proteins expressed in E. coli. b) Confocal microscopy of HEK293T cells showing transiently 
expressed fluorescent protein (FP)-tagged TREX1 proteins (green), TOPRO3 staining of nuclei (red) and overlay (yellow). Similar 
expression patterns were obtained for wild-type protein and for proteins derived from constructs containing mutations associated 
with AGS and RVCL in CHO, HL-60 and HeLa cells (data not shown). c) Protein blot analysis of untransfected cells (1) and cells 
transfected with enhanced yellow fluorescent protein (eYFP) (2), wild-type TREX1 (3), TREX1 mutants (4,5) and the C-terminal 106 
amino acids (6), all linked to eYFP.
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The TREX1 proteins found in individuals with RVCL lack part of the C terminus. In haploinsuf-
ficient individuals, thismay prevent an interaction with the SET proteins and therefore may 
prevent formation of the SET complex. The SET complex is hypothesized to target DNA repair 
factors, including TREX1, to damaged DNA under conditions of oxidative stress11,12. Lack of 
sufficient TREX1 associated with the SET complex may result in failure of granzyme A–mediated 
cell death12. Alternatively, the dissemination of untethered TREX1 in the nucleus and cytoplasm 
may have detrimental effects, especially on endothelial cells. 
The clinical syndromes in these families and the study of their mutations should deepen our 
understanding of exonuclease function, homeostasis of the endothelium and events leading to 
premature vascular aging. RVCL and cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL) represent two examples of monogenic disease 
featuring a cerebral microangiopathy for which the genetic defects are now known and from 
which we can gain new insights into the origin of strokes and dementia. 
We obtained consent from all participants in this study, and the study was approved by the 
Office for Protection of Research Subjects at UCLA and the Human Research Protection Office at 
Washington University School of Medicine.
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Supplementary Material
Supplementary Fig. 1. Schematic representation of FP constructs expressed in mammalian cells. The FP was cloned at the amino-
terminus of TREX1 and mutants. A carboxyl-terminal segment of the last 106 amino acids of wild-type TREX1 was also prepared 
(C-106). The arrow indicate approximate sites of the mutations.
Supplementary Table 1. The 32 candidate genes sequenced prior to the discovery of TREX1 as the causative gene for RVCL.
Gene  Name  Gene ID  OMIM
AMIGO3 Adhesion molecule with Ig‐like 386724  N/A
 domain 3
ATRIP  ATR interacting protein  11277  606605
CACNA1D Voltage‐dependent L‐type calcium 776  114206
 channel subunit alpha‐1D
CACNA2D2 Calcium channel voltage dependent, 9254  607082
 alpha‐ 2/ Delta Subunit 2
CCR1  Chemokine (C‐C motif) receptor 1  1230  601159
CCR2  Chemokine (C‐C motif) receptor 2  1231  601267
CCR3  Chemokine (C‐C motif) receptor 3  1232  601268
CCR9  Chemokine (C‐C motif) receptor 9  10803  604738
CELSR3 Cadherin, EGF LAG seven‐pass G‐type 1951  604264
 receptor 3
CSPG5  Chondroitin sulfate proteoglycan 5  10675  606775
CTNNB1 Catenin (cadherin‐associated 1499  116806
 protein), beta 1
CX3CR1  Chemokine (C‐X3‐C motif) receptor 1  1524  601470
CXCR6  Chemokine (C‐X‐C motif) receptor 6  10663  605163
DAG1  Dystroglycan 1 (dystrophinassociated 1605  128239
 glycoprotein 1)
ENTPD Ectonucleoside triphosphate 956  603161
 diphosphohydrolase 3
GNAT1 Guanine nucleotide binding protein, 2779  139330
 alpha transducing activity
 polypeptide 1
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GPX1  Glutathione peroxidase 1  2876  138320
LAMB2  Laminin, beta 2 (laminin S)  3913  150325
MAP4  Microtubule‐associated protein 4  4134  157132
PH4 PH‐4 hypoxia‐inducible factor prolyl 54681  N/A
 4‐hydroxylase
PLXNB1  Plexin B1  5364  601053
RASSF1 Ras association (RalGDS/AF‐6) 11186  605082
 domain family 1
RHOA  Ras homolog gene family, member A  387  165390
RIS1  TMEM158 transmembrane protein 25907  N/A
 158 (RIS‐1 Ras‐induced senescence 1)
RPL29  Ribosomal protein L29  6159  601832
RPSA  Ribosomal protein SA  3921  150370
SEMA3F  Semaphorin 3F  6405  601124
Scotin  Scotin  51246 6 07290
SEMA3B Sema domain, immunoglobulin 7869  601281
 domain (Ig), short basic
 domain, secreted, (semaphoring) 3B
STAB1  Stabilin 1  23166  608560
TRAIP  TRAF interacting protein  10293  605958
VIPR1 Vasoactive intestinal peptide 7433  192321
 receptor 1
N/A, not applicable. GeneID, and OMIM identities are indicated.
Table 2. Mutations identified in TREX1 in RVCL.
#  Mutation  Frameshift  Reference  Geographical (Background)
1  3688_3689insG  V235  Grand et al  North America (European)
2  3688_3689insG  V235  Storimans et al Netherlands
   Terwindt et al
3  3727_3730dupGTCA  T249  Jen et al  North America (Chinese)
4 3688_3689insG  V235  Grand et al  North America
    (Ashkenazi‐Jewish)
5  3691_3692insA  T236  Weil et al  Germany
6  3835_3836insA  R284  Cohn et al  Australia
7  3688_3689insG  V235  Unpublished  North America
8  3688_3689insG  V235  Unpublished  Australia
9  3843_3844insG  L287  Unpublished  Netherlands
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Supplementary Videos 1-4 Legends.
Supplementary Video 1
Confocal microscopy video showing functional consequences of RVCL associated TREX1 mutations 
as modeled in transiently expressed HEK293T cells. Fluorescent protein (green) and TOPRO3 
stained nuclei (blue). Fluorescence expression pattern of fluorescent protein (FP) alone. The 
protein is diffusely distributed in the cytoplasm and in the nucleus.
Supplementary Video 2 
Confocal microscopy video showing functional consequences of RVCL associated TREX1 mutations 
as modeled in transiently expressed HEK293T cells. Fluorescent protein (green) and TOPRO3 
stained nuclei (blue). Fluorescence expression pattern of wild type TREX1 tagged with the fluo-
rescent protein (FP-TREX1). This fusion protein is found in a perinuclear compartment and is 
excluded from the nucleus.
Supplementary Video 3
Confocal microscopy video showing functional consequences of RVCL associated TREX1 mutations 
as modeled in transiently expressed HEK293T cells. Fluorescent protein (green) and TOPRO3 
stained nuclei (blue). Fluorescence expression pattern of mutant TREX1, tagged with the fluores-
cent protein (FP-V235 fs). The mutant form of TREX1 exhibits an expression pattern identical to 
the fluorescent protein (FP) alone.
Supplementary Video 4
Confocal microscopy video showing functional consequences of RVCL associated TREX1 mutations 
as modeled in transiently expressed HEK293T cells. Fluorescent protein (green) and TOPRO3 
stained nuclei (blue). Fluorescence expression pattern of carboxylterminal 106 amino acids of 
TREX1 tagged with the fluorescent protein (FP-C-106). This fusion protein is found in a peri-
nuclear compartment and is excluded from the nucleus. This pattern is identical to the native 
exonuclease, implicating this short stretch of amino acids in mediating the perinuclear localiza-
tion of the protein.
Supplemental Methods
Samples
We analyzed DNA samples from nine families with clinical symptoms of RVCL (Supplementary 
Table 2). Informed consent was obtained from all patients, in accordance with procedures and 
regulations of the Institutional Review Boards.
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Mutation detection
Genomic DNA was isolated from peripheral blood leukocytes or immortalized cell lines from con-
senting subjects as approved by IRB. In specific cases (Washington University Genome Sequenc-
ing Center), Phi29-based whole genome amplification was performed on genomic DNA samples. 
Gene sequences of candidate genes were extracted from GenBank (www.ncbi.nlm.nih.gov) and 
Ensembl (www.ensembl.org) databases. Primers to amplify the coding exons and exon-intron 
boundaries of candidate genes were designed with the PrimerDesign script that is based on the 
use of the Primer 3 program. Universal (forward and reverse) tails were added to the 5’ ends of 
amplification primers to serve as the sequencing primer sites (primer sequences and PCR condi-
tions are available on request). Direct sequencing of purified PCR products was done by using 
dye-terminator chemistry and electrophoresed on a MegaBase500 (Amersham Biosciences, Princ-
eton, NJ) capillary sequencer or either the ABI3700 or ABI3730 automated sequencer (Applied 
Biosystems, Foster City, CA). The sequence traces were assembled and scanned for variations from 
the reference sequence using the PolyScan informatics suite or Vector NTI suite 9.0.0 program 
(Invitrogen, Carlsbad, CA). The tagged variations were then manually reviewed. All detailed pro-
tocols are available on request.
For further mutational analysis of TREX1, primers were designed to amplify the coding exons of 
TREX1 (Supplementary Table 3). Purified PCR amplification products were sequenced using dye-
terminator chemistry and electrophoresed on a MegaBase500 (Amersham Biosciences, Princeton, 
NJ) capillary sequencer or an ABI3700 sequencer (Applied Biosystems, Foster City, CA). Sequenc-
ing was analyzed using PolyPhred. Anonymized control samples were screened by sequencing. 
Controls were matched with the ethnic origins of the mutations. The RVCL TREX1 mutations were 
not detected in 192 Caucasian (HD100CAU, Coriell), 192 Chinese (HD100CHI, Coriell) and 300 
Dutch control alleles.
Supplementary Table 3. Primers and PCR conditions for TREX1 exon.
Primer  Primer Sequence Forward  Primer Sequencen Reverse
1  tgtaaaacgacggccagtatggtggtgagagggacagacc  caggaaacagctatgaccaaagatgagggtctgcatggg
2  tgtaaaacgacggccagtgaatgtgctggtcccactaagg  caggaaacagctatgaccaaggctaggagcaggttggc
3  tgtaaaacgacggccagtctctccctgtgtgtggctcc  caggaaacagctatgaccttgtgacagcagatggtcttgg
4  tgtaaaacgacggccagtctaggcagcatctacactcgcc  caggaaacagctatgaccatcctgctagggaaagtgaggg
The appropriate universal sequencing primer was used for either reading the forward or reverse strand of all amplicons. Forward 
sequencing primer (5’-TGTAAAACGACGGCCAGT-3’); reverse sequencing primer (5’-CAGGAAACAGCTATGACC-3’). Incubation conditions: 
temperature, 60°C; Mg2+ concentration, 1.5 mM.
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Haplotype analysis
For 20 microsatellite markers in the chromosome 3p21.1-p21.3 region, standard PCRs were per-
formed using a PTC200 thermal cycler (Bio-Rad Laboratories, Foster City, CA). PCR products were 
analyzed on an ABI3700 sequencer (Applied Biosystems, Foster City, CA) and genotypes were 
assigned using GENESCAN and GENOTYPER software (Applied Biosystems, Foster City, CA). Two 
investigators scored genotypes independently. In addition, 13 SNPs in the region closely flank-
ing TREX1 were typed by direct sequencing. Disease haplotypes were constructed by inspection 
of segregation.
Molecular cloning, mutagenesis, expression, and purification of E. coli proteins
Mutations (V235fs, T249fs and R114H) were constructed using the cDNA clone encoding TREX1 
variant 1 (Origene TC304415) as a template for site-directed mutagenesis. Oligos used for muta-
genesis were as follows:
V235fs (5’ CATGTATGGGGGTCACAGCCTCTG 3’ and 5’ CAGAGCGTGTGACCCCCATACATG 3’)
T249fs (5’ TCTGCTGTCAGTCACAACCACTGC 3’ and 5’ GCAGTGGTTGTGACTGACAGCAGATG 3’)
R114H (5’ AGCCTTCCTGCGGCACCAGCCACAGCCCTGG and 3’ ACCAGGGCTGTGGCTGGTGCCGCAGGAAGGC).
In the case of TREX1, V235fs, T249fs and R114H, the inserts were subcloned by PCR using the 
TREX1 cDNA clone as a template into the E. coli expression vector pET28a+-1 {a derivative of 
pET28a+ (Novagen) created in house} containing an Nterminal 6x His epitope tag. Correct clones 
were transformed into the E. coli strain BL21CodonPlus (DE3)-RIL (Stratagene, La Jolla, CA). Cells 
containing the TREX1 plasmids were grown at 37°C to an Absorbance600 of 0.6. Isopropyl-1-thio-
β-D4 galactopyranoside was added to a final concentration of 1 mM and the cultures incubated 
at 37°C for an additional 3h. Cells were then harvested and the pellets were stored at -80°C. 
For purification of recombinant proteins, cells were resuspended in cold sonication buffer (50 
mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, 5 mM beta mercaptoethanol, 1 mM imidazole, and 
1mM PMSF). The cell suspension was sonicated and centrifuged at 15,000 g at 4°C for 20 min 
to obtain a cleared lysate. Histagged proteins were batch adsorbed to Ni-NTA Agarose (Qiagen, 
Valencia, CA) for 1 h at 4°C. The beads were washed extensively in wash buffer (sonication buffer 
containing 25 mM imidazole) and packed into a 5 ml polypropylene (Qiagen) column. After addi-
tional washes, fractions were collected during elution with five column volumes of elution buffer 
(sonication buffer containing 250 mM imidazole). Fractions containing His-TREX1 proteins were 
identified by SDS-PAG electrophoresis and Western blotting with an anti-HIS-HRP conjugated 
antibody (Clontech, Mountain View, CA) or, alternatively, with Coomassie Brilliant Blue staining. 
The samples were pooled, concentrated and aliquots of the purified proteins frozen at -80°C.
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Exonuclease assays
1 μg of Poly(dA) (GE Healthcare, Princeton, NJ) was labeled at the 3’ end with 32P dATP (GE 
Healthcare) using Terminal Transferase (Roche Diagnostic Corp., Indianapolis, IN). Reactions 
containing 50 mM Tris pH 8.5, 4 mM MgCl2, 1 mM DTT, 10 μg BSA, 0.01 g radiolabeled poly(dA) 
substrate, and recombinant exonuclease TREX1 protein were incubated in a total volume of 100 l 
at 37°C. Aliquots were removed at the indicated times and ethanol precipitated in the presence 
of 50 μg denatured calf thymus DNA (Sigma-Aldrich, St. Louis, MO). Ethanol-soluble radioactivity 
released into the supernatant was measured by scintillation counting.
Generation of N-terminally-tagged TREX1 constructs
To directly visualize TREX1 within the living cell, all TREX1 forms were N-terminally tagged with 
the enhanced yellow fluorescent protein (eYFP). For clarity, the epitope tag is designated hereaf-
ter as fluorescent protein (FP) tag. At the wavelength employed it gives green fluorescence. The 
FP coding sequence was excised via EcoRI/BsrGI from sT-DAF-eY 1. This fragment was utilized in 
a three-fragment ligation with EcoRI/XbaI-digested CD59dGPI 2 and the respective BsrGI/XbaI-
digested PCRderived TREX1 forms (see below). This resulted in aminoterminal tagging of TREX1 
FP-TREX1, FP-V235fs and FP-T249fs). Wild-type FP was expressed from the second cistron of sT-
DAF. Wild-type TREX1 (FP-TREX1) was used as a template DNA to generate the Aicardi-Goutieres 
R114H mutant (FP-R114H) by site-directed mutagenesis as described above. To study the effect 
on cellular localization of the carboxyl-terminus of TREX1, a FP-tagged fusion protein containing 
the last 106 amino acids of native TREX1 was generated (FPC106). A 646 bp BsrGI/BsaI fragment 
was excised from FP-TREX1, to remove the entire aminoterminus including all exonuclease sites. 
The cohesive ends were then blunted and the linearized 4532 bp fragment relegated, resulting in 
FP-C106. All PCR-derived DNA fragments and ligation products were verified by DNA sequencing.
Confocal Microscopy
HEK293T cells (7 x 105 on cover slides in 6-well plates) were transiently transfected overnight 
with 1.5 μg of each construct using TransIT-293 (Mirus, Madison, WI), according to manufac-
turer’s directions. Following two washes in PBS, the cells were fixed for 30 min at room tem-
perature (RT) in PBS containing 2% paraformaldehyde. Following two washes in PBS, the cover 
slides were incubated for 30 min at RT in PBS containing a 1/2000 dilution of Topro3 (Molecular 
Probes, Carlsbad, CA) to visualize the nuclei, washed again with PBS and mounted on slides over 
night with ProLong Gold (Molecular Probes). Samples were examined using a Zeiss LSM 510 laser 
scanning confocal microscope and images were processed using Image Examiner Software (Zeiss, 
Jena, Germany).
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Expression, SDS-PAGE, and Western blotting
Following overnight transient transfection of HEK293T cells (described above), cells were washed 
with PBS, lysed with 1% Nonidet P-40, 0.05% SDS in PBS with 2 mM PMSF for 15 min at 4ºC, 
and centrifuged at 12,000 g for 10 min. Supernatants were immediately evaluated or frozen at 
-80 ºC. The Western blot was loaded with 5 x 105 cell equivalents per lane on non-reduced and 
electrophoresed (10% SDS-PAG). Following transfer to nitrocellulose, the blots were probed with 
1:4000 dilution of monoclonal anti-GFP antibody JL-8 that recognizes both GFP and YFP (Clon-
tech Laboratories) and then HRP donkey anti-mouse IgG (Amersham Biosciences).
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disorder with a complex genetic 
background. Some 14–75% of SLE patients report neurological and psychiatric symptoms and 
are diagnosed with neuropsychiatric-SLE (NPSLE).1 Many of these patients also have cerebral 
white matter hyperintensities (WMH). The aetiology and genetic background of NPSLE is largely 
unknown. 
In 2007, mutations in the TREX1 gene, encoding the major mammalian 3′-5′ DNA exonuclease, 
were identified in nine out of 417 SLE patients.2 In addition, TREX1 has been associated with 
disorders that are often associated with cerebral WMH, migraine(-like symptoms) and other 
manifestations of brain disease.3,4 Consequently, we considered TREX1 an excellent candidate for 
NPSLE. 
Results
We scanned genomic DNA of 60 NPSLE patients (table 1) for exonic TREX1 mutations using 
direct sequencing,5 and identified a novel heterozygous p.Arg128His mutation in one NPSLE 
patient. This DNA belonged to a postmenopausal woman who was admitted to our hospital 
because of lethargy and progressive migraine-like headache for 2 weeks. Previously, she was 
diagnosed with SLE6 associated with pleuritis, Coombs positive autoimmune haemolytic anaemia, 
thrombopenia, and tested positive for antinuclear antibody (ANA) and anti-dsDNA antibodies. 
SLE manifestations were successfully treated with corticosteroids. Two years before admission, 
she was treated with prostacyclin infusions, corticosteroids and azathioprine for severe Raynaud’s 
phenomenon with imminent gangrene of the fingers. On admission, she became increasingly 
confused and obtunded. Neurological examination revealed aphasia and bilateral Babinski signs. 
General physical examination and cerebrospinal fluid analysis were normal. Laboratory tests 
for ANA, anti-ENA, anticardiolopin IgM, anti-SSA and anti-SSB were positive. Brain MRI showed 
generalised atrophy, extensive symmetric cerebral WMH and cerebellar infarcts (figure 1A,B) 
without evidence for recent ischaemia. She was diagnosed with NPSLE7 and treated for 3 days 
with daily doses of 1000 mg intravenous methylprednisolone and recovered after a few days. One 
year later she developed lupus nephritis class IV as confirmed by kidney biopsy. 
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Table 1 Characteristics of neuropsychiatric systemic lupus erythematosus patients (n=60), of which 25 patients had white matter 
hyperintensities
 n (%) n (%)
Female  56 (93)
Age (years)
  Mean±SD  37.2±13.4
  Median  37.1
SLE duration (years)
  Mean±SD  6.4±5.5
  Median  5.2
NPSLE duration (years)
  Mean±SD  1.9±3.8
  Median  0.1
Malar rash  21 (35)
Discoid rash  26 (43)
Photosensitivity  18 (30)
Oral ulcers  12 (20)
Arthritis  42 (70)
Serositis  33 (55)
Renal disorder  28 (47)
Haematological disorder  36 (60)
Immunological disorder  57 (95)
ANF  58 (97)
APS  16 (27)
aCL_IgM*  29 (48)
aCL_IgG*  39 (65)
LAC†  16 (27)
Active NPSLE  45 (75)
Inactive NPSLE  15 (25)
Aseptic meningitis  2 (3)
Cerebrovascular disease  24 (40)
Headache  15 (25)
Mononeuropathy  2 (3)
Movement disorder  1 (2)
Myelopathy  3 (5)
Cranial neuropathy  4 (7)
Plexopathy  1 (2)
Polyneuropathy  1 (2)
Seizures  12 (20)
Acute confusional state  4 (7)
Cognitive dysfunction  19 (32)
Mood disorder  4 (7)
Psychosis  4 (7)
*Data unavailable for one patient, †data unavailable for seven patients. aCL, anticardiolipin; ANF, antinuclear factor; APS, antiphos-
pholipid syndrome; LAC, lupus anticoagulans; NPSLE, neuropsychiatric-SLE; SLE, systemic lupus erythematosus.
Discussion
We suggest that mutation p.Arg128His is causing NPSLE in the patient for several reasons. The 
mutation was not found in 400 control chromosomes, nor in 1712 healthy individuals, previously 
screened by Lee-Kirsch et al.2 Furthermore, the mutation is located within the highly conserved 
second exonuclease domain (figure 1C). Notably, a crystallisation study of TREX1 by de Silva and 
colleagues8 showed that specific hydrogen bonds of Arg128 are involved in the destabilisation of 
double-stranded DNA to provide single-stranded DNA for the enzyme active site. Ultimate proof 
of pathogenicity should be provided by future functional studies. 
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Figure 1 MRI abnormalities in the p.Arg128His TREX1 mutation carrier with neuropsychiatric systemic lupus erythematosus. 
(A) FLAIR image shows symmetric white matter hyperintensities in the capsula interna, capsula externa and periventricular white 
matter. (B) T2-weighted image shows three small infarcts in the right cerebellar hemisphere as indicated by the white arrow. 
(C) Schematic representation of the TREX1 protein, showing the position of p.Arg128His as well as previously identifi ed SLE muta-
tions. 2 Exo I, II and III represent the exonuclease regions. PII represents the polyproline II motif and TMH the transmembrane helix.
Here we confirm TREX1 as a genetic factor in SLE. Moreover, we were able to show involvement of 
TREX1 in one out of 60 NPSLE patients, of which 25 had extensive WMH. Clinical characteristics of 
NPSLE patients with or without WMH were not different, except perhaps for a higher occurrence 
of cognitive dysfunction in the group with WMH (52 vs 17%) (data not shown). No exonic TREX1 
DNA variants were identified in the other 59 NPSLE patients refl ecting the genetic heterogeneity 
in NPSLE.
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Migraine is a common episodic neurological disorder, typically presenting with recurrent attacks 
of severe headache and autonomic dysfunction. Apart from rare monogenic subtypes, no genetic 
or molecular markers for migraine have been convincingly established. We identified the minor 
allele of rs1835740 on chromosome 8q22.1 to be associated with migraine (P = 5.38×10−9, odds 
ratio = 1.23, 95% CI 1.150–1.324) in a genome-wide association study of 2,731 migraine cases 
ascertained from three European headache clinics and 10,747 population-matched controls. 
The association was replicated in 3,202 cases and 40,062 controls for an overall meta-analysis 
P value of 1.69×10−11 (odds ratio = 1.18, 95% CI 1.127–1.244). rs1835740 is located between 
MTDH (astrocyte elevated gene 1, also known as AEG-1) and PGCP (encoding plasma glutamate 
carboxypeptidase). In an expression quantitative trait study in lymphoblastoid cell lines, 
transcript levels of the MTDH were found to have a significant correlation to rs1835740 (P = 
3.96×10−5, permuted threshold for genome-wide significance 7.7×10−5). To our knowledge, our 
data establish rs1835740 as the first genetic risk factor for migraine.
Introduction
The recent boom of genome-wide association studies (GWAS) has had a major impact on our 
current view of genetic susceptibility to common traits and complex disorders. However, central 
nervous system disorders are under-represented among the conditions for which such associations 
have been found1. To our knowledge, no GWAS or common, robustly established linked genetic 
variants have been reported for major episodic neurological disorders (ICD-10 codes G40–G44, 
migraine, epilepsy and ataxias). However, there is substantial genetic information for rare 
Mendelian forms of migraine, epilepsy and ataxia, which classifies them as channelopathies 
associated with compromised neurotransmitter homeostasis2. So far, there is no evidence for the 
contribution of ion channel variants in common forms of these diseases3,4.
Migraine is an episodic neurological disorder with complex pathophysiology, affecting 8% of 
males and 17% of females5 in the European population. Migraine ranks among the 20 most 
disabling diseases and has been estimated as the most costly neurological disorder, with a 
considerable impact on public health6. Clinically, the International Classification of Headache 
Disorders (ICHD-II7) recognizes two main common forms of migraine: migraine with aura and 
migraine without aura. The two forms are distinguished from each other based on the presence 
of aura, a period of variable and diverse neurological symptoms that precede the headache phase. 
Individuals may have attacks of only migraine without aura, or only migraine with aura, or 
they may have a combination of both types in variable proportions. There is debate among the 
scientific community whether migraine with aura and migraine without aura attacks represent 
GWA study for migraine with aura 6.1
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two distinct disorders or if they are merely variations of a single disease having a common 
complex genetic background. Migraine headache is believed to be caused by activation of the 
trigeminovascular system and the aura by cortical spreading depression, a slowly propagating 
wave of neuronal and glial depolarization8–10. However, these are considered to be downstream 
events, and it is unknown how migraine attacks are initiated.
To identify variants associated with the common forms of migraine, we carried out a two-stage 
GWAS in seven European migraine case collections (six clinic-based and one population-based) 
(Supplementary Fig. 1). In the discovery stage, we studied 3,279 migraineurs (1,124 Finnish, 
1,276 German and 879 Dutch individuals) recruited from headache clinics and genotyped 
using Illumina arrays against population-matched controls (10,747 individuals) recruited from 
preexisting population-based GWAS (Supplementary Note). In the replication stage, a further 
3,202 cases and 40,062 population-matched controls from Iceland, Denmark, The Netherlands 
and Germany were studied. 
Results
Diagnoses were made by headache experts using a combination of questionnaires and individual 
interviews that were based on the ICHD-II guidelines7. Due to the overlap between individuals 
having migraine with aura and those having migraine without aura, we analyzed the following 
diagnostic subgroups: (i) ‘all migraine’, defined as all individuals with migraine irrespective of 
subtype; (ii) ‘migraine with aura only’, defined as individuals who only have attacks where aura 
is present; (iii) ‘both migraine with aura and migraine without aura’, defined as individuals with 
attacks both with and without aura; and (iv) ‘migraine without aura only’, defined as individuals 
with only attacks of migraine without aura. 
We used a multipopulation Cochran-Mantel-Haenszel (CMH) association analysis and a significance 
threshold of P ≤ 5×10−8 in our analyses. In the discovery sample, 2,731 cases and 10,747 controls 
(Table 1) passed quality control steps, and 429,912 markers were successfully genotyped (Online 
Methods). A quantile-quantile plot of the CMH analysis (Supplementary Fig. 2) and an overall 
inflation factor (λ) of 1.08 were used as final quality control measures. 
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Table 1 Study populations used in the two stages of the study
      Individuals  Individuals  Individuals
      with both  with  with
   Total  Men (%)  Women (%)  MA and MO (%)  MA only (%)  MO only (%) 
Discovery stage 
Finland  Cases  1,064  19.8  80.2  94.4  5.6   0.0
  Controls  3,513  47.4  52.6  –  –   –
Germany  Cases  1,029  18.9  81.1  70.2  29.8   0.0
  Controls  2,317  45.1  54.9  –  –   –
The Netherlands  Cases  655  17.2  82.8  65.9  34.1   0.0
  Controls  4,917  41.7  58.3  –  –   –
Total GWAS
  Cases  2,731  18.8  81.2  78.5  21.5   0.0
  Controls  10,747  44.3  55.7  –  –   –
Replication stage
Iceland  Cases  900  22.5  77.5  63.0  21.8   15.2
  Controls  35,221  57.4  42.6  –  –   –
Denmark  Cases  1,116  22.4  77.6  26.3  43.3   30.5
  Controls  1,353  44.5  55.5  –  –   –
The Netherlands  Cases  349  18.3  81.7  59.8  40.2   0.0
  Controls  2,082  43.9  56.1  –  –   –
Germany  Cases  837  11.6  88.4  0.0  0.0   100.0
  Controls  1,406  37.3  62.7  –  –   –
Total replication  Cases  3,202  19.1  80.9  33.8  25.6   41.0
  Controls  40,062  55.6  44.4  –  –   –
Overall  Cases  5,933  19.0  81.0  54.4  23.7   22.1
meta-analysis Controls  50,809  53.2  46.8  –  –   –
MA, migraine with aura; MO, migraine without aura.
Only one marker, rs1835740 on chromosome 8q22.1, showed significant association with migraine 
in the multipopulation CMH analysis (Fig. 1 and Supplementary Fig. 3). Eleven further loci were 
found with P ≤ 5×10−5 (Supplementary Table 1). The minor allele (A) of marker rs1835740 was 
associated with migraine with P = 5.38×10−9 and odds ratios ranging between 1.21 and 1.33 (Table 
2). Two nearby markers with the highest linkage disequilibrium (LD) to rs1835740 (rs982502, r2 
= 0.59, P = 1.34×10−4 and rs2436046, r2 = 0.69, P = 1.78×10−5) also showed association with 
migraine (Supplementary Table 2). Haplotype analysis detected a 27-kb haplotype (P = 5.35×10−8) 
(Supplementary Fig. 4 and Supplementary Table 3). In the HapMap Phase II data11, the variant is 
located between two close recombination hotspots, and analysis using the ssSNPer program12 
demonstrated that no long-range LD to rs1835740 exists within a 5-Mb window, strongly 
suggesting that the causative variant in this region is tagged by the minor allele of rs1835740 
(Fig. 1). The 2-Mb window around rs1835740 was also imputed against the 1000 Genomes data 
(August 2009 release), but no other marker showed evidence of association exceeding that for 
rs1835740 (Fig. 1). Conditional analysis of the SNPs around rs1835740 showed no additional 
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independent signals (Supplementary Table 2). The proportion of genetic variance explained by 
the rs1835740 variant was estimated to be between 1.5% and 2.5%, depending on the heritability 
estimate used, and the population attributable risk was estimated to be 10.7% using previous 
methodology13.
Figure 1 Cochran-Mantel-Haenszel association results for combined analysis of the three study populations between 97.5 Mb and 
99.0 Mb on chromosome 8q22.1. Diamonds show the position and P value for each marker in the region, with colors representing 
the extent of linkage disequilibrium (measured in r2) with the marker rs1835740, and blue circles indicate the locations and 
P-values of the imputed markers. For rs1835740, P-values are shown for both the original GWAS and the meta-analysis of all 
migraine samples in the study (denoted by asterisk). The blue graph shows the local recombination rate based on HapMap Phase 
II data11. The red line denotes the threshold for genome-wide significance (P ≤ 5×10−8). This figure was generated using a modified 
version of the script available at http://www.broadinstitute.org/node/555.
To confirm and extend our results, we performed a replication study on the only marker with 
genome-wide significance in the discovery stage: rs1835740. The diagnostic subgroups used in 
the discovery stage were also applied to the replication stage. Replication was successful in two 
‘migraine with aura only’ subsets (Danish, P = 0.015, OR = 1.29 and Icelandic, P = 0.038, OR = 
1.36), in the Icelandic ‘migraine without aura’ set (P = 0.0292, OR = 1.18) and in the Icelandic 
‘all migraine’ group (P = 0.010, OR = 1.18) (Table 2). Overall, the A allele of marker rs1835740 was 
overrepresented (OR = 1.05–1.36; Table 2) in each subset of all replication samples except in the 
Danish ‘both migraine with aura and migraine without aura’ group (OR = 0.99). The effect was 
consistently stronger in the ‘migraine with aura only’ groups than other migraine subgroups (Fig. 
2). It should be noted that the majority of the groups that did not reach formal replication were 
small and had limited power. Meta-analysis was conducted using the CMH test for each diagnosis 
subgroup alone as well as for all migraine samples together, with the latter group showing a final 
P = 1.69×10−11 (Table 2).
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Table 2 Association results for marker rs1835740 using the CMH test 
  Diagnosis  n (cases)  n (controls)  Case alleles (MAF)  Control alleles (MAF)  P-value  OR (95% CI)
GWAS 
Finland  All migraine  1,064  3,513  548/1,576 (0.258)  1,553/5,461 (0.221)  0.000447  1.22 (1.093–1.368)
Germany  All migraine  1,029  2,317  515/1,537 (0.251)  998/3,632 (0.216)  0.00142  1.22 (1.079–1.378)
The Netherlands  All migraine  655  4,917  329/963 (0.255)  2,086/7,742 (0.212)  0.000876  1.26 (1.098–1.437)
Discovery stage
  MA only  589  10,747  313/859 (0.267)  4,637/16,385 (0.216) 3.07×10−5  1.33 (1.164–1.528)
  Both MA & MO  2,142  10,747  1,071/3,193 (0.251) 4,637/16,385 (0.216) 2.69×10−6  1.21 (1.115–1.304)
  All migraine  2,731  10,747  1,384/4,052 (0.255) 4,637/16,385 (0.216) 5.38×10−9  1.23 (1.150–1.324)
Replication stage
Denmark  MA only  483  1,353  244/722 (0.253)  562/2,144 (0.208)  0.015  1.29 (1.050–1.583)
  Both MA & MO  293  1,353  121/465 (0.206)  562/2,144 (0.208)  0.951  0.99 (0.785–1.255)
  MO only  340  1,353  153/527 (0.225)  562/2,144 (0.208)  0.333  1.11 (0.900–1.362)
  All migraine  1,116  1,353  518/1,714 (0.232)  562/2,144 (0.208)  0.069  1.15 (0.989–1.344)
Iceland  MA only  137  35,221  70/204 (0.255)  14,212/56,230 (0.202) 0.0380  1.36 (1.017–1.812)
  Both MA & MO  196  35,221  82/310 (0.209)  14,212/56,230 (0.202) 0.7256  1.05 (0.812–1.350)
  MO only  567  35,221  261/873 (0.230)  14,212/56,230 (0.202)  0.0292  1.18 (1.017–1.376)
  All migraine  900  35,221  413/1,387 (0.229)  14,212/56,230 (0.202)  0.010  1.18 (1.041–1.334)
The Netherlands  MA only  212  2,082  100/324 (0.236)  909/3,255 (0.218)  0.406  1.11 (0.873–1.399)
  Both MA & MO  137  2,082  66/208 (0.241)  909/3,255 (0.218)  0.382  1.14 (0.853–1.513)
  All migraine  349  2,082  166/532 (0.238)  909/3,255 (0.218)  0.250  1.12 (0.925–1.350)
Germany  MO only  837  1,406  396/1,278 (0.240)  629/2,183 (0.224)  0.3206  1.08 (0.932–1.241)
  MO onlya  837  541  396/1,278 (0.240)  218/864 (0.201)  0.0307  1.23 (1.019–1.480)
Meta-analysis 
  All “MA only”  1,421  49,403  727/2,109 (0.256)  20,320/78,464 (0.206)  6.98×10−8  1.29 (1.173–1.408)
  All “Both MA & MO”  2,768  49,403  1,340/4,176 (0.243) 20,320/78,464 (0.206)  1.09×10−5  1.17 (1.089–1.248)
  All “MO only”  1,744  37,980  810/2,678 (0.232)  15,403/60,557 (0.203)  0.0105  1.12 (1.028–1.230)
  All “All migraine”  5,933  50,809  2,877/8,963 (0.243) 20,949/80,647 (0.206)  1.69×10−11  1.18 (1.127–1.244)
MA, migraine with aura; MO, migraine without aura. Genome-wide significant values and successful replications are shown in boldface. 
aValues in this row were calculated after excluding an outlier control sample. The German replication control set consisted of several small 
samples. The largest of these had a considerably deviating minor allele frequency (MAF) (MAF = 0.238, n = 865) compared to other 
German (average MAF = 0.216, n = 3,260) and Central European control sets (average MAF = 0.212, n = 9,560). Thus, values with both 
including and excluding the outlier control sample are presented in the case allele and control allele columns. The meta-analysis value 
includes all control samples (without the outlier control group, “all migraine without aura samples,” P = 0.00107, OR = 1.18, 95% CI 
1.068–1.298 and “all migraine samples,” P = 8.43 × 10−13, OR = 1.20, 95% CI 1.143–1.264.
Marker rs1835740 is located between two potentially interesting candidate genes, MTDH and PGCP. 
We analyzed the effect of this marker’s genotype on the expression of genes within a 2-Mb window 
in fibroblasts, primary T cells and lymphoblastoid cell lines (LCL) obtained from umbilical cords14. 
In the expression quantitative trait locus (eQTL) analysis, the rs1835740 genotype was found to 
have significant correlation to the transcript levels of the nearby MTDH gene in LCLs (Table 3 and 
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Supplementary Table 4), with the risk allele A being associated with higher expression levels 
(Fig. 3). This is in line with previous studies, which have proven that expression analyses in LCL 
cells are informative in neurological and neuropsychiatric traits15–17. No significant association 
was detected in fibroblasts or primary T cells. The eQTL analysis suggested that rs1835740 is a 
cis regulator of MTDH in LCLs.
Figure 2 For each dataset, the horizontal line indicates the 95% CI, and the number above the line indicates the point estimate of 
the odds ratio. MA only, individuals whose attacks are always accompanied with aura; both MA, MO, individuals with attacks with 
and without aura; MO only, individuals whose attacks never include aura.
Table 3 Association of rs1835740 genotype with gene expression levels
SNP  Gene  Strand SNP  coordinate  Gene start  Distance  SRC P
rs1835740  UQCRB  −  98,236,089  97,311,911  924,178  0.0013226
rs1835740  MTDH  +  98,236,089  98,725,583  489,494  0.0000396a
rs1835740  HRSP12  −  98,236,089  99,183,743  947,654  0.0028748
Genes with nominal or higher P values of expression association to rs1835740 genotype in the Spearman rank correlation
test are shown.
aThis value surpassed the significance threshold 7.7×10−5 (corresponding to a 0.001 permutation threshold after 10,000 permuta-
tions). Gene start refers to the location of 5′ end of the gene if on the positive strand and the 3′ end if on the negative strand. 
Locations and distances are given in base pairs and are according to NCBI build 36. SRC, Spearman rank correlation.
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Figure 3. A box-plot of the quantified expression values for MTDH/AEG-1, ordered based on sample genotype of rs1835740. 
Normalised expression levels in lymphoblastoid cell lines using Illumina’s WG-6 v3 Expression BeadChip array shown. In each group, 
the small pyramid indicates median value, the shaded area represents the lower and upper quartiles, and the crosses show the 
minimum and maximum values in the expression data.
Discussion
The location of the associating sequence variant, rs1835740, between two genes involved in 
glutamate homeostasis, PGCP and MTDH, suggests that this region contains elements that could 
regulate either or both of these flanking genes; the eQTL analysis pointed to the latter. Although 
MTDH has mainly been studied in relation to carcinogenesis18, previous studies in cultured as-
trocytes have shown that MTDH downregulates SLC1A2 (also known as EAAT2 and GLT-1)18–22, 
the gene encoding the major glutamate transporter in the brain. Furthermore, knock-out mice 
lacking the EAAT2 protein from their brains have been shown to suffer from lethal spontaneous 
epileptic seizures23. Despite the limitations in extrapolating eQTL findings from LCL cells directly 
to brain tissue, these data suggest a plausible link between the identified variant and glutamate 
regulation. This is a tempting hypothesis, as this neurotransmitter has long been suspected to 
play a key role in migraine pathophysiology24. 
Although the evidence provided here is indirect, accumulation of excess glutamate in the synap-
tic cleft through downregulation of EAAT2 or an increase in PGCP activity (or both) would pro-
vide a putative mechanism for the occurrence of migraine attacks. It is reasonable to speculate 
that this accumulation can increase susceptibility to migraine through increased sensitivity to 
cortical spreading depression, the likely mechanism for the migraine aura9,10, as well as through 
glutamate involvement in central sensitization, which has been postulated to be the underlying 
mechanism of allodynia during a migraine attack25.
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Neither this study nor our previous study3 yielded evidence for association of ion channel 
genes to common forms of migraine. Thus, even if the contribution of ion channel genes is well 
established in Mendelian forms of paroxysmal neurological disorders, such as familial hemiplegic 
migraine (FHM)26–29, their direct role in more common forms of paroxysmal neurological disorders 
remains open. Interestingly, previous studies suggested that the imbalance of glutamate release 
and clearance is a key component of the pathogenesis of FHM; the underlying mutation in 
FHM lies in CACNA1A, ATP1A2 or SCN1A30,31. The results of the present study support the 
hypothesis that complementary pathways such as the glutamate system may tie the Mendelian 
channelopathies with the pathogenetic mechanisms of more common forms of episodic neurological 
disorders, such as migraine. Alterations in the functionally related EAAT1 transporter have been 
identified in other episodic phenotypes (such as episodic ataxia 6 (ref. 32) and a phenotype 
with episodic ataxia, hemiplegia and seizures33), providing an example of the link between EAAT 
transporters and episodic disorders. Future studies should be conducted to specifically test this 
hypothesis.
In summary, to our knowledge, we have identified the first robust genetic association to mi-
graine. As our cases were mainly selected from specialized headache clinics, subsequent studies 
are needed to establish the contribution of rs1835740 in population-based migraine cohorts. 
These population-based cohorts may represent a different severity spectrum and possibly also 
a somewhat different underlying combination of genetic susceptibility variants. The effect of 
rs1835740 is stronger in individuals with migraine with aura than in those with migraine with-
out aura, but further studies are needed to confirm the role of the variant in different migraine 
subgroups. This variant explains only a small fraction of the overall genetic variance in migraine, 
and future GWAS, perhaps with different ascertainment schemes, will likely identify additional 
loci explaining more of the genetic variance.
Methods
Methods and any associated references are available in the online version of the paper at http://
www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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We jointly analyzed samples from three migraine with aura collections from Finland, Germany 
and The Netherlands with population-matched controls obtained from preexisting studies. This 
discovery phase was followed by a replication study of the top SNP, rs1835740, in samples from 
individuals with migraine from Denmark, Iceland, The Netherlands and Germany. Characteristics 
of each study sample are described in Table 1, and the recruitment and ascertainment of cases 
and controls are described in the Supplementary Note. 
Discovery stage genotyping 
DNA was extracted from the subjects’ blood samples using standard methods. Genotyping of the 
GWAS samples was done at the Wellcome Trust Sanger Institute on the Illumina 610K (for the 
Finnish and German samples) and the Illumina 550K (for the Dutch samples) SNP microarrays 
following the Infinium II protocol from the manufacturer (Illumina Inc.). Genotype calling was 
performed using the Illuminus software34.
Replication stage genotyping 
For the replication study, all Danish cases and 459 migraine-free controls were genotyped using 
the Centaurus platform (Nanogen Inc.), and 904 additional controls were genotyped at deCODE 
genetics using the Illumina HumanHap650 BeadArray. The Icelandic cases and controls were gen-
otyped using the Illumina HumanHap 317K, 370K, 610K or 1M bead arrays at deCODE genetics. 
The Dutch replication cohort was genotyped using the TaqMan technology (Applied Biosystems, 
Life Technologies) at Leiden University Medical Center. The German replication cases were geno-
typed using Illumina HumanHap 610K array at the Institute of Human Genetics at the Helmholtz 
Zentrum, Munich.
Expression study
The GenCord resource, a collection of cell lines derived from umbilical cords of 75 newborns of 
Western European origin born at the maternity ward of the University of Geneva Hospital, was 
used for the expression study. Sample collection was performed on full-term or near-full-term 
pregnancies to ensure homogeneity for sample source age. Three cell types were derived: (i) 
primary fibroblasts, (ii) LCLs and (iii) primary T cells14. Total RNA was extracted from these cells 
and two one-quarter-scale MessageAmp II reactions (Ambion) were performed for each extrac-
tion with 200 ng of total RNA. 1.5 μg of cRNA was hybridized to Illumina’s WG-6 v3 Expression 
BeadChip array to quantify transcript abundance35. Intensity values were log2 transformed and 
normalized independently for each cell type using quantile normalization for sample replicates 
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and median normalization across all individuals. Each cell type was renormalized using the mean 
of the medians of each cell type’s expression values. DNA samples were extracted from umbilical 
cord tissue LCLs with the Puregene cell kit (Gentra-Qiagen), and genotyping was performed using 
the Illumina 550K SNP array (Illumina Inc.) to obtain the SNP genotypes for the samples.
Statistical analysis of the genome-wide scan data 
Stringent per-SNP and per-sample limits were implemented in order to obtain high-quality data. 
Quality control measures were as follows: exclusion of samples with call rates <97%, non-compa-
rable ancestry as measured using multidimensional scaling plots from PLINK36, possible contami-
nation as identified by being an extreme heterozygosity outlier and cryptic relatedness (low-level 
relatedness to a large number of samples) and non-cryptic relatedness of πˆ >12.5%. From the 
initial 3,279 cases and 12,369 controls, 2,731 cases and 10,747 controls passed all quality control 
criteria, and 531 cases and 1,622 controls were excluded. The majority of case exclusions were 
due to quality issues on the 550K chips, and the majority of control exclusions were due to low-
level relatedness in the Dutch control set. SNPs were excluded for having a minor allele frequency 
of <1% or for departing from Hardy-Weinberg equilibrium with P < 10−6 in cases or controls. Only 
completely overlapping SNPs from the three populations were used, leaving a total of 429,912 
SNPs for analysis. To ascertain whether the control samples were properly matched to the cases, 
a population-specific inflation factor and an overall genomic inflation factor (λ) were estimated 
using the median χ2 value from a 1 degree-of-freedom allelic χ2 test. For the Finnish samples, 
λ = 1.05; for the German samples, λ = 1.07; for the Dutch samples, λ = 1.09; and the overall λ = 
1.08, suggesting reasonably well matched controls in each case. Differences between cases and 
controls were assessed between each SNP and disease status using a two-tailed CMH test for 2 × 
2 × K stratified data (where K = 3), as implemented in PLINK v1.06. To exclude long-range LD for 
the identified variant, we used the program ssSNPer12 to demonstrate that no SNP within a 5-Mb 
window had high LD to rs1835740 in HapMap Phase II data.
Conditional analysis for secondary effects
In addition to rs1835740, two other SNPs on 8q22.1, rs2436046 and rs982502, showed a CMH 
P < 10−3 (Table 2 and Fig. 2). Based on our data, rs2436046 (r2 = 0.68) and rs982502 (r2 = 0.59) 
are in moderate LD with rs1835740. To evaluate whether these signals were independent from 
the top SNP association signal, the association between migraine and SNP alleles was tested us-
ing logistic regression, conditioning on rs1835740 as implemented in PLINK v1.06. Conditioning 
on rs1835740, no evidence of additional independent signals was found either for rs2436046 or 
rs982502 (P = 0.89 and P = 0.47) (Supplementary Table 3), suggesting that the moderate associa-
tion of rs2436046 and rs982502 observed in the CMH test is the result of these SNPs being in LD 
with rs1835740.
126
Meta-analysis of discovery and replication samples
The CMH test was used for the meta-analysis, with a nominal covariate used to distinguish each 
sample collection from the others. For the replication in Icelandic and Danish samples, associa-
tion analysis was carried out using a likelihood procedure37, and results were adjusted for related-
ness by dividing the χ2 statistics by an inflation factor estimated through simulation38.
Imputation 
For each cohort, imputation of the untyped markers in the 2-Mb region around rs1835740 
was carried out using IMPUTE v2 with the recommended options39. Haplotypes from the 1000 
Genomes Project (August 2009 release) and haplotypes from HapMap Phase 3 were used as 
reference panels.
eQTL analysis
Association between genotypes and expression was analyzed using Spearman rank correlation 
for all SNPs with a 2-Mb window centered on the transcription start site of the gene. Significance 
was assessed by comparing the observed P values at a 0.001 threshold with the minimum P values 
from each of 10,000 permutations of the expression values relative to genotypes35.
URLs 
Control populations: Finland—Health2000 study, http://www.nationalbiobanks.fi; Finland—
Helsinki Birth Cohort study, http://www.nationalbiobanks.fi; Germany—KORA S4/F4 study, 
http://www.helmholtz-muenchen.de/kora; Germany—PopGen study, http://www.popgen.de; 
Germany—HNR study, http://www.recall-studie.uni-essen.de/recall_info.html; Illumina iContr-
olDB, http://www.illumina.com; The Netherlands—Rotterdam I and III studies, http://www.
epib.nl/research/ergo.htm; the Netherlands—Lumina study, http://www.lumc.nl/hoofdpijn. 
Other URLs: International Headache Genetics Consortium, http://www.headachegenetics.org; 
ssSNPer, http://gump.qimr.edu.au/general/daleN/ssSNPer/; GWAS plotter, http://www.broadin-
stitute.org/node/555; HapMap Phase 2 and 3 data, http://www.hapmap.org.
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Supplementary Material
Supplementary Figure 1. Study design. In the initial study, migraine with aura (MA) patients from three clinic-based collections 
were analyzed in a joint genome-wide association analysis. The most significant association signal was replicated in an independent 
Danish clinic-based sample and an Icelandic population-based sample, containing MA and migraine without aura (MO) samples, as 
well as in a German clinic-based MO-specific sample.
Supplementary Figure 2. Quantile-quantile plot of the results in the Cochran-Mantel-Haenszel analysis 
Asterisk denotes marker rs1835740. Black line represents the distribution of p-values under the null given study inflation factor 
lambda of 1.08.
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Supplementary Figure 3. Genome-wide Cochran-Mantel-Haenszel results for association between each marker and migraine with 
aura in the combined analysis of the three initial study populations. Red line denotes the threshold of genome-wide significance  
(p ≤ 5×10-8). Only marker rs1835740 on 8q22.1 exceeded this threshold.
Supplementary Figure 4. Nine SNP sliding window haplotype analysis and local haplotype structure around marker rs1835740 on 
chromosome 8q22.1. In the upper part of the figure, the black pyramids show single-marker association results for each marker. 
The horizontal lines show the length and overall P-values for the nine marker sliding windows in the haplotype analysis. The lower 
part of the figure shows the Haploview D’ matrix in the GWA study analysis data, with estimated LD blocks using the Gabriel et al. 
method1. Black stars denote the location of rs1835740 and the black arrows denote the 3’ end of PGCP in either part of the figure
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Supplementary tables
Supplementary Table 1. Association signals with p ≤ 5×10-5 and with multiple nearby associating SNPs
SNP  Chr  Location  P-value  OR  95% CI  Location  Gene 
rs12084862  1  244269837  8.20x10-6  1.17  1.09-1.25  intragenic  SMYD3 
rs17528324  2  118572626  4.13x10-6  1.27  1.15-1.41  intragenic  INSIG2 
rs17862920  2  234492734  1.26x10-5  0.776  0.693-0.870  intragenic  TRPM8 
rs2038761  6  2625766  2.02x10-5  0.865  0.809-0.925  intragenic  MYLK4 
rs6456880  6  29071227  2.18x10-5  0.873  0.819-0.929  intragenic  ZNF311 
rs7753655  6  49644523  4.29x10-6  0.852  0.796-0.912  intergenic  - 
rs10888075  8  13804790  1.04x10-5  1.21  1.11-1.31  intergenic  near SGCZ 
rs10111769  8  21003036  1.49x10-5  1.15  1.08-1.23  intergenic  - 
rs2042600  11  19709275  2.28x10-5  0.876  0.824-0.932  intragenic  NAV2 
rs3794331  13  44951545  2.70x10-5  1.28  1.14-1.43  intragenic  COG3 
rs473422  15  56453633  1.03x10-5  0.864  0.820-0.922  intergenic  near AQP9
Footnote: Locations and distances in basepairs, according to NCBI build 36. Only the SNP with the lowest p-value is reported for 
each locus.
Supplementary Table 2. Conditional analyses for the two SNPs with moderate linkage disequilibrium to rs1835740 in chromosome 
8q22.1
Chr  SNP A  SNP B  r2  SNP A P-value  SNP B P-value  SNP B given A 
8   rs1835740  rs2436046  0.69  5.12x10-9   1.78x10-5   0.892 
8   rs1835740  rs982502  0.59  5.12x10-9   1.34x10-4   0.4
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Supplementary Table 3. Nine SNP sliding window haplotype analysis on the chromosome 8q22.1 associated region 
from Supplementary Figure 2
Haplotype  First SNP  Last SNP  Chi-sq.  D.f.  Overall P-value 
1   rs1431890  rs1835740  43.07  16  2.730x10-04 
2   rs10504970  rs982502  43.10  17  4.643x10-04 
3   rs920576  rs1155199  41.37  13  8.291x10-05 
4   rs2436051  rs7845920  48.48  14  1.093x10-05 
5   rs16895256  rs7845940  47.68  12  3.553x10-06 
6   rs17737465  rs1431884  46.52  10  1.156x10-06 
7  rs2436046  rs6990629  51.62  9  5.327x10-08 
8   rs2436047  rs1155021  48.93  10  4.196x10-07 
9   rs1835740  rs1835742  53.46  10  6.107x10-08 
10  rs982502  rs11783877  45.23  8  3.327x10-07 
11  rs1155199  rs4734357  41.91  8  1.410x10-06 
12  rs7845920  rs7822798  39.34  9  9.995x10-06 
13  rs7845940  rs7838062  32.98  8  6.208x10-05
The nine SNP window in bold is the one referred to in the text. N.B. haplotype value shown in text is for the single haplotype, above 
values for the association of the whole haplotype distribution.
Supplementary Table 4. SNPs with nominal or higher p-values for association with expression levels of MTDH/AEG-1
SNP  Gene SNP  coordinate  Gene start  Distance  SRC P-value 
rs11783750  MTDH/AEG-1  98 865 219  98 725 583  139 636  0.0018741 
rs10105830  MTDH/AEG-1  98 307 895  98 725 583  417 688  0.0004235 
rs1835740  MTDH/AEG-1  98 236 089  98 725 583  489 494  0.0000396* 
rs7845920  MTDH/AEG-1  98 247 132  98 725 583  478 451  0.0014652
Footnote: * indicates surpassing the significance threshold 7.7 x 10-5 (corresponding to a 0.001 permutation threshold after 10,000 
permutations). SRC = Spearman rank correlation. Locations and distances in basepairs, according to NCBI build 36. Numbers in bold 
are statistically significant.
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Supplementary Note: Clinical subject ascertainment and control samples 
Ethical aspects
Written informed consent was obtained from all participants, and the study was approved by 
the respective local research ethics committees of the Helsinki University Central Hospital, Pain 
Clinic Kiel in Kiel, the Department of Neurology at Klinikum Großhadern, Ludwig-Maximilians-
University in Munich, and the University of Leiden Medical Centre. Informed consent was ob-
tained from all patients.
Initial study
The initial genome-wide association study consisted of three patient samples, collected from 
headache clinics in Finland, Germany and the Netherlands.
In Finland, 1,124 Finnish migraine with aura (MA, and MA/MO) patients were recruited. Each 
patient belongs to a multigenerational family with at least three family members with migraine. 
Patients were examined by a neurologist, and fulfilled the validated Finnish Migraine Specific 
Questionnaire for Family Studies (FMSQFS
2). In cases of insufficient or conflicting information, a 
follow-up interview was conducted by telephone. All patients were diagnosed by the same head-
ache specialist (M. Kallela) according to the current International Headache Society diagnostic 
criteria (ICHD-II)3.
In Germany, patient recruitment was done at two sites, in Kiel and in Munich. At the Pain Clinic 
in Kiel, a total of 994 German MA and MA/MO patients were recruited to a patient collection 
maintained at the Universities of Bonn and Cologne. All patients were diagnosed according to the 
ICHD-II3 by headache specialists4. The detailed migraine anamnesis was obtained either by face-
to-face interviews or by telephone interviews standardized by using a comprehensive migraine 
questionnaire. The second German set of 282 MA and MA/MO cases were recruited and examined 
by a headache specialist at the Klinikum Großhadern of the Ludwig-Maximilians-University, Mu-
nich. Phenotyping was based on a German translation of the FMSQFS
2. Whenever the information 
was insufficient or conflicting, an additional telephone interview was performed. Information 
was obtained on all aspects of the ICHD-II3 criteria as well as on other aspects (such as age at 
onset, prodromal symptoms, triggers, acute and prophylactic medication, family history, general 
past medical history, co-morbidity and place of birth).
In the Netherlands, 879 MA and MA/MO patients were available from the clinic-based Leiden Uni-
versity Migraine Neuro Analysis (LUMINA) study. Self-reported migraineurs were recruited via the 
project’s website. A set of screening questions validated previously in a population-based study5 
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was used first. Participants fulfilling the screening criteria completed then the extended ques-
tionnaire focusing on signs and symptoms of migraine headache and aura as outlined in ICHD-II3. 
Individual diagnoses were made using an algorithm based on these criteria. The algorithm diag-
nosis was validated by a semi-structured telephone interview performed by experienced study 
physicians or by well-trained medical students. Specific attention was paid to migraine aura. A 
subset of the patients was asked to participate upon visiting the outpatient clinic.
Replication studies
The replication phase of the study consisted of four separately recruited migraine patient sam-
ples from Denmark, Iceland, the Netherlands and Germany.
The Danish replication sample comprised 825 MA subjects of which 776 were successfully geno-
typed. Of these, 483 patients suffered from only MA attacks and 293 from both MA and MO 
attacks. Patients were selected from the Danish National Patient Register and from case files 
from neurological clinics, 1,365 took part in a screening telephone interview. If the proband was 
diagnosed with MA, the proband and selected relatives were diagnosed according to the ICHD-I6 
in a validated telephone interview (M. Kirchmann or A.H.). 305 Danish MO patients were selected 
from case files at the Danish Headache Center and diagnosed as mentioned above (ICHD-II3) in an 
extensive semi-structured telephone interview performed by trained physicians. In addition 81 
MO subjects were identified during recruitment of the MA families. Thus, 386 MO patients were 
recruited and 340 successfully genotyped.
The Icelandic replication samples were recruited from three sources: first, a list of patients pro-
vided by two neurologists (401 potential participants), second, responses to an advertisement in 
the newsletter of the Icelandic Migraine Society (137 participants), and third, responses to a brief 
screening questionnaire mailed to a random sample of 20,000 Icelanders, aged 18–50 years and 
living in the Reykjavik area. All Icelandic recruits were asked to answer the comprehensive vali-
dated deCODE Migraine Questionnaire 2 or 3 (DMQ2 or DMQ37). The questionnaire was designed 
based on ICHD-II3. The reliability of the MA and MO diagnoses based on the DMQ3 was assessed 
using a physician-conducted interview as an empirical index of validity. In total 1,612 subjects 
reporting five or more headache attacks were genotyped. Of them, 712 subjects reported atypi-
cal symptoms, preventing reliable IHS classification through questionnaire data only, and were 
excluded from the analysis. In total, the Icelandic sample consists of 567 MO patients, and 333 
MA patients either with or without the MO attacks.
The German replication cohort includes 837 MO cases from the Department of Neurology of the 
Ludwig-Maximilians-University, Munich, Germany. Phenotyping followed the same protocol as 
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described for the Munich patient sample. The Dutch replication sample includes 356 Dutch MA or 
MA/MO patients that were recently recruited through the clinic-based Leiden University Migraine 
Neuro Analysis (LUMINA) study. The diagnosis and classification followed the same procedure as 
in the initial Dutch sample. Nature 
Control samples
Population-matched control samples were obtained from previously genotyped studies (for links 
to studies, see URL section of Online Methods). 1,881 Finnish controls originated from the Hel-
sinki Birth Cohort study8 and 2,173 controls from the Health2000 study, genotyped on the Il-
lumina 660K or 610K platforms. 840 German controls were obtained from the KORA S4/F4 study9, 
380 controls from the HNR study10 and 677 from PopGen study11, all genotyped on the Illumina 
550K platform. In addition, 444 controls were obtained from Illumina iControlDB by querying all 
Caucasian samples genotyped on the Illumina 550K platform on June 30th, 2008 and filtering 
these samples based on stratification as observed from multidimensional scaling plots of all exist-
ing German samples, and keeping only those identified as being of German descent. 974 Dutch 
controls were obtained from the Rotterdam study I12, genotyped on the Illumina 550K platform 
and imputed to cover all markers on the 610K platform. For each replication study, the group 
providing a replication dataset supplied a matched control cohort; the controls for the Danish 
and Icelandic replications were provided by deCODE, and German controls were obtained from the 
MARS study13 and from GlaxoSmithKline14 and Rotterdam study III.
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Migraine is a common neurovascular disorder with a genetically complex pattern of inheritance. 
Linkage and association studies in the common forms of migraine have had limited success 
as they lacked robust replication of initial findings. Recent availability of high-throughput 
genotyping methodology makes genome-wide association studies (GWAS) feasible and provided 
a much better opportunity for identifying gene variants for complex diseases, including 
migraine. Here we first performed a GWAS on 330 migraine cases and 1,216 controls of the 
Erasmus Rucphen Family (ERF) study population, a Dutch genetically isolated population. The 
most significant association was observed with single nucleotide polymorphism (SNP) rs7200027 
(P-value 1.34x10-7), an intergenic SNP on chromosome 16. Another 220 SNPs in the ERF GWAS 
had a P-value below 10-4. A subsequent meta-analysis of migraine GWA data from five additional 
population-based cohorts of the Dutch-Icelandic (DICE) consortium indicated that rs7200027 
only showed a significant signal in ERF. In fact, of the SNPs in the ERF GWAS with a P-value <10-4, 
only rs11636768 reached that significance level in the meta-analysis. Rs11636768 resides in an 
intergenic region on chromosome 15 between the ATP/GTP binding protein-like 1 (AGBL1) gene 
and the non-protein coding RNA 52 (NCRNA00052) gene. In addition, the meta-analysis itself 
gave unique opportunities to search for migraine variants that surface in this large set of 10,980 
individuals (2,446 cases and 8,534 controls). The strongest association in the meta-analysis was 
observed with rs9908234 (P-value 8.0x10-8) that is located in the nerve growth factor receptor 
(NGFR) gene. Notably, NGFR was previously considered a strong candidate for migraine due to 
its involvement in the trigeminal pain system. Future studies will have to show the relevance of 
these findings as GWAS and meta-analysis signals need to be replicated and the functionality of 
gene variants needs to be investigated with functional studies. 
Introduction
Migraine is a common neurovascular brain disorder that is characterized by attacks of severe 
unilateral, often pulsating headache.1 Two main types of migraine are distinguished based on 
the presence of an aura that can precede the headache: migraine with aura (MA) or without aura 
(MO). Although MA and MO have been considered distinct disease entities2,3, it is now more and 
more accepted that they do present different expression forms of the same disease.4-6  
Gene identification in the common forms of migraine has been notoriously difficult. 
Except for a genetic association with a single nucleotide polymorphism (SNP) in the 
5’,10’-methylenetetrahydrofolate reductase (MTHFR) gene, no genetic factors have been identified 
for common migraine; likely because most association studies were underpowered and therefore 
replicated poorly (for review see De Vries et al. 2009)7. Thus far, successes in migraine genetics 
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come primarily from studies in familial hemiplegic migraine (FHM), a rare monogenic subtype 
of MA that is considered a suitable model for common migraine.8 Three genes were identified, 
all encoding ion transporters.9-11 Functional research on FHM gene mutations indicated that 
abnormal neurotransmission of glutamatergic neurons in the cortex plays an important role in 
FHM and possibly the common forms of migraine.12 
Here we performed a genome-wide association study (GWAS) which tests for association between 
a trait and hundreds of thousands of SNPs in the genome. Recently, the first GWAS of migraine 
was performed using clinic-based cohorts.13 The present study is the first GWAS in migraine 
using population-based cohorts. We first performed a GWAS in the Erasmus Rucphen Family 
(ERF) study, a genetic isolate in the Southwest of the Netherlands, in which we identified 360 
migraine cases and 617 non-headache controls.14 Gene identification is expected to be easier in 
genetically isolated populations as, i) these populations have limited genetic heterogeneity due 
to a relatively small number of founders and genetic drift, and ii) environmental factors may be 
more homogeneous.15 Subsequently, we performed a meta-analysis by combining migraine GWAS 
data of, in total, six population-based cohorts (2,446 cases and 8,534 controls) of the Dutch-




Our study has a two-step design. First, we performed a GWAS on 330 migraine cases from the 
ERF population. In the second step, we performed a meta-analysis on 2,446 migraine cases from 
six different population-based cohorts (i.e., ERF, AGES, the Rotterdam study, NESDA, NTR1, and 
NTR2) of the DICE consortium. Details on the populations and genotyping are described in the 
following paragraphs.
Populations: Subjects and phenotypes
Six different population-based migraine cohorts (ERF, AGES, the Rotterdam study, NESDA, NTR1, 
and NTR2) were included in this study (Table 1). Of them, only the ERF population is a genetically 
isolated population and contains related individuals. In the ERF, AGES, the Rotterdam study, 
NESDA, NTR1, and NTR2; 330, 357, 349, 756, 378 and 276 migraine cases were included for this 
study, respectively. Migraine in all populations was diagnosed based on the ICHD-II criteria of 
the International Headache Society.1 However, in the NESDA, NTR1 and NTR2 cohorts, migraine 
diagnoses were determined by means of latent class analysis (LCA) of IHS migraine symptoms.16 
The ERF cohort is a population-based cohort that was not selected based on specific phenotypes. 
In stead, the NESDA, NTR1 and NTR2 cohorts were initially collected to study major depressive 
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disorder (MDD). Therefore, MDD is enriched compared to the other cohorts. The AGES cohort 
and the Rotterdam study were initially collected to study risk factors for disease at older age. 
A detailed description on the populations and migraine case finding is provided below. All 
individual GWA studies were approved by local ethics committees.
Table 1 Descriptives for the samples included in the meta-analysis.
 ERF AGES NESDA NTR1 NTR2 Rotterdam
Subjects      
Total N 1546 3219 1530 1593  1094 1998
N cases (♂, ♀) 330 (81, 249) 357 (71, 286) 756 (165, 591)  378 (69, 309)  276 (59, 217) 349 (79,270)
N controls (♂, ♀) 1216 (615, 601) 2862 (1281,1581) 774 (322, 452) 1215 (509, 706) 818 (396, 422) 1649 (805,844)
mean age & SD 48.4 (±14.6) 51.22 (±6.33) 42.9 (±12.5) 44.8 (±15.0) 48.6 (±14.4) 55.37 (±4.51)
            
Genotyping & Imputation            
 Illumina
  HumanHap300
 HumanHap370       Illumina Infinium 
 Affymetrix  Perlegen/ Perlegen/ Illumina II
 250K Nsp  Affymetrix Affymetrix Human660W- HumanHap550
platform  array Illumina 370CNV 600K 600K Quad BeadChip version 3.0
software used MACH MACH 1.0.16 IMPUTE IMPUTE IMPUTE MACH 1.0.15
reference set HapMap CEU HapMap CEU HapMap CEU HapMap CEU HapMap CEU HapMap CEU
NCBI build 36 36 36 36 36 36
hapmap release 22 22 22 22 24 22
# snps analyzed 2,135,034 2,408,991 2,432,125 2,431,993 2,542,087 2,450,030
Software for 
analysis 
imputed data ProbABEL ProbABEL SNPTEST SNPTEST SNPTEST ProbABEL
ERF
The ERF study is a family-based study in a genetically isolated population in the Southwest 
of the Netherlands. This young genetic isolate was founded in the mid-18th century. Minimal 
immigration and/or marriages occurred between surrounding settlements for social and religious 
reasons. The ERF population includes 3,465 individuals that are living descendants of 22 couples 
with at least six children baptized in the community church around 1850–1900. The subjects 
were unselected with respect to phenotypes. Details about the extensive genealogy and pedigree 
of the population are described elsewhere.17 
Migraineurs were identified using a three-stage previously validated screening procedure.18 The 
screening procedure in ERF was described by Stam et al.14 In brief, all participants filled out 
a concise screening questionnaire on headache and aura symptoms, and those who screened 
positive also completed a detailed questionnaire. All participants who screened positive were 
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telephone-interviewed to clarify their clinical symptoms. Final diagnosis was always made after 
this telephone interview and in consultation with a neurologist (GMT) specialized in headache. 
The control group consisted of ERF participants negative for migraine based on the written 
questionnaire. 
Data from 1,546 ERF participants; 330 migraineurs and 1,216 (non-migraine) controls were 
included in this study. Of the migraine cases, 249 (75%) were female and 81 (25%) were male; 
of the controls, 601 (49%) were female and 615 (51%) were male. The mean age of the study 
subjects was 48.4 years (SD = 14.6).  
AGES
The Reykjavik Study is a population-based cohort study established in 1967 to prospectively 
study cardiovascular disease in Iceland. The cohort included a random sample of men and women 
born between 1907 and 1935 originating from Reykjavik. In 2002, the Reykjavik Study continued 
as the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study to examine risk factors, 
genetic susceptibility, and gene-environment interactions in relation to disease and disability in 
old age. Headache data were collected as part of the Reykjavik study. Details on the Reykjavik 
and AGES-Reykjavik Studies are described in detail elsewhere.19-22 
For this study, a modified version of the 1988 International Headache Society (IHS) criteria 
was used (IHC. 1988). Subjects reporting headache at least once a month were asked whether 
their headaches were accompanied by any of the following migraine features: nausea/vomiting, 
unilateral location, photophobia, visual disturbance during or preceding headache, and unilateral 
numbness preceding headache. Individuals were defined as having migraine with aura if they 
had visual or sensory aura, or both. Subjects with at least 2 of the non-aura symptoms were 
classified as having migraine without aura. Details were described elsewhere.23 In the present 
study, both migraine with and without aura were included as cases. The remaining individuals 
were considered controls. 
The AGES-Reykjavik study contains 357 migraine cases; 286 were female (80%) and 71 were male 
(20%). The control group consisted of 1581 females and 281 males. Mean age of all study subjects 
was 51.03 years (SD = 6.37). 
NESDA 
The NESDA cohort consisted of 1,530 unrelated individuals from the Netherlands. Most of them 
had major depressive disorder (MDD) and were genotyped in the context of the Genetic Association 
Information Network (GAIN) MDD study.24 For phenotypic assessment, the NESDA participants 
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underwent a 4-hour baseline assessment at one of seven clinic sites at the beginning of the study. 
This assessment included an interview on somatic health, functioning and health care use, and 
the administration of several written questionnaires. Migraine was assessed using a questionnaire 
that provided information on the symptoms listed in the ICHD-II criteria. Individuals screening 
positive for a screening question (‘do you ever experience headache attacks, for instance 
migraine?’) subsequently answered a set of more detailed questions about their headaches. This 
information was used to determine the presence of eight of the symptoms present in the ICHD-
II criteria: moderate/severe pain intensity, aggravation by physical activity, pulsating quality, 
nausea/vomiting, photo-/phonophobia. The IHS migraine symptom variables were analyzed with 
Latent Class Analysis (as in Nyholt et al. 2005)16 to determine each participant’s affection status 
for migrainous headache. The program Latent Gold 4.0 (Statistical Innovations, Inc., Belmont, 
MA) was used to perform the LCA. Individuals belonging to LCA classes 2 and 3 (CL2 and CL3) 
were considered migraine patients; individuals of LCA classes 0 and 1 (CL0 and CL1) were used as 
controls. Previously it was shown that all individuals that were considered affected in the latent 
class analysis (i.e., CL2 or CL3) were diagnosed as affected by applying IHS migraine criteria.5 
In the NESDA sample 1,383 subjects had MDD; 147 had a low risk for MDD. In the sample of the 
present study, we included 756 migraine cases (713 with MDD and 43 with a low risk for MDD) 
and 774 controls (670 with MDD and 104 with a low risk for MDD). In the case group, 591 (78%) 
were female and 165 (22%) were male. In the control group, 452 (58%) females and 322 (42%) 
males were present. The mean age of the study cohort was 42.9 years (SD = 12.5).  
NTR1
The Netherlands Twin Registry (NTR) collects phenotype data in Dutch twins, their parents, 
siblings and partners. The migraine data were collected in the context of a longitudinal study 
on health, lifestyle and personality. The first NTR (i.e., NTR1) cohort was genotyped as part of 
the GAIN project, a GWA study originally designed to find genes for major depressive disorder.24 
The majority of the 1,481 subjects were selected for low risk of MDD; 112 subjects were MDD 
patients. Migraine was assessed with a questionnaire that provided information on the symptoms 
listed in the ICHD-II criteria. The headache questions were embedded in surveys that were held 
in the context of a longitudinal study on health, lifestyle and personality. The data used in this 
study were collected in 2002 and 2004. Both surveys included the same set of headache items. 
Data collection procedures are described in detail elsewhere.25,26 When a participant answered 
the headache section in both surveys, the survey of 2004 was used. Final migraine diagnosis was 
based on the LCA method as described above for the NESDA cohort.
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Migraine data were available for 1,593 individuals: 378 cases (56 with MDD and 322 with a low 
risk for MDD), and 1,215 controls (56 with MDD and 1,159 with a low risk for MDD). In the case 
group, 309 (82%) were female and 69 (18%) were male. In the control group, 706 (58%) females 
and 509 (42%) males present. The mean age of the study population was 44.8 years (SD = 15.0). 
NTR2
The second cohort from the Netherlands Twin Registry (i.e., NTR2) was an unselected sample. For 
1,094 individuals, migraine data were available. Migraine case finding in NTR2 was similar as for 
NTR1 and is described in the section above. 
NTR2 contained 276 migraine cases, including 217 (79%) females and 59 (21%) males. The control 
group consisted of 818 controls, consisted of 422 (52%) females and 396 (48%) males. The mean 
age in this cohort was 48.6 years (SD = 14.4). 
Rotterdam Study
This sample included participants of the Dutch Rotterdam Study, a prospective population-based 
cohort study among persons 55 years or older who were living in Ommoord, a well-defined district 
of Rotterdam.27 The aim of the study was to investigate causes of frequent chronic diseases, 
with a focus on cardiovascular, neurologic, psychiatric, and ophthalmic diseases. The original 
cohort consisted of 7,983 participants and was expanded in 2000 with 3,011 participants and 
again in 2006 with another 3,919 persons who were 45 years of age or older. At study entry, all 
participants underwent a structural interview and a physical examination, which was repeated 
every 3-4 years. The migraine questionnaire was introduced into the core study protocol in 2006 
(response rate of 64.8%). The migraine questionnaire was based on the ICHD-II criteria and was a 
modified questionnaire according to the questionnaire used in the GEM study.18 The first question 
was “Have you ever experienced a severe headache that affected your daily activities?” If the 
answer was negative or if it was clearly indicated that the participants experienced a severe 
headache due to other causes, such as a tumor, sinusitis, stroke, trauma or meningitis, no further 
questions on headaches were asked. If the answer to the first question was positive, headache 
duration and headache frequency were asked. Next, if a person experienced headaches of which, 
1) the duration was between 4 and 72 hours (untreated) or the participant did not know the 
answer to this question, because they always treated their headache attacks, and 2) the attack 
frequency was two or more attacks in a lifetime, details on the characteristics and symptoms of 
the headaches were asked. These included age of onset, unilateral location, pulsating quality, 
aggravation by daily activities, sensitivity to light and sound, nausea or vomiting. The frequency 
of the symptoms accompanying the headaches was assessed and defined as never, sometimes, 
half of the time and more than half of the time. In this group of participants, questions on 
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medication use were assessed. Furthermore, every participant was asked about aura symptoms 
and physician diagnosis, if they ever had a severe headache. If the participant experienced 
an aura or the physician had diagnosed migraine, questions on medication use were assessed. 
Participants whose duration of headache was unknown, because they always used medication to 
prevent or treat the attack, were considered migraineurs if they fulfilled the remaining ICHD-II 
criteria. Individuals who were not classified as migraineurs were regarded as controls.
For the present study, we used data from persons from the second cohort expansion (2006 to 2008) who 
completed the migraine questionnaire. Migraine data were available for 1,998 unrelated individuals, 
including 349 cases (270 females (77%) and 79 males (23 %)) and 1,649 controls (844 females (51%) 
and 805 males (49%)). The mean age of the study sample was 55.37 years (SD = 4.51).
Genotyping and imputation
Genotypes were already available for all cohorts, and were not generated for this meta-analysis 
which explains why different genotyping platforms were used. After imputation, for all 
populations approximately 2.5 million genotypes were available for GWA. All SNPs were located 
in autosomes. The meta-analysis was performed on 2,394,913 SNPs. Detailed information for the 
genotyping of the individual cohorts is provided below.
 
ERF
Genotyping was performed on several different platforms (Illumina HumanHap300, HumanHap370, 
Affymetrix 250K Nsp array). These sets were merged and genotypes for 2,585,854 SNPs were 
imputed to HapMap CEU, release 22, NCBI build 36 using the MACH program. Data were filtered 
for rare variants and linkage disequilibrium (LD). SNPs with a minor allele frequency (MAF) below 
5% were excluded, and SNPs with an r2 below 0.3 were excluded.
AGES
Genotyping was performed using the Illumina 370CNV platform. Genotypes for approximately 2.5 
million SNPs were imputed using the MACH 1.0.16 program, using HapMap CEU as the reference 
set, based on NCBI build 36, HapMap release 22.
NTR1 and NESDA
Genotyping for the GAIN sample was conducted by Perlegen Sciences (Mountain View, CA, USA). 
The unfiltered dataset contained 599,156 unique SNPs. For the final analysis dataset, SNPs were 
required not to have gross mapping problems, ≥2 genotype disagreements in 40 duplicated 
samples, ≥2 Mendelian inheritance errors in 38 complete trio samples, MAF below 1%, or over 
5% missing genotypes in either cases or controls. A total of 427,049 autosomal SNPs met these 
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criteria and were included in the analyses. Genotypes for approximately 2.5 million SNPs were 
imputed using the IMPUTE software, using the HapMap CEU data (release 22, NCBI build 36) 
(https://mathgen.stats.ox.ac.uk/impute/impute.html), as reference. For each SNP, an r2 value 
was calculated using the QUICKTEST program (http://toby.freeshell.org/software/quicktest.
shtml). SNPs were excluded if the Hardy-Weinberg equilibrium (HWE) test in controls produced a 
P-value <10-6, the MAF was smaller than 1%, and the r2 was smaller than 0.3, leaving 2,432,125 
SNPs for analysis in the NESDA sample and 2,431,994 in the NTR1 sample. 
NTR2
Genotyping for 657,366 was performed SNPs on the Human660W-Quad BeadChip. SNPs were excluded 
based on MAF below 1%, missing genotype rate above 5% or HWE P-value <10-5. After quality control, 
515,781 SNPs remained for further analysis. Genotypes of approximately 3.8 million SNPS were 
imputed with the IMPUTE program28, using the HapMap CEU data (release 24, NCBI build 36), available 
from the IMPUTE website, as reference. Imputed SNPs were excluded if they had a MAF below 1% or 
an r2 below 0.3, leaving 2,506,433 SNPs for analysis. 
Rotterdam Study
Genotyping was performed using the Illumina Infinium II HumanHap550 chip, version 3.0. A 
total of 572,129 SNPs were genotyped. SNPs were excluded based on the following criteria: HWE 
P-value <10-6, call rate <98% and a MAF <1%. The number of SNPs that survived quality control 
was 514,139. Genotypes were imputed for 2,543,888 SNPs, using the Hapmap CEU (build 36, rel. 
22) as reference. Imputations were performed in MACH 1.0.15. SNPs were excluded if they had a 
MAF <0.01 or an r2 < 0.3, leaving a total of 2,450,030 SNPs for analysis. 
GWA analysis in ERF
For each of the 2,135,034 SNPs, logistic regression was performed, using an additive genetic 
model, while adjusting for age and sex. Uncertainty in the inferred genotype from the imputation 
was accounted for by utilizing the estimated genotype probabilities (implemented in ProbABEL). 
Data were filtered for rare variants and LD (MAF <0.05 were excluded; SNPs with r2 below 0.3 
were excluded). We accounted for relatedness between study participants; genomic control was 
applied with a study-specific λ factor being 1.17.
GWAS for meta-analysis
In each sample, a logistic regression association test was performed, with sex, age, and age2 
included as covariates, under an additive model. Age2 was included to account for potential 
nonlinearity of the age effect, because the prevalence of migraine is lower in both younger and 
older individuals.29 Uncertainty of imputation was taken into account in the analyses. The data of 
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AGES, ERF and the Rotterdam Study were analyzed with ProbABEL30, NESDA, NTR1 and NTR2 were 
analyzed using SNPTEST.28 The study specific genomic inflation factors (λ) were 1.002, 1.000, 
1.006, 1.013, 1.000 and 1.021 for AGES, ERF, NESDA, NTR1, NTR2 and Rotterdam, respectively. 
Next, a meta-analysis was performed on 10,890 individuals of the six population-based migraine 
cohorts using the METAL program (http://www.sph.umich.edu/csg/abecasis/metal/). Since 
different phenotype definitions were used in the different samples, the effect sizes are not 
directly comparable between studies. Therefore, a pooled Z-score approach was used. With the 
pooled Z-score method, an overall Z-score is calculated based on the summed Z-scores from the 
individual studies, weighted by each study’s sample size. The weights are calculated as the square 
root of (Nstudy/Ntotal). The squared weights sum to one. The sign of the Z-score indicates the 
direction of effect. To ensure that meta-analysis results were indeed based on a substantial 
number of samples, hence SNPs (N=184,350 present for less than 70% of all participants) were 
excluded from the meta-analysis. This left a total of 2,394,913 SNPs for analysis. Annotation of 
GWAS results was performed with WGA viewer, version 1.26E.
Literature-based relationships
Literature-based relationships between genes in the specific gene sets and migraine were studied 
using the Anni text-mining program (Anni version 2.1)31. For each gene or disorder a concept 
profile was generated by the program. A concept profile is a summary of all concepts directly 
co-mentioned with the disease or gene concept (i.e. the main concept) in PubMed abstracts. 
The strength of association for each concept with the main concept is calculated using 2x2 
contingency tables and the uncertainty coefficient. The association between two concept profiles 
is calculated using vector based matching (e.g. inner product score) over the concepts that the 
two profiles have in common. 
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Results
GWAS in the ERF population
Using the ProbABEL package, which is suitable for imputed genotypes, we performed a GWAS with 
2,585,854 SNPs in ERF. The Q-Q plot for the GWA-analysis is shown in figure 1A. We corrected for 
residual inflation using genomic control using the genomic inflation factor λ, which is calculated 
as the median observed χ² divided by the median expected χ² based on 1 df, and was 1.17 
for ERF. The genome-wide plot of probability values for individual SNPs against their genomic 
position shows that none of the SNPs reached the threshold for genome-wide significance (set to 
a P-value of 5.0x10-8) (figure 1B). However, 22 SNPs showed suggestive associations with P-values 
below 10-5 (Table 2); 221 SNPs had P-values below 10-4. 
Figure 1 A Quantile-Quantile (Q-Q) plot showing the expected (x-axis) and observed distribution of –log10 (P-value) in our GWAS 
analysis in the ERF population. The genomic factor (λ) was 1.17. B Genome-wide signal intensity (Manhattan) plot showing indi-
vidual probability values per chromosome for the GWAS in ERF. Solid red line indicates the threshold for genome-wide significance 
(P-value = 5.0x10-8), solid black line indicates the threshold for suggestive association (P-value = 1.0x10-5), and the dotted black 
lines indicates a P-value threshold of 1.0x10-4.
The strongest associated SNP in ERF, rs7200027 (P-value 1.34x10-7, OR 0.63 (CI 0.53-0.75), resides 
on chromosome 16. The minor allele is overrepresented in the controls compared to the cases, 
indicating a protective effect of the minor allele. Rs7200027 is an intergenic SNP located 50 Kb 
upstream of the TMEM148 gene, which encodes a transmembrane protein with unknown function. 
The regional association plot shows that the SNPs surrounding rs7200027 are in relatively low 
LD and therefore show only limited to no association (figure 2). The second best SNP on the list 
is rs17379695 (P-value 2.52x10-7) which is an intronic SNP located in the solute carrier organic 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2 Regional plot for associations in the region surrounding the top hit (rs720027). All SNPs (indicated as squares) are plot-
ted with their –log (P-value) against their genomic position. Colour of the squares represents the degree of LD between the SNPs, 
with white representing no LD till dark red representing complete LD. Light blue line represents estimated recombination rates.  
Furthermore, we explored the 221 top SNPs (with P-values <10-4) from the ERF GWAS using 
a text-mining program and by comparing the SNP locations to previously reported migraine 
linkage regions. The 221 top SNPs are located within or close to 84 different genes. Literature-
based relationships between these genes and migraine were studied using the Anni text-mining 
program (Anni version 2.1)31. Neuronal cell adhesion molecule 1 (NCAM1), located on chromosome 
11, was identified as the best migraine candidate gene according to literature-based connections 
with the concept ´migraine´. In the top list, two SNPs located upstream of NCAM1 had a P-value 
<10-4 (rs4937776 (6.37x10-5) and rs4937786 (6.39x10-5)). The text-mining program did not show 
any meaningful results for the 16 genes (for 7 a concept profile was present) in the 22 top SNPs 
with P-value <10-5. None of the 22 top SNPs (P-value <10-5) were located in known migraine 
linkage regions, although rs17212806 is located in relative proximity to the linkage region on 
chromosome 14q21.2-q22.3.32 Of the 221 top SNPs, 46 SNPs were located in 8 known migraine 
linkage loci.
 
Most significant SNPs from the ERF GWAS in other population-based cohorts
As described above, the most significant association in the ERF GWAS was obtained with 
rs7200027. When performing the meta-analysis for all six population-based migraine cohorts 
the P-value of this SNP increased to >10-4, indicating that the association was less clear in other 
populations. In fact, the association with rs7200027 was only observed in ERF. When comparing 
the top SNPs (P-value <10-4) from the ERF GWAS and the meta-analysis, only rs11636768 surfaced 
in both studies (PERF-GWAS 5.9x10-6 and P Meta-analysis 3.2x10-7). Importantly, the direction of the effect 
for this SNP was identical for all six populations, which adds weight to the association finding. 
Moreover, it was the second best SNP in the meta-analysis (Table 4). SNP rs11636768 is located on 
chromosome 15q25 between the NCRNA00052 gene encoding non-protein coding RNA 52 and the 
150
AGBL1 gene encoding ATP/GTP binding protein-like 1, but the SNP is located outside the known 
migraine linkage regions on chromosome 15.33,34 Interestingly, approximately 0.5 Mb downstream 
of the rs11636768 SNP the NTRK3 gene is located, which encodes a member of the neurotrophic 
tyrosine receptor kinase (NTRK) family.
FHM genes in ERF GWA and in the meta-analysis
This study also provides an excellent opportunity to investigate the role of FHM genes in large 
population-based migraine cohorts. We investigated whether SNPs in the three known FHM genes 
showed any signal in the ERF GWAS and meta-analysis data sets. Genotypic information was 
available for CACNA1A (202 SNPs in ERF, 241 SNPs in the meta-analysis), ATP1A2 (19 SNPs in ERF, 
20 SNPs in the meta-analysis), and SCN1A (97 SNPs in ERF, 99 SNPs in the meta-analysis) (Table 
3). For both the ERF GWAS and the meta-analysis the most significant association was obtained 
with SNPs in the ATP1A2 gene. In the ERF GWAS, 5 SNPs had a P-value <0.01 (all were intronic 
SNPs). Three of them were in close LD (r2<0.8). Highest association in ATP1A2 was obtained for 
SNP rs4656883 (P-value 1.4x10-3). In the meta-analysis, 5 SNPs had a P-value <0.001; highest 
association was found for rs2854248 (P-value 3.62x10-4). This SNP had a P-value of 0.009 in ERF. 
For the CACNA1A gene, only weak association signals were observed: in both data sets less than 
10% of the CACNA1A SNPs showed P-values below 0.01; none were below 0.003. For the SCN1A 
gene, none of the SNPs showed any sign of association, neither in the GWA study nor in the 
meta-analysis.
Table 3A Results in ERF GWAS for monogenic migraine genes 
FHM genes          
Gene  Most significant SNP P-value Beta SNPs  SNPs SNPs SNPs Total nr’s
Symbol Location in ERF GWAS    P < 0.001 P < 0.01 P < 0.05 P < 0.1 of SNPs 
CACNA1A 19p13 rs7248281  0.0030 0.29 0 16 44 56 202
ATP1A2 1q21-q23 rs4656883  0.0014 0.46 0 5 7 7 19
SCN1A 2q24.3 rs13397210  0.1434 0.26 0 0 0 0 97
Table 3B Results in meta-analysis for monogenic migraine genes
FHM genes 
    Most significant        Total
Gene     SNP in  Pooled  Pooled  Direction  SNPs  SNPs  SNPs  SNPs  number
Symbol Location  meta-analysis  Z-score  P-value  of effect  P<0.001  P<0.01  P<0.05  P<0.1  of SNPs
CACNA1A 19p13 rs3764615 2.903 0.003695 -+++-+ 0 9 17 37 241
ATP1A2 1q21-q23 rs2854248 3.566 0.0003618 ++++++ 3 4 5 8 20
SCN1A 2q24.3 rs12151636 2.142 0.03218 +?+-++ 0 0 1 1 99
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Previously identified common migraine genes; MTHFR and AEG-1 
Next, we investigated whether previously identified common migraine gene variants showed a 
signal for association in our population-based cohorts. The first gene variant that we studied 
was the C677T SNP (rs1801133) in the MTHFR gene that surfaced in several candidate-gene-based 
association studies performed for migraine (for review see De Vries et al. 2009)7. However, in 
both the ERF GWAS and the meta-analysis, no significant association was found for this SNP. In 
addition, we testes the top SNP (rs1835740) that was identified in a GWAS of large clinic-based 
cohorts (testing in total 2,748 MA patients and 10,747 controls).13 SNP rs1835740 resides close to 
the astrocyte elevated gene-1 (AEG-1) gene, which has relevance to the pathway identified in FHM. 
Neither the ERF GWAS nor the meta-analysis showed any sign of association for this specific SNP.
Meta-analysis-specific migraine variants 
The meta-analysis comprising 2,446 migraine cases and 8,534 control individuals revealed a 
unique large data set with potential for identification of novel genetic migraine factors itself. The 
Q-Q plot for this meta-analysis is shown in figure 3A. The genomic inflation factor λ was 1.022. 
None of the SNPs reached a P-value <5x10-8; the threshold for genome-wide significance (figure 
3B). However, the threshold for suggestive association (P-value <10-5) was observed for 32 SNPs 
(Table 4). The most significant result was obtained for SNP rs9908234 (P-value 8.00x10-8), which 
is located in the nerve growth factor receptor gene NGFR. Genotypic information was available 
for 17 SNPs in this gene, but none of the other SNPs were found associated with migraine, likely 
because none were in high LD with rs9908234 (figure 4). Notably, this SNP was genotyped only 
in the NTR1 and NESDA samples, but was imputed in the other samples. 
Figure 3 A. Quantile-Quantile (Q-Q) plot showing the expected (x-axis) and observed distribution of –log10 (P-value) in our 
meta-analysis. The genomic factor (λ) for all six samples was 1.022. B. Genome-wide signal intensity (Manhattan) plot showing in-
dividual probability values per chromosome for the meta-analysis. Solid red line indicates the threshold for genome-wide significance 
(P-value = 5.0x10-8), solid black line indicates the threshold for highly suggestive association (P-value = 1.0x10-5), and the dotted 
black lines indicates the P-value threshold of 1.0x10-4.
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Table 4 Most significant SNPs per region in the meta-analysis.
     Distance       N SNPs 
    Closest  to gene      Direction  in region
SNP  Chr  Position (bp)  Type  gene  (bp)  A1  A2  Freq A1  P-value  of effect  (P<10-5)
rs9908234  17  44932347  intronic  NGFR  0  A  G  0.93  8.0x10-08 ------  1
rs11636768  15  85496515  intergenic  AC020687  321903  A  G  0.15  3.23x10-07 ++++?+  1
rs10275320  7  20148579  intronic  MACC1  0  A  G  0.15  1.56x10-06 ------  8
rs4939879  18  45399981  intergenic  LIPG  26705  A  G  0.47  1.82x10-06 ++++++  1
rs4861775  4  180553645  intergenic  AC017087.1  -709541  A  C  0.81  3.28x10-06 ------  1
rs986222  10  91920867  intergenic  AL139340.2  -7170  A  G  0.46  3.37x10-06 ++++++  16
rs6107848  20  6539116  intergenic  AL121911  82010  A  G  0.37  5.90x10-06 +++++-  1
rs140174  22  22252983  intronic  IGLL1  0  A  G  0.75  6.98x10-06 ------  1
rs1146161  1  115460299  intergenic  AL109660.1  13497  A  C  0.18  9.27x10-06 ++++++  1
rs4742323  9  7276743  intergenic  KDM4C  111095  C  G  0.61  9.70x10-06  ------  1
Note. The best SNP per region is shown, as well as the number of SNPs in the region with a P-value <10-5. The “Direction” column 
shows the direction of effect of the best SNP in the region, for each of the six samples, in the following order: AGES, ERF, NESDA, 
NTR1, NTR2, Rotterdam. A question mark indicates the SNP has not been tested for a particular sample, because it was removed 
during quality control. A1 is the effect allele in the meta-analysis, A2 is the non-effect allele. Positions are based on NCBI Build 36. 
The frequency of A1 was calculated as a weighted average across all samples.
Figure 4 Plot showing the LD structure between the SNPs tested in the NGFR gene. Rs9908234 was not in LD with any of the other 
SNPs tested.
No less than 340 SNPs had P-values <10-4, and were analyzed with text-mining program Anni that 
can prioritize genes for follow up studies. Of all 86 genes associated with these SNPs, NGFR was 
identified as the best candidate based on literature connections with the concept ‘migraine’. 




Here we performed the first GWA study for migraine in population-based cohorts. Initially, we 
performed a GWAS in the ERF population, a genetically isolated population in the Southwest of 
the Netherlands, in which several loci and/or variants for complex disorders, such as metabolic 
syndrome35 and type 2 Diabetes36 were identified. The present study was designed to identify 
genetic variants for migraine using available genotypic data from 1,546 individuals of the ERF 
population. The most significant association with migraine was obtained for SNP rs7200027 
located on chromosome 16q24 (P-value 1.34x10-7, OR 0.63 (CI 0.53-0.75)), indicating a protective 
effect for the minor allele of this SNP. The SNP is located 50 Kb upstream region of TMEM148, a 
gene with a thus far unknown function. The second-best SNP in the top list, rs17379695 (P-value 
2.52x10-7) is an intronic SNP located in the SLCO1C1 gene located on chromosome 12p12, which 
encodes the solute carrier member 1C1 from the organic anion transporter family. At present, it is 
not clear how this organic anion transporter that is predominantly expressed in the microvessels 
of the brain and the choroid plexus that transports brain-specific thyroid hormone into the 
brain, may cause migraine. Also, no association with a brain disorder is at present known with 
genetic variations in this gene. Notably, other solute carriers have previously been implicated in 
several brain disorders, such as episodic ataxia, epilepsy and mental retardation.37-39 Of note, no 
migraine linkage peaks have been reported on chromosomes 12p12 and 16q24. Clearly, without 
robust replications and/or functional analysis of the identified variants, the relevance of these 
findings remains uncertain. 
GWA meta-analysis
The availability of five additional population-based cohorts with GWA data gave unique 
opportunities for performing the first meta-analysis for migraine in population-based cohorts. 
This analysis was based on GWAS data from 10,890 individuals (2,446 cases, 8,534 controls) of 
European ancestry. The highest association in the meta-analysis was observed for SNP rs9908234 
(P-value 8.00x10-8) in the nerve growth factor receptor (NGFR) gene on chromosome 17. NGFR 
is part of a large superfamily of tumor necrosis factor receptors.40 Together with tyrosine kinase 
receptor A (TrkA), NGFR belongs to the two receptors that bind neural growth factor (NGF), 
which acts as a peripheral pain mediator, and is upregulated in many chronic pain conditions, 
particularly in inflamed tissues.40 NGF can activate and sensitize primary afferent neurons that 
express TrkA, thereby producing hyperalgesia41, which has some relevance to allodynia that is 
reported for many migraine patients.42 NGFR is not directly linked to migraine in the literature, 
however there is evidence for the involvement of NGF in chronic headache disorders43; increased 
levels of NGF were observed in the cerebrospinal fluid (CSF) of patients with chronic daily 
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headache. In contrast, Blandini et al.44 found reduced peripheral levels of NGF in migraineurs. 
Based on current knowledge, the hypothesis that NGFR mediates NGF-induced sensitization of 
trigeminal neurons is proposed as an explanation for migraine headache.  
When we compared the top SNPs from the ERF GWAS data with those of the meta-analysis data, 
SNP rs11636768 is the only SNP that obtained a P-value <10-4 in both studies. This SNP is located 
between the NCRNA00052 gene encoding non-protein coding RNA 52 and the AGBL1 gene that 
encodes the ATP/GTP binding protein-like 1. No other SNPS in this region showed a P-value <10-4. 
The NTRK3 gene, encoding a member of the neurotrophic tyrosine receptor kinase (NTRK) family, 
is located ~0.5 Mb upstream to this SNP. This gene is located in the same pathway as the NGFR 
gene and can be linked to migraine and/or pain pathophysiology. Future studies need to show 
whether this association can be replicated in other populations, and whether the affect allele of 
the rs11636768 SNP has an effect on expression of the NTRK3 gene.
Migraine linkage studies; loci previously implicated in migraine 
Except for the hemiparesis, migraine symptoms largely overlap between FHM and common 
migraine patients. Consequently, FHM genes are considered good candidate genes for common 
migraine. However, there is debate whether the same genes (i.e., ion transporters) play a role in 
common migraine. Recently, Nyholt et al studied 155 ion transport genes in the human genome 
in Finnish MA patients to investigate their involvement in common migraine.45 There were no 
indications that the FHM genes played an important role in common migraine. Except for a few 
SNPs in the CACNA1A gene, none had nominal significant P-values. It was suggested that there 
still may be SNPs in these genes, or in other ion transporters, that are associated with migraine 
but with very low effect sizes and could therefore not be detected in this study due to the power. 
However, because of the much larger sample size of our present study, we had the opportunity to 
test SNPs in FHM genes. A possible role of the ATP1A2 gene is most likely for the ATP1A2 gene, 
similar to what was described in a genetic study by Todt et al.46 Also several linkage studies 
supported a possible role of ATP1A2 in common migraine.47,16 
Migraine association studies; genes previously implicated in migraine 
Many other candidate genes are tested and reported for migraine, however the majority of these 
genes were tested in small samples sizes with limited power and replication was lacking.7 Of them 
the MTHFR gene, and more specifically the functional SNP (rs1801133), is the most promising 
genetic finding. This SNP is associated with MA in several studies48,49, but did not replicate 
neither in the ERF GWA study nor in the meta-analysis. Also a very recent finding from a clinic-
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based GWAS in MA, the SNP (rs1835740) that is located in the vicinity of the AEG-1 gene13, did 
not replicate in the present study. For rs1835740 this could be explained by the fact that we 
studied a population-based cohort of common migraine patients, not specified for MO or MA. 
Perhaps this AEG-1 SNP is only associated with clinic-based migraine with aura. 
Future studies will show whether our results can be replicated in other migraine populations, and 
what the true value of these GWA studies will be for improvement of our knowledge on migraine 
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The CACNA1A gene encodes the α1 subunit of voltage-gated CaV2.1 calcium channels. Several 
mutations in CACNA1A are associated with familial hemiplegic migraine (FHM), a rare monogenic 
subtype of migraine with aura that can be accompanied by cerebellar ataxia and/or epilepsy. 
Two extremes of the FHM clinical spectrum are seen with missense mutations R192Q and 
S218L. Whereas patients with the R192Q mutation suffer from pure FHM without additional 
neurological features, S218L patients show a particularly severe phenotype with FHM, cerebellar 
ataxia, seizures, and brain edema after a mild head trauma. Recently, transgenic knock-in (KI) 
Cacna1a mouse models were generated that carry either the R192Q or the S218L mutation. Here 
we investigated their RNA expression profiles under basal conditions in the occipital cortex 
and the cerebellum because of their relevance to the aura and ataxia, respectively. Expression 
differences were most pronounced in the cerebellum of S218L mice and could be linked to their 
ataxic phenotype, qPCR was used to validate these results. Remarkably, tyrosine hydroxylase, a 
marker of delayed cerebellar maturation, is strongly up-regulated in the cerebellum of S218L 
mice, which was confirmed by immunohistochemistry. In addition, neuronal pathways, such 
as neurotransmitter synthesis pathways are up-regulated in the cerebellum of S218L mice. In 
contrast, only modest differences in expression profiles were observed in the cortex of both KI 
mice, despite pronounced consequences at the molecular and neurobiological level. Our findings 
indicate that the migraine-associated phenotype cerebellar ataxia is reflected in the basal RNA 
expression profiles. 
Introduction
Familial hemiplegic migraine (FHM) is a rare Mendelian subtype of migraine with aura that is 
characterized by transient hemiparesis during the aura phase.1 FHM is considered a relevant 
model for the common forms of migraine, because, (i) apart from the hemiparesis, the aura 
and headache features are identical to those in non-hemiplegic migraine types2, and (ii) many 
patients also have non-hemiplegic migraine attacks.3-5 Three FHM genes have been identified that 
all encode subunits of ion transporters.6 The FHM1 gene, CACNA1A, encodes the pore-forming 
α1 subunit of voltage-gated CaV2.1 calcium channels that are located mainly at presynaptic 
terminals throughout the central nervous system where they regulate neurotransmitter release.7 
CaV2.1 channels are expressed throughout the brain, but are particularly high expressed in the 
cerebellum.8 FHM1 mutations can be associated with pure FHM, such as in R192Q mutation 
carriers9, or can be complex and severe with FHM and associated cerebellar ataxia, seizures, 
mild head trauma-induced cerebral edema, and even fatal coma, in patients with the S218L 
mutation.10,11 
RNA expression profiling in FHM mice 7
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The migraine aura is caused by cortical spreading depression (CSD), a wave of neuronal and glial 
cell depolarization that originates in the occipital cortex and slowly propagates over the brain 
cortex.17,13 The headache phase likely results from an activation of the trigeminovascular system 
(TGVS)14, a system that consists of the neurons innervating the cerebral vessels. In animal studies, 
CSD was shown to activate the TGVS and thereby headache mechanisms.15 Of the associated 
neurological phenotypes, the cause of cerebellar ataxia is most clear. Evidence from natural 
Cacna1a mouse mutants revealed that an irregularity in the firing of cerebellar Purkinje cell 
neurons is the likely underlying cause.16,17 Notably, subclinical cerebellar signs were observed in 
migraine patients and found more pronounced in migraine with aura than in migraine without aura.18 
To investigate the neurobiological consequences of FHM1 mutations, transgenic Cacna1a knock-in 
(KI) mouse models were generated that either carry the FHM1 R192Q or the S218L mutation.19,20 
Whereas S218L KI mice show a similar, complex, phenotype as S218L patients, the R192Q KI 
mice do not exhibit an overt behavioral phenotype. At the neurobiological level, however, both 
KI mouse mutants show multiple gain-of-function effects, such as an increased neuronal calcium 
influx, increased neurotransmitter release, and enhanced susceptibility to cortical spreading 
depression (CSD); all of which are more pronounced in S218L mice.19-21 Here we investigated 
the RNA expression profiles in the occipital cortex (the origin of CSD and the aura) and the 
cerebellum (the origin of the ataxia) to investigate whether molecular changes are associated 
with the pathophysiology of at least some of the migraine-associated clinical features. Expression 
profiles were shown to be remarkably stable, and specific differences in gene expression were 
demonstrated that could be linked to ataxia-relevant pathways. 
Materials and Methods
Animals
Transgenic knock-in (KI) mice were generated by gene targeting of the Cacna1a gene that carry 
either the human FHM1 R192Q or S218L mutation, in which the neomycin selection cassette was 
removed by in vivo deletion by crossing the KI mice with Cre deleter mice.19,20 Homozygous KI 
mice and wild-type mice of both genders aged 7-10 weeks were used. KI mice were backcrossed 
with C57BL/6J for five (R192Q) and for three (S218L) generations. Each group consisted of six 
mice (biological replicates), unless mentioned otherwise (Table 1). Confirmatory genotyping was 
performed by PCR analysis on genomic DNA from tail biopsies. Animal care and procedures were 
approved by the local ethical committee according to national guidelines. 
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Table 1 Experimental groups of mice
Genotype Brain structure Gender (n)
Wild-type mice Cerebellum Male (6)
   Female (6)
  Occipital cortex Male (6)
   Female (6)
S218L knock-in mice Cerebellum Male (6)
   Female (5)
  Occipital cortex Male (6)
   Female (5)
R192Q knock-in mice Cerebellum Male (6)
  Occipital cortex Male (n=6)
Dissections of brain structures
Animals were sacrificed by cervical dislocation and brains were rapidly removed from the skull. 
Brain material was dissected and snap-frozen in liquid nitrogen within 15 minutes and stored 
at -80°C until RNA isolation. Brain material was dissected in nine parts: the cerebellum (in two 
halves), both hemispheres of the cortex (with each hemisphere further dissected in three parts, 
one containing the occipital cortex), and the brainstem. 
RNA isolation 
The right half of the cerebellum and the occipital third of the right cortex were chosen for expression 
profiling. For total RNA isolation, the Macherey Nagel RNA isolation kit (Düren, Germany) was used 
in combination with an Ultra-turrax T25 Polytron (Janke & Kunkel, Staufen, Germany) mechanical 
homogenizer. In brief, frozen tissue was crunched using a mortar under liquid nitrogen. Subsequently, 
tissue was homogenized in lysis buffer using the Polytron. Total RNA was bound to silica membrane 
of Macherey Nagel columns, while contaminating DNA was removed by rDNase. At the end of the 
procedure, total RNA was eluted with RNase-free water. RNA integrity was determined using the 
Agilent 2100 Bioanalyzer total RNA nanochips (Agilent, Foster City, USA, CA). All RNA samples that 
were included in the study had a minimal RIN (RNA integrity number) value of 7.0. 
Gene expression profiling using Illumina microarrays
Biotin-labelled cRNA was produced using a linear amplification kit (IL1791; Ambion, Austin, 
USA, TX) using 300 ng of total RNA as input. cRNA samples were hybridized on Illumina mouse-6 
Bead Chips, which contain 44,505 probe IDs. Chip hybridizations, washing, Cy3-streptavidin 
(Amersham Biosciences, Uppsala, Sweden) staining, and scanning were performed on an Illumina 
Bead Station 500 platform (San Diego, http://www.illumina.com) using reagents and protocols 
supplied by the manufacturer. 
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Gene expression profile data analysis
Resulting data files were loaded into Rosetta Resolver version 7.2 (Rosetta Biosoftware, Seattle, 
WA). Raw data were normalized using the standard Rosetta error model for Illumina arrays. 
Differences in gene expression between groups were evaluated using an error-weighted two-way 
analysis of variance with genotype and gender as factors and Benjamini-Hochberg FDR was used 
for multiple testing corrections (FDR, P < 0.05). Post-hoc analysis was performed using Tukey-
Kramer (FDR, P < 0.05). Cerebellum and occipital cortex profiles were analyzed separately. A 
‘cortical’ signature representing genes that are differently expressed in the cortex of both mutant 
mice was selected based on ANOVA statistics and post-hoc analysis. Genes with a significant ANOVA 
P-value for the parameter genotype, and that based on the post-hoc analysis were differently 
expressed between mutant mice (both S218L and R192Q) and wild-type mice were selected. 
Similarly, an ‘ataxia’ signature was created that represents genes that were differently expressed 
in the cerebellum of the S218L mice. Using the Ontologizer program (http://compbio.charite.de/
index.php/ontologizer2.html) function labels were ascribed to each gene. Genes were grouped 
into categories according to these function labels to determine over- or underrepresentation of 
certain categories. These over-or underrepresentation analyses were only performed on gene sets 
containing over 100 genes.
Literature-based relationships
Literature-based relationships between genes in the specific gene sets and migraine were studied 
using the Anni text-mining program (Anni version 2.1).22 For each gene or disorder a concept 
profile was generated by the program. A concept profile is a summary of all concepts directly 
co-mentioned with the disease or gene concept (i.e. the main concept) in PubMed abstracts. 
The strength of association for each concept with the main concept is calculated using 2x2 
contingency tables and the uncertainty coefficient. The association between two concept profiles 
is calculated using vector based matching (e.g. inner product score) over the concepts that the 
two profiles have in common. 
Quantitative RT-PCR
The same RNA samples were used for evaluation of microarray results by quantitative PCR (qPCR). 
Genes that were selected for qPCR had a fold-change of at least 1.3 and detectable expression 
levels. First-strand cDNA was synthesized using random hexamer primers. Subsequently, qPCRs were 
performed on the MyiQTM Single-Color Real-Time PCR Detection System (Bio-Rad, Hercules, USA, CA) 
using gene-specific primers (Supplemental Table 1). cDNAs were analyzed in duplicate, after which 
the average cycle threshold (Ct) was calculated per sample. To correct for input differences between 
mutant and wild-type samples, Ct values were corrected per tissue for the differences in housekeeping 
gene Gapdh expression. Differential expression was calculated using Student’s t-test.
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Immunohistochemistry of tyrosine hydroxylase
Mice were anaesthetized with Nembutal (50 mg/kg, i.p.) and perfused intracardially with 
phosphate buffered saline (PBS) followed by 4% paraformaldehyde in 0.1 M phosphate buffer 
(pH 7.4). Post-fixation was performed for 2 h in 4% buffered paraformaldehyde followed by 
overnight incubation in 10% sucrose in 0.1 M phosphate buffer at 4ºC. Next, tissue was embedded 
in 10% sucrose with 11% gelatin, fixed with 30% sucrose in 4% buffered paraformaldehyde 
for 2.5 h at room temperature, followed by overnight incubation in 30% sucrose in 0.1 M 
phosphate at 4 ºC. Tissue was cut into 40 µm sagittal sections and processed for free-floating 
immunohistochemistry. Briefly, sections were incubated in 10% heat-inactivated normal horse 
serum, 0.5% Triton X100 in Tris-buffered saline (TBS) for 2 h and then incubated with primary 
rabbit anti-tyrosine hydroxylase antibody (AB152, 1:2,000; Chemicon, Temecula, USA, CA), 
diluted in TBS containing 1% normal horse serum, 0.4% Triton X100 at 4 ºC. Secondary biotin-
labeled goat anti-rabbit antibody (1:200; Vector Laboratories, Burlingame, USA, CA) incubation 
was performed for 2 h at room temperature. Finally, for detection, sections were incubated with 
the avidin-biotin kit (Vector Laboratories) for 2 h at room temperature, washed, and developed in 
0.1 mg/ml diaminobenzidine with 0.005% H2O2.
Single Nucleotide Polymorphism analysis  
Using the Mouse Genome Informatics (MGI) database (http://www.informatics.jax.org/), SNPs 
surrounding the Cacna1a locus on mouse chromosome 8 were selected that could distinguish C57BL/6J- 
and 129/Ola-derived sequences. Using genomic tail DNA, SNP genotypes for all mutant mice that were 
included in the study were determined by standard PCR combined with direct sequencing.
Results
Here we studied RNA expression profiles of cerebellar and occipital cortex tissue of two Cacna1a 
KI mouse models of migraine. In line with data from previous studies that revealed similar CaV2.1 
α1 protein expression levels between genotypes19,20, Cacna1a RNA expression levels were similar 
between genotypes, except for an apparent down-regulation of Cacna1a (Fold change -1.25; 
P = 0.01) in cerebellum of R192Q mice (Table 2). No other meaningful genotypic differences were 
detected in gene expression levels of CaV auxiliary subunits (i.e., β1-4, γ1-8 and α2δ1-3), except 
for minor differences in Cacnb1, Cacnb3 and Cacnb4 and in Cacng7 in the occipital cortex of S218L 
mice (Supplementary Table 2). 
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Table 2 Expression levels of genes encoding pore-forming subunits of CaV channels 
  Cerebellum  Occipital cortex
Gene R192Q S218L R192Q S218L
Cacna1a -1.29 (0.02)* -1.13 (0.19) -1.24 (0.06) -1.11 (0.37)
Cacna1b -1.06 (0.27) 1.01 (0.90) -1.08 (0.28) 1.00 (0.97)
Cacna1c -1.13 (0.08) -1.04 (0.60) -1.04 (0.62) -1.08 (0.38)
Cacna1d -1.05 (0.67) 1.21 (0.09) -1.04 (0.86) -1.01 (0.94)
Cacna1e 1.01 (0.96) -1.11 (0.50) -1.12 (0.52) -1.03 (0.85)
Cacna1f 1.06 (0.62) -1.03 (0.76) -1.08 (0.56) 1.06 (0.71)
Cacna1g -1.05 (0.57) -1.08 (0.27) -1.03 (0.93) 1.12 (0.69)
Cacna1h 1.02 (0.84) 1.42 (0.004)* 1.03 (0.74) 1.07 (0.48)
Cacna1i 1.02 (0.80) -1.01 (0.81) -1.07 (0.36) -1.01 (0.82)
Cacna1s 1.18 (0.09) 1.06 (0.52) -1.09 (0.36) 1.03 (0.82)
Numbers represent the mean fold-change for each gene transcript seen in the respective mutant mice compared to wild-type mice; 
P-value for this fold change is indicated between the brackets. *Fold-change with a P < 0.05.
To further assess gene expression profiles in Cacna1a KI and wild-type mice, a two-way ANOVA 
was performed for cerebellum and cortex separately, with genotype and gender as factors. 
The effect of gender was not remarkable. In the cerebellum, only 16 genes were significantly 
differentially expressed between males and females; for the occipital cortex only 10 genes were 
significantly differentially expressed. For both the cerebellum and occipital cortex, a large 
portion of significantly differentially expressed genes (DEGs) between genotypes are located on 
chromosome 8, which contains the Cacna1a gene that was modified by gene targeting. Although 
KI mice and wild-type mice were backcrossed with C57BL/6J for several generations, the region 
directly flanking the Cacna1a gene remained of 129 genetic background. It is therefore unclear 
whether the ‘chromosome 8 genes’ are differently expressed because of the presence of an FHM1 
mutation or a different genetic background.23 To investigate this further, we determined the 
genomic boundaries of 129-derived chromosome 8 regions in the FHM1 mice. The 129-derived 
region flanking the Cacna1a gene extended maximally 37 Mb upstream to 46 Mb downstream of 
the R192Q mutation and 37 Mb upstream and 52 Mb downstream of the S218L mutation. As the 
129-derived region covered most of chromosome 8 in at least some of the mice, we decided to 
exclude all genes located on chromosome 8 from the gene signatures used for subsequent analyses. 
After chromosome 8 exclusion, only 22 DEGs remained for the occipital cortex of R192Q KI mice. 
For S218L KI mice, only 10 genes were differentially expressed in the occipital cortex. Notably, 
without chromosome 8 exclusion 61 and 67 DEGs were observed for R192Q KI and S218L KI mice, 
respectively. However, in the cerebellum, the number of DEGs after chromosome 8 exclusion was 
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considerably higher: 82 for R192Q KI and 335 for S218L KI mice. We believe that the relatively 
low number of DEGs is not due to lack of power, given the fact that our experiment easily picked 
up genes from the chromosome 8 region with relatively subtle changes in gene expression.
Because the occipital cortex is most relevant for the observed increased susceptibility to cortical 
spreading depression (CSD) in KI mice, we selected a ‘cortical’ gene signature by selecting genes 
that were differentially expressed in the occipital cortex of both mutant mice models (figure 
1A). Notably, nine out of 10 DEGs were differentially expressed in both strains of mutant mice 
(Table 3); all showing only modest fold-changes. Six genes (i.e., Lsm10, Gpr34, Gpr23, Ctxn3, Gli3 
and Tnnc1) were up-regulated in both strains, whereas one gene (Cort) was up-regulated in one 
and down-regulated in the other; two genes (i.e., Camkk1 and Tom1l2) were down-regulated in 
both strains. 
Figure 1 A. Differentially expressed genes in the occipital cortex of mutant KI mice. Only nine genes are differentially expressed in 
the occipital cortex of both KI mouse models (‘cortical’ signature). B Differentially expressed genes in cerebellum. No less than 296 
genes are differentially expressed in the cerebellum of S218L KI mice compared to R192Q KI and wild-type mice (‘ataxia’ signature). 
Table 3 Genes that are differentially expressed in the occipital cortex of both R192Q and S218L mice (‘cortical’ signature)
Genes Description P-value ANOVA  Fold change Fold change
  (parameter genotype) (S218L vs wild-type) (R192Q vs wild-type)
Camkk1 calcium/calmodulin-dependent 
 protein kinase kinase 1, alpha 3.80 x 10-6 -1.06 (0.05) -1.29 (4.04.10-16)
Cort Cortistatin 0.01 -1.17 (0.02) 1.19 (3.1 x 10-3)
Ctxn3 cortexin 3 8.33 x 10-3 1.25 (2.1 x 10-4) 1.35 (2.20 x 10-8)
Gli3 GLI-Kruppel family member GLI3 0.03 1.16 (2.4 x 10-3) 1.28 (2.1 x 10-4)
Gpr23 G protein-coupled receptor 23 0.04 1.26 (1.1 x 10-3) 1.38 (5.51 x 10-6)
Gpr34 G protein-coupled receptor 34 6.08 x 10-8 1.34 (5.5 x 10-10) 1.43 (9.44 x 10-12)
Lsm10 U7 snRNP-specific Sm-like protein 0.03 1.12 (9.0 x 10-4) 1.16 (4.80 x 10-4)
Tnnc1 troponin C, cardiac/slow skeletal 0.03 1.19 (0.04) 1.45 (4.0 x 10-5)
Tom1l2 target of myb1-like 2 (chicken) 2.53 x 10-3 -1.47 (2.0 x 10-5) -1.53 (1.33 x 10-7)
Numbers represent the mean fold-change for each gene transcript seen in the respective mutant mice compared wild-type mice. The 
numbers in brackets represent the P-value for the respective fold change.
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Also for the cerebellum, from which the cerebellar ataxia originates, we extracted a signature (i.e., 
‘ataxia’ gene signature) containing genes that were differentially expressed in the cerebellum of 
S218L KI mice (compared to R192Q KI and wild-type mice). The ‘ataxia’ signature contained 296 
genes (Figure 1B). Using the Ontologizer program, a GO term analysis was performed for under- or 
over-representation of functional categories and yielded significant overrepresentation of four 
biological processes GO terms (Table 4). All four were related to neurotransmitter synthesis. 
Subsequently, qPCR analyses were performed for five DEGs from these pathways and essentially 
confirmed the findings of the microarray experiments (Figure 2). Using the Anni text-mining 
program we investigated possible literature-based relationships between the term ataxia and 
the genes in the ‘ataxia’ gene signature. The Ppp2r2b gene, encoding brain-specific regulatory 
subunit of the protein phosphatase PP2A, and the Gfap gene, encoding glial fibrillary acidic 
protein, showed most obvious literature-based relationships with ataxia. Ppp2r2b and Gfap were 
both upregulated in the cerebellum of the S218L KI mice with a fold-change of 1.2 (P = 6.4x10-4) 
and 1.6 (P = 2.9x10-4), respectively.
Table 4 Pathways that were significantly overrepresented in the ‘ataxia’ gene signature (P < 0.05 after Benjamini-Hochberg correc-
tion for multiple testing)
Gene Symbol Gene Description Fold change (P-value)
GO:0042401 biogenic amine biosynthetic process
Agmat Agmatine ureohydrolase (agmatinase) 2.71 (4.27 x 10-9)
Ddc Dopa decarboxylase 1.26 (7.60 x 10-4)
Hdc Histidine decarboxylase -1.92 (4.73 x 10-7)
Th Tyrosine hydroxylase 13.12 (3.92 x 10-20)
Tph2 Tryptophan hydroxylase 2 1.58 (6.90 x 10-4)
GO:0042398 amino acid derivative biosynthetic process
Agmat Agmatine ureohydrolase (agmatinase) 2.71 (4.27 x 10-9)
Ddc Dopa decarboxylase 1.26 (7.60 x 10-4)
Hdc Histidine decarboxylase -1.92 (4.73 x 10-7)
Th Tyrosine hydroxylase 13.12 (3.92 x 10-20)
Tph2 Tryptophan hydroxylase 2 1.58 (6.90 x 10-4)
GO:0042423 catecholamine biosynthetic process
Ddc Dopa decarboxylase 1.26 (7.60 x 10-4)
Hdc  Histidine decarboxylase -1.92 (4.73 x 10-7)
Th Tyrosine hydroxylase 13.12 (3.92 x 10-20)
GO:0042136 neurotransmitter biosynthetic process
Gad2 Glutamic acid decarboxylase 2 1.20 (2.00 x 10-5)
Th  Tyrosine hydroxylase 13.12 (3.92 x 10-20)
Tph2 Tryptophan hydroxylase 2 1.58 (6.90 x 10-4)
Output generated using Ontologizer programm
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Figure 2. Quantitative PCR analysis of genes altered in the cerebellum of S218L mice. Data are expressed as fold changes (means ± 
SD), normalized to Gapdh mRNA expression, where the values for wild-type mice were set at 1.00 or -1.00. * P < 0.05 compared to 
the wild-type mice. 
The most striking fold-change in the ‘ataxia’ gene signature was seen for tyrosine hydroxylase 
(Th) (fold-change 13.1; P = 3.92x10-20). Th up-regulation was also observed at the protein level, 
as evidenced by strong immunoreactivity in a considerable number of Purkinje cells specifically 
in the cerebellum of S218L mice (Figure 3). 
Figure 3. Protein expression of tyrosine hydroxylase (Th) in the cerebellum. Immunohistochemistry using Th-specific antibody 
(brown signal). Some Purkinje cells stain positive in the S218L mutant. Left panel: wild-type, right panel: S218L. M: molecular layer, 
PC: Purkinje cell layer, G: Granule cell layer, WM: white matter. 
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Discussion
Here we performed the first gene expression study in transgenic KI mouse models carrying human 
pathogenic FHM1 mutations R192Q and S218L in an attempt to increase our insight in the 
molecular consequences of these mutations in migraine pathophysiology.
Despite considerable insight in the pathophysiology of migraine attacks, it is still largely 
unknown how attacks begin and to what extent the migraine brain is different from a healthy 
brain. Therefore, we studied RNA expression profiles of brains of migraine mouse models under 
basal conditions. We investigated the third most caudal part of the cortex (that includes the 
visual cortex) because CSD, the electrophysiological substrate of the migraine aura, originates 
in this area of the cortex.13 In addition, we studied the cerebellum because cerebellar ataxia 
originates from this area of the brain and cerebellar ataxia is a prominent part of the phenotype 
of S218L mice. 
In line with earlier studies on these mouse models that revealed unchanged numbers of functional 
CaV2.1 channels at the plasma membrane
19,20, mRNA expression levels of the mutated Cacna1a 
gene were relatively similar between genotypes. Therefore, FHM1 mutations do not seem to affect 
this gene at the RNA level. Similarly, no clear changes in gene expression levels were observed for 
other subunits of CaV channels. Consequently, we postulate that the clinical features seen in mice 
and patients with FHM1 gene mutations are likely more the result of changed functionality of 
CaV2.1 channels, perhaps in combination with changes in downstream targets of these channels.
As both KI mutants were generated on a mixed C57BL/6J x 129SvEv genetic background19,20, 
despite being back-crossed to C57BL/6J for several generations, one should take into account 
that gene sequences on chromosome 8 that flank the mutated Cacna1a gene are still of 129 
origin. Valor and Grant have shown that remnant 129 sequences may lead to gene expression 
differences because of mixed genetic differences at this location.23 Indeed, when comparing 
expression profiles from mutant KI and wild-type mice, we observed a much higher than expected 
frequency of DEGs located in close proximity of the mutated Cacna1a gene. Unlike what was 
reported in their study, no selection cassette, which is known to profoundly affect expression of 
neighbouring genes, was present in our mice. Therefore, in our study it is more likely that gene 
expression differences are the direct consequence of subtle differences in genetic background 
(i.e., 129Sv vs. Bl6). Although we do not have any evidence for it, we postulate that perhaps the 
presence of 32-bp LoxP sequences that are still present in the targeted locus, might have a cis-effect 
on gene expression of neighbouring genes.
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Although molecular and electrophysiological studies have shown that neuronal excitability is 
increased in the KI mutants, we could show that this is not accompanied with prominent gene 
expression changes in the occipital cortex (at least under unchallenged conditions). In fact, 
only nine genes were differentially expressed in the cortex of mutant KI mice. In contrast, 
many expression differences were observed in the cerebellum of the mutant KI mice; especially 
in the cerebellum of the S218L mice. This may be expected since mice (and patients) with the 
S218L mutation suffer from cerebellar ataxia. GO term analysis with the S218L-specific ‘ataxia’ 
gene signature showed significant overrepresentation of genes belonging to pathways involved 
in neurotransmitter synthesis. Especially catecholamine neurotransmitter (i.e., dopamine and 
serotonin) pathways were differentially expressed.
In the S218L-specific ‘ataxia’ gene signature, the largest fold-change was observed for the 
tyrosine hydroxylase (Th) gene, which encodes the rate-limiting enzyme of the biosynthetic 
pathway of catecholamines, dopamine, norepinephrine and epinephrine.24 Th overexpression was 
confirmed at the protein level with immunohistochemistry (Figure 3). Th is transiently expressed 
in the cerebellum during development, but absent (or very low expressed) in the cerebellum of 
adult mice.25 Hence, Th expression in the adult cerebellum is considered a marker for delayed 
maturation of the cerebellum. Interestingly, also other ataxic mouse models with natural Cacna1a 
mutations (i.e., Rolling Nagoya, Tottering, and Leaner) show a high, persistent Th expression in 
the adult cerebellum.26-28 However, as phosphorylation of several serine residues is absent in 
up-regulated Th in these mice, but important for Th activity29,30, it is unclear whether also Th 
function is abnormal in Cacna1a mutant mice. Notably, a recent expression profiling study in 
Purkinje cell degeneration mice, which are characterized by degeneration of cerebellar Purkinje 
cells and progressive ataxia, showed a 2-fold increase in expression of the Th gene.31
Several genes in the S218L-specific ‘ataxia’ gene signature can be linked to cerebellar ataxia 
relevant pathways. For example 5’ non-coding CAG expansions in the PPP2R2B gene, which 
encodes a brain-specific regulatory subunit of the protein phosphatase PP2A holoenzyme, cause 
spinocerebellar ataxia type 12 (SCA12).32 The repeat expansion leads to increased PPP2R2B 
expression33, similar to what was found in the cerebellum of the S218L KI mice. In addition, 
mutations in glial fibrillary acidic protein (GFAP) are associated with infantile and juvenile 
Alexander disease; a rare leukodystrophy of the cerebellum.34 Gait ataxia is a common clinical 
feature in patients with adult-onset Alexander disease.35-37 
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In conclusion, the occipital cortex of the KI mouse models of migraine did not show prominent 
expression differences. The transcriptome of the occipital cortex in migraine mice was remarkably 
stable. This enables future profiling studies that aim to investigate the consequences on RNA 
expression of triggers relevant to migraine. On the other hand, certain differences in RNA 
expression profiles of the cerebellum of the S218L KI mice could be linked to ataxia. 
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Supplementary Tables
Supplemental Table 1. Primers used for qPCR
Gene symbol Gene description Primer sequence Amplicon size
Adcyap1 Adenylate cyclase activating polypeptide 1 F 5’-TTTCCTAGACACCAATGACCA-3’  79 bp
  R 5’-GACACTGCTATGCATTATTATCCC-3’ 
Agmat Agmatine ureohydrolase (agmatinase) F 5’-TATGATCTCTCTGGTAACACAGC-3’  101 bp
  R 5’-TCAGGAACACAGACTCAGAC-3’ 
Hdc Histidine decarboxylase F 5’-GTCAAGGACAAGTACAAGCTG-3’ 84 bp
  R 5’-ATCTGCCAATGCATGAAGTC-3’ 
Tac1 Tachykinin 1 F 5’-CAGCAGTTCTTTGGATTAATGG-3’ 92 bp
  R 5’-CTGGCCATGTCCATAAAGAG-3’ 
Th Tyrosine hydroxylase F 5’-AGCCCTACCAAGATCAAACC-3’ 75 bp
  R 5’-GCATAGTTCCTGAGCTTGTC-3’    
Supplemental Table 2. Expression levels of genes encoding the auxiliary subunits of the CaV2.1 channel in both tissues for both KI mice 
  Cerebellum  Occipital Cortex
Gene R192Qa S218La R192Qa S218La
Genes encoding the auxiliary subunits
Cacnb1 1.19 (0.06) 1.28 (0.007)* -1.16 (0.03)* -1.02 (0.68)
Cacnb2 1.1 (0.51) -1.09 (0.29) 1.15 (0.11) 1.01 (0.85)
Cacnb3 1.05 (0.43) 1.04 (0.70) -1.28 (0.03)* -1.09 (0.42)
Cacnb4 1.05 (0.55) -1.09 (0.39) 1.08 (0.64) -1.19 (0.08)
Cacng1 1.07 (0.43) -1.02 (0.78) 1.16 (0.08) 1.08 (0.32)
Cacng2 -1.06 (0.25) -1.02 (0.67) 1.02 (0.50) -1.04 (0.31)
Cacng3 1.04 (0.54) -1.12 (0.35) 1.02 (0.88) -1.14 (0.18)
Cacng4 1.06 (0.47) 1.09 (0.48) -1.10 (0.38) 1.12 (0.35)
Cacng5 1.06 (0.39) 1.10 (0.13) -1.16 (0.12) 1.12 (0.17)
Cacng6 -1.09 (0.78) -1.31 (0.44) -1.16 (0.54) -1.46 (0.07)
Cacng7 1.12 (0.44) -1.12 (0.46) -1.26 (0.26) -1.39 (0.04)*
Cacng8 -1.03 (0.85) 1.21 (0.10) -1.12 (0.46) -1.03 (0.75)
Cacna2d1 1.04 (0.76) -1.29 (0.12) 1.24 (0.22) -1.01 (0.74)
Cacna2d2 1.01 (0.83) 1.11 (0.13) 1.10 (0.27) 1.02 (0.80)
Cacna2d3 -1.01 (0.92) 1.06 (0.25) -1.05 (0.29) -1.04 (0.33)
Cacna2d4 1.09 (0.41) 1.01 (0.92) -1.00 (0.99) 1.02 (0.68)
aFold change of respective mutant mice compared to wild-type mice, P-value for the respective fold change is indicated between 






Migraine is an episodic neurovascular disorder that is characterized by severe headache, autonomic, 
and other neurological symptoms.1 The identification and characterization of migraine genes 
and molecular pathways will help increase our knowledge of migraine pathophysiology. As the 
identification of genetic susceptibility factors for complex disorders is particularly challenging, 
this thesis also focused on alternative approaches to improve our insight in the molecular 
mechanisms of migraine. These approaches range from genetic and functional studies of gene 
mutations in rare monogenic migraine subtypes (e.g., hemiplegic migraine and other disorders 
with a high migraine prevalence) to genetic studies in a Dutch genetically isolated population, 
and gene expression studies in transgenic migraine mouse models. 
8.1 Hemiplegic migraine: a monogenic form of migraine with aura 
Genetic studies in FHM: genes encode ion transporters
A successful approach to identify genes and unravel pathways for migraine has been the 
investigation of monogenic subtypes of the disease. The best example is Familial Hemiplegic 
Migraine (FHM), a rare form of migraine with aura. FHM can be considered a model for the 
common forms of migraine because the headache and aura features, apart from the hemiparesis, 
are identical2 and two-thirds of FHM patients have, in addition to attacks of FHM, also attacks of 
common non-hemiplegic migraine.3 Linkage studies in FHM families resulted in the identification 
of three FHM genes; CACNA1A (FHM1), ATP1A2 (FHM2) and SCN1A (FHM3). The fact that not all 
FHM families are linked to one of these three known FHM loci implies that there are additional 
FHM genes. 
The CACNA1A FHM1 gene encodes the α1 subunit of CaV2.1 channels.4 Until now, 28 different FHM1 
missense mutations have been described (figure 1). FHM1 mutations are associated with a broad 
spectrum of clinical features. Besides hemiplegic migraine, FHM1 patients can have cerebellar 
ataxia5-9 and/or epilepsy.10,11 FHM1 patients carrying the S218L mutation can have a particularly 
severe phenotype with attacks that can be triggered by mild head trauma and that in some cases 
may lead to fatal, cerebral edema and coma.12-15 In Chapter 2.1, we report on a monozygotic twin 
pair with a novel de novo CACNA1A V1696L mutation. This mutation causes an overlap syndrome 
between FHM and alternating hemiplegic of childhood (AHC), a severe neurological childhood 
disorder that shares several clinical features with FHM. This study provided the first evidence that 
a mutation in the CACNA1A gene can cause an AHC/FHM overlap syndrome. 
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Figure 1. Mutations in the α1 subunit of the voltage-gated CaV2.1 Ca2+ channel encoded by the FHM1 CACNA1A gene (Genbank 
Ac. nr. X99897). The protein is located in the plasma membrane and contains four repeated domains, each encompassing six 
transmembrane segments. Symbols: Circle with solid line = FHM, circle with dotted line = SHM. Asterisk = Mutation for which also 
SHM was reported, black circles mutation was tested for functional consequences, white circle mutation was not tested for functional 
consequences
The second FHM gene, ATP1A2 (FHM2) encodes the α2 subunit of sodium-potassium pumps.16 To 
date many mutations in the ATP1A2 gene have been described (Figure 2) and the vast majority is 
associated with pure FHM without additional clinical symptoms.16-20 However, some are associated 
with FHM and cerebellar problems21, benign familial neonatal convulsions (BFIC)22, epilepsy18,23, 
or permanent mental retardation.18,24 In Chapter 2.2 we present a novel ATP1A2 G855R mutation 
with functional consequences. Besides hemiplegic migraine, mutation carriers can also have 
febrile seizures. With this study, we further expanded the clinical spectrum associated with 
ATP1A2 mutations. Also non-hemiplegic migraine phenotypes were found to be associated to 
some ATP1A2 mutations, including basilar migraine25 and even common migraine26, although 
causality has not been established for all mutations by testing their functional consequences. 
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Figure 2. Mutations in the α2 subunit of the Na+,K+ ATPase encoded by the FHM2 ATP1A2 gene (Genbank Ac. nr. NM_000702). The 
protein is located in the plasma membrane and contains ten transmembrane segments. Symbols: Circle with solid line = FHM, circle 
with dotted line = SHM, circle with horizontal striped pattern = basilar-type migraine, circle with vertical striped pattern = common 
migraine. Asterisk = mutation for which also SHM was reported, black circles = mutation was tested for functional consequences, 
white circle = mutation was not tested for functional consequences.
Finally, the SCN1A (FHM3) gene encodes the α1 subunit of neuronal NaV1.1 voltage-gated 
sodium channels.27 The SCN1A gene is a well-known epilepsy gene with over 100 mutations 
that are associated with childhood epilepsy, i.e., severe myoclonic epilepsy of infancy (SMEI) or 
generalized epilepsy with febrile seizures (GEFS+).28,29 Only five FHM3 mutations (Figure 3) have 
been identified. First confirmation of SCN1A as a migraine gene is described in Chapter 2.3. The 
SCN1A L1649Q mutation was identified in a Caucasian North American FHM family with ‘pure’ 
FHM, without cerebellar signs or epilepsy symptoms. The third FHM3 mutation was identified in a 
FHM family in which three out of five carriers of the L263V mutation had generalized tonic-clonic 




Figure 3. Mutations in the α1 subunit of the voltage-gated NaV1.1 Na+ channels encoded by the FHM3 SCN1A gene (Genbank Ac. nr. 
NM_006920). The protein is located in the plasma membrane and contains four repeated domains. Symbols: Black circles = mutation 
was tested for functional consequences, white circle = mutation was not tested for functional consequences.
Functional studies of FHM mutations
Functional consequences of FHM gene mutations have been studied in cellular and animal 
models. At the single channel level, FHM1 mutations were shown to cause opening of CaV2.1 
channels at more negative voltages and have an enhanced channel open probability, compared 
to normal channels.31-33 These gain-of-function consequences predict an increased calcium influx 
and increased neurotransmission. The generation and analysis of transgenic knock-in migraine 
mice with human pathogenic FHM1 mutations (i.e., FHM1 R192Q and FHM1 S218L mutant mice) 
revealed gain-of-function consequences of these mutations34,35; not only with respect to calcium 
influx, but also for spontaneous and evoked neurotransmission at the neuromuscular junction, a 
synapse in the peripheral nervous system where transmitter release is predominantly determined 
by CaV2.1 calcium channels. Most relevant for migraine pathophysiology, in both strains of mutant 
mice, the threshold for inducing a CSD was lowered and the propagation velocity of the CSD wave 
was increased. Whereas FHM1 R192Q migraine mice have no overt phenotype, FHM1 S218L mice 
exhibit cerebellar ataxia, seizure susceptibility, and head trauma induced brain edema as also 
seen in FHM1 S218L patients. These observations indicate that the FHM1 mutant mice are useful 
models to study the pathophysiology of migraine in vivo. Future studies have to reveal exactly 
how a lower activation threshold of mutated CaV2.1 calcium channels can lead to an episodic 
disease. One may envisage that only when the stimulus is strong (for instance with repetitive 
neuronal firing) and the threshold is temporarily lowered (for instance by hormonal changes), 
hyperexcitability of neurons in a susceptible brain leads to a cascade ending with a full-blown 
migraine attack. 
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The functional consequences of a large number of ATP1A2 mutations causing either FHM or SHM 
have been investigated in various in vitro assays. Many were shown to be dysfunctional as they 
– unlike wildtype - were not (or only partially) able to rescue cell survival in assays in which 
endogenous sodium potassium pumps were inactivated by the drug ouabain.36 In these assays, 
wildtype or mutant α2 Na+,K+- ATPase cDNAs were made insensitive to the ouabain challenge. More 
detailed functional studies revealed that FHM2 mutations G301R, T376M, L764P, W887R, R855R 
lead to non-functional proteins37,36,38,39 or sodium potassium pumps with partial activity with 
decreased (in the case of T345A and A606T) or increased (in the case of R689Q, M731T, R763H, 
and X1021R) affinity for potassium.40,41,38 For five FHM2 mutations (i.e., R383H, R689Q M731T, 
R763H, and R834Q) a reduced turn-over rate was shown. Since FHM2 mutations compromise 
pump function, Atp1a2 knockout mice may serve as a good model for FHM. However, Atp1a2 
knockout mice that lack the α2 subunit have a very severe phenotype and die immediately 
after birth because of their inability to take a first breath.42,43 Heterozygous mice are viable and 
exhibit enhanced fear and anxiety following conditioned fear stimuli.42 These mice have not been 
evaluated as potential migraine mouse models.
The functional consequences of three FHM3 mutations have been investigated.27,44 Whereas early 
functional studies of FHM3 mutations Q1489K and L1649Q revealed various gain-of-function effects 
when using a cardiac NaV1.5 cDNA as backbone for making the constructs
27,44, more recent studies 
that investigated the consequences of these FHM3 mutations in the more appropriate NaV1.1 
protein revealed clear loss-of-function effects.45 The third FHM3 mutation L263V that in patients 
causes FHM and in the majority of carriers also generalized tonic-clonic epilepsy, essentially had 
gain-of-function effects.45 It was hypothesized that loss of sodium channel activity primarily 
disturbs the functioning of inhibitory neurons, where the NaV1.1 normally are expressed
46,47, 
whereas gain of activity has a predominant effect on excitatory neurons. Interestingly, when 
overexpressed in neurons, depending on the test paradigm, the Q1489K mutation seemed to 
have functional consequences fitting either with hyperexcitability or hypoexcitability (i.e., self-
limiting hyperexcitability capacity)48, but this has not been tested in knock-in mice.  
8.2 How do FHM mutations cause disease?
Can the molecular genetic findings of the three FHM genes (CACNA1A, ATP1A2 and SCN1A) be 
integrated into a common pathway? More specifically, can we link the functional consequences 
of the three genes to for instance an increased propensity for CSD? Mutant CaV2.1 calcium 
channels from FHM1 R192Q and S218L knock-in mice predict increased glutamate release in 
the cerebellar cortex and thereby can easier induce, maintain, and propagate CSD; this is in 
line with the observed decreased threshold for CSD in knock-in mice.34,35 FHM2 mutations in 
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the sodium-potassium pump predict in vivo reduced glial uptake of K+ and glutamate from the 
synaptic cleft. FHM3 mutations in the NaV1.1 sodium channel predict in vivo hyperexcitability 
of excitatory neurons. Therefore, the consequence of FHM1, FHM2, and FHM3 mutations all seem 
to cause increased levels of glutamate and K+ in the synaptic cleft and thereby facilitate CSD 
(Figure 4). The increased propensity for CSD could well explain the aura, but, it remains to be 
established whether this also would result in a more readily activated trigeminovascular system 
with structures in the brainstem from which the headache originates. 
 
Figure 4. Schematic representation of a glutamatergic sysnapse and the proteins encoded by the three FHM genes and the SLC1A3 
gene (adapted from Barret et al. 2008). NaV1.1 channels (encoded by SCN1A) are essential for the generation and propagation of action 
potentials. In response to an action potential, calcium enters the cell via CaV2.1 channels (encoded by CACNA1A) and glutamate will be 
released by vesicles into the synaptic cleft. Potassium in the synaptic cleft is removed in part by the action of the Na+/K+-ATPase (encoded 
by ATP1A2) which is located at the surface of glial cells (astrocytes). Removing extracellular K+ generates a Na+ gradient, which drives 
uptake of glutamate from the cleft by transporters, for example, EAAT1 (encoded by SLC1A3). Energy is required and achieved by glucose 
utilization after uptake from blood vessels. Gain-of-function mutations in CaV2.1 and loss-of-function mutations in the ATPase, NaV1.1 
and EAAT1 will each lead to of increased general excitability.
8.3 Do FHM genes play a role in SHM?
Not all hemiplegic migraine patients are part of FHM families. So-called sporadic hemiplegic 
migraine (SHM) patients do exist, and exhibit clinical symptoms that are very similar to those 
of familial cases.49 For instance, SHM - like FHM - patients can have attacks of common migraine 
that are not associated with hemiparesis. Also the prevalence of familial and sporadic hemiplegic 
migraine in the population is similar; both are rare with a prevalence of approximately 0.01%.50 
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Therefore, an interesting question is whether FHM genes also play a role in SHM? Previously, only 
one study addressed that question, and investigated the involvement of the CACNA1A gene in 
27 SHM patients; two CACNA1A mutations were identified.51 Chapter 3 of this thesis describes a 
study that reports a systematic mutation screen of all three FHM genes in 39 clinic-based ‘pure’ 
SHM patients without cerebellar signs or epilepsy. About 15% of our SHM patients had mutations 
in FHM genes; predominantly in the ATP1A2 gene. SHM could not be explained by mutations in 
known FHM genes in the majority of patients. The frequency of mutations was even lower in 
a Danish population-based study.52 In one hundred SHM patients only 8 sequence variants in 
CACNA1A and ATP1A2, of which only 2 were considered pathogenic, were identified; no functional 
studies were performed to proof causality. This indicates a difference between Dutch and Danish 
patients, diagnosis, and/or mutation detection methodology. Regardless, these genetic studies 
indicate that (i) SHM belongs to the genetic migraine spectrum, and that (ii) other genetic factors 
likely play a role in SHM. Future research must show whether these patients have a mutation in 
yet undiscovered hemiplegic migraine genes, or whether they have an unfavorable combination 
of low-risk gene variants present in a single patient. 
8.4 Is it possible to translate genetic results from HM to common migraine?
As the main clinical symptoms of headache and aura are similar in FHM and common migraine, 
it is thought that they may share a common pathophysiology.3 Several studies have investigated 
the role of FHM1 and FHM2 loci in the common forms of migraine. These studies led to conflicting 
results with some evidence in favor of the hypothesis53-55,26, while others find no evidence for 
their involvement in common migraine.56-58 Some of the studies hypothesized that mutations 
found in FHM may cause common migraine, while it is more likely that ‘milder’, less penetrant, 
DNA variants are involved. A recent comprehensive study, including some 2800 migraine patients 
from various European countries, tested whether common DNA variants in ion transport genes are 
involved in common migraine.59 Over 5,000 SNPs in 155 ion transport genes (including the three 
FHM genes) were studied, but none of the original significant SNPs (66 SNPs in 12 genes) was 
significant across all four replication cohorts. From this study it seems that common variants in 
ion transport genes do not play a major role in susceptibility for common migraine. Rare variants 
or variants with a very small effect size would not have been detected with this study design.
8.5 Genetic studies in other disorders in which migraine is prevalent 
Another approach to identify genes and pathways for complex disorders is to study disorders 
that are comorbid with that particular genetically complex disease. Migraine can be part of 
the clinical spectrum of certain monogenic disorders. A good example is Cerebral Autosomal 
Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) (for recent 
review see Stam et al)60. CADASIL is caused by mutations in the NOTCH3 gene, which encodes the 
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Notch3 receptor that plays a key role in vascular smooth muscle cell function in small arteries 
and arterioles of the brain.61 Up to one-third of CADASIL patients suffers from migraine with 
aura, where migraine often is the presenting clinical symptom.62 The link with MA and not the 
more frequent MO, suggests that increased susceptibility for CSD is somehow caused by NOTCH3 
mutations. This hypothesis is strengthened by the fact that transgenic Notch3 mice have a decreased 
threshold for CSD.63 A second example is Retinal Vasculopathy with Cerebral Leukodystrophy 
(RVCL) that is caused by mutations in the TREX1 gene that encodes the major mammalian 3’-5’ 
DNA exonuclease (Chapter 5.1). RVCL originally was described in three families under different 
disease names; cerebroretinal vasculopathy (CRV), hereditary vascular retinopathy (HVR), and 
hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS).64-67 RVCL is primarily 
characterized by progressive blindness due to vascular retinopathy and can be associated with 
a wide range of systemic and cerebral symptoms, including cerebral infarcts and white matter 
hyperintensities, vascular dementia, liver and kidney dysfunction, Raynaud’s phenomenon, 
and migraine. Particularly in a Dutch RVCL family, migraine and Raynaud’s phenomenon are 
prominent.66 Comorbidity of migraine with CADASIL and RVCL indicates that cerebral or meningeal 
vasculopathy and vascular dysfunction may play a role in migraine.68 TREX1 mutations were also 
identified in other vascular and immune-related disorders, such as Systemic Lupus Erythomatosus 
(SLE) and Familial Chilblain Lupus (FCL).69,70 Chapter 5.2 describes a TREX1 mutation screen in 
60 patients with neuropsychiatric SLE (NPSLE), with and without white matter hyperintensities 
(WMH). We identified the first gene mutation in a NPSLE patient with WHM. Interestingly, this 
patient also has severe migrainous headache, which is known to be common in SLE patients.71  
Another pathway that is important in migraine pathophysiology is the ‘neuronal hyperexcitability 
pathway’. Depression and epilepsy are two genetic disorders in which neuronal hyperexcitability 
is thought to play a role. It is consistently found that migraine patients have an increased risk 
for migraine and epilepsy. This relation is bi-directional, meaning that patients with depression 
or epilepsy also have an increased risk for migraine.72-77 This reinforces the hypothesis that 
overlapping pathways play a role in migraine and epilepsy and in migraine and depression. 
For instance co-occurrence of epilepsy and migraine was reported for several FHM mutation 
carriers.22,11,78,21,79 Recent genetic research points to yet another gene that seems to fit perfectly 
into the FHM pathway of cortical hyperexcitabiltiy: the SLC1A3 gene that encodes EAAT1, a 
glutamate transporter that is located on astrocytes (Figure 4). A P290R mutation in this gene was 
shown to cause severe episodic ataxia and progressive ataxia, seizures, alternating hemiplegia, 
and migraine headache.80 Mutant EAAT1 showed severely reduced glutamate uptake. In Chapter 4, 
we describe a novel C186S EAAT1 mutation in a patient with episodic ataxia. Functional studies 
showed a modest but significant reduction of glutamate uptake, which is in line with the milder 
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phenotype. Because of the known relation between ataxia and hemiplegia with FHM1 mutations, 
the finding of SLC1A3 mutations causing both ataxia and hemiplegia has potential relevance for 
FHM as well.    
8.6 Linkage studies in common migraine 
A major genetic strategy to identify migraine susceptibility genes has been classical linkage 
analysis that aims to find linked chromosomal loci using a family-based approach. Over the 
years, a number of chromosomal loci (Table 1) have been identified using either migraine without 
or with aura patients diagnosed according to the International Headache Criteria (i.e., IHS 
diagnosis).1 However, with a few exceptions, replication of initial findings was unsuccessful. One 
of the most promising migraine susceptibility loci resides on chromosome 4; initial linkage to 
chromosome 4q24 in Finnish MA families81 was replicated in an Icelandic sample of MO patients.82 
Although the Finnish and Icelandic migraine loci are not identical, but seem to overlap, it is 
yet unclear whether they harbor different migraine susceptibility genes. Lack of success with 
the linkage approach probably is due to the high prevalence of migraine making it difficult to 
ascertain “clean” pedigrees for linkage where migraine genes from spouses do not interfere with 
the analysis. 
Table 1 Summary of relevant linkage results performed for migraine using the International Headache Classification (IHC) classifica-
tion guidelines.
Chromosomal locus Phenotype Genotyping method Reference
1q31  MA, MA/MO* Regional microsatellite markers Lea et al. 2002
4q21 MO Genome-wide scan Bjornsson et al. 2003
4q24 MA Genome-wide scan Wessman et al. 2002
6p12.2-p21.1 MA/MO Genome-wide scan Carlsson et al. 2002
10q22-q23  MA Genome-wide scan Anttila et al. 2008
11q24 MA Genome-wide scan Cader et al. 2003
14q21.2-q22.3 MO Genome-wide scan Soragna et al. 2003
15q11-q13 MA Regional microsatellite markers Russo et al. 2005
19p13 MA Regional microsatellite markers Jones et al. 2001
Xq25-q28 MA/MO Regional microsatellite markers Nyholt et al. 1998; 2000
MO = migraine without aura; MA = migraine without aura; *Only suggestive linkage for MA/MO combined.
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In the last few years, linkage studies made use of alternative phenotyping approaches that are 
based either on individual migraine traits in “trait component analysis (TCA)” or that use a 
combination of clinical migraine features in “latent class analysis (LCA)”. Whereas TCA is rather 
straightforward, LCA involves a complex statistical empirical clustering approach based on factor 
analysis that combines the information of several migraine symptoms.83,84 The classification 
reflects disease severity and does not specifically separate MO from MA. In principle, TCA and to a 
certain degree LCA, reflects the underlying processes in migraine pathophysiology as they utilize 
the questionnaire-based information in a more optimal manner, compared to the dichotomous 
IHS end diagnosis.85 It can be expected that by using TCA, the clinical heterogeneity will be 
reduced, since traits better reflect the biological pathways that are influenced by specific genetic 
variations. Several migraine loci were identified using this alternative phenotyping strategy (see 
Table 2).
Table 2 Summary of linkage results performed for migraine grouped for phenotyping methods Latent Class Analysis (LCA) and Trait 
Components Analysis (TCA).
Chromosomal   Phenotypic trait (analysis method)* Reference
locus
4q24  Age at onset, photophobia, phonophobia, photo- and  Anttila et al. 2006 
phonophobia, pain intensity, unilaterality, pulsation,  
nausea and vomiting (TCA) 
5q21  Pulsation (LCA) Nyholt et al. 2005
10q22-q23  Migrainous headache (LCA) Anttila et al. 2008
10q22-q23   Unilaterality, pulsation, pain intensity,  Anttila et al. 2008 
nausea/vomiting, photophobia, phonophobia (TCA) 
17p13  Pulsation (TCA) Anttila et al. 2006
IHS = International Headache Society; LCA = Latent Class Analysis; TCA = Trait Component Analysis. *Order based on level of signifi-
cance (most significant trait mentioned first).
8.7 Candidate gene association studies
In common disorders, such as migraine, many common genetic factors (present in more than 1–5% 
of the population) are thought to play a role in disease susceptibility. This phenomenon is known 
as the ‘common disease, common variant’ hypothesis. A frequently used strategy to identify 
these common gene variants for common disorders are case-control association studies.86-89 These 
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studies test for significant differences in allele frequencies between cases and controls. Many 
candidate gene association studies have been performed in migraine research; mainly of genes 
involved in the serotonin and dopamine pathways - but also in other genes with an already 
suspected function in migraine pathophysiology. Unfortunately, the majority of the associations 
could not be replicated, suggesting that many of the original findings may in fact represent false 
positive findings (for review see De Vries et al)90. Studies often contained rather low numbers of 
cases and controls; the ones that used 275 cases and controls or more are summarized in Table 
3. A positive exception is a recent study that analyzed several SNPs in ten different genes from 
the dopamine system in over 600 MA cases and controls using a two-step design and showed a 
positive association with single SNPs in DBH, DRD2 and the SLC6A3 genes, also after multiple 
testing.91 Functional consequences of any of these associated SNPs are still unknown. 
 
Another promising association finding seems to be with the 5’,10’-methylenetetrahydrofolate 
reductase (MTHFR) gene. MTHFR is a key enzyme in folate and homocysteine metabolism.92 Most 
studies found an association of the T-allele of the MTHFR C677T polymorphism with migraine 93-
98, although negative findings have been reported as well.99,100 The T-allele results in moderately 
increased levels of homocysteine that may cause migraine through a vascular endothelium 
dysfunction effect, but evidence for this hypothesis is still lacking. Recently, also two meta-
analyses were reported for MTHFR and migraine.101,102 Both studies revealed that the T-allele is 
associated with MA, but not with migraine without aura or migraine overall. However when the 
results in one of the meta-analyse were stratified for ethnicity, the results were driven by studies 
in non-Caucasian populations.102 
8.8 Genome wide association studies
In recent years, high-throughput genotyping techniques developed rapidly allowing extensive 
genotyping in large cohorts for Genome Wide Association Studies (GWAS) became feasible. In 
contrast to hypothesis-driven candidate gene-based association studies, GWAS do not require 
prior knowledge about the disease mechanism. In Chapter 6, GWA studies in migraine are 
described. The first GWAS was conducted for the migraine subtype MA by the International 
Headache Consortium (Chapter 6.1). The initial study cohort contained a total of 2,748 clinic-
based European MA cases, of which 655 cases were of Dutch origin and were collected via the 
LUMINA (Leiden University Migraine Neuro Analysis) initiative.103 The most significantly associated 
SNP (P-value 5.1 x 10-9) is located on chromosome 8q22.1 and could be replicated in several 
independent migraine cohorts.104 Interestingly, the associated allele of this SNP was significantly 
correlated with expression levels of the adjacent AEG-1 gene. AEG-1 is expressed on astrocytes and 
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downregulates EAAT2, which is an important glutamate transporter in the brain that is important 
for glutamate from synaptic cleft.105 The AEG-1 gene seems to perfectly fit into the ‘glutamate 
pathway’ that is seen in FHM and common migraine.
For Chapter 6.2 we initially performed a GWAS for migraine in the Erasmus Rucphen Family (ERF) 
population, and subsequently this data was included in the first meta-analysis for migraine. 
The ERF population is a well-studied Dutch genetically isolated population, which resides in 
the Southwest of the Netherlands and consists of roughly 3,000 descendants of a relatively 
small numbers of founders in the mid 18th century. The main advantage of genetic studies in 
genetically isolated populations is that these populations are more homogeneous due to their 
relatively small number of founders that underwent rapid population expansion (i.e., genetic 
drift).106 In our GWA study none of the in total approximately 2.5 million SNPs reached genome-
wide significance (i.e., a P-value < 5.0 x 10-8). However, several SNPs in genes that seem relevant 
to migraine pathophysiology showed nearly significant association with migraine. Subsequently a 
meta-analysis was performed using the GWAS data of six population-based cohorts from the Dutch 
Icelandic (DICE) consortium, including the ERF cohort. For only one SNP a P-value below 10-4 was 
obtained in both the GWA in ERF and the meta-analysis study. The best SNP in the meta-analysis 
was located in the neuronal growth factor receptor gene (NGFR), which is a good candidate gene 
for migraine, due to is relevance to pain perception. Future replication and/or functional studies 
must reveal their true relevance to migraine pathophysiology. 
The most significant SNP from the clinic-based GWAS did not show a signal in the ERF GWAS 
and in the meta-analysis of the population-based migraine cohorts. This might be due to the 
difference between population-based and clinic-based migraine patients. Perhaps this specific 
SNP has an effect on disease severity. Furthermore, previous studies for other disorders also 
showed that often different GWAS for the same disease do not yield the same peaks107, which 
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8.9 Gene expression studies in knock-in migraine mouse models 
The availability of transgenic FHM1 knock-in mouse models34,35, gave opportunities to investigate 
gene expression profiles in brain tissues. The difference in severity of clinical features in patients 
with the R192Q (pure FHM) and the S218L mutation (FHM with cerebellar ataxia, epilepsy and 
increased susceptibility to head trauma induced brain edema) is reflected in the mouse models 
with the same FHM1 mutations. The fact that the more ‘severe’ mouse model also exhibits more 
profound changes in neuronal calcium influx, (cortical) neurotransmission, and susceptibility to 
CSD warrants an in-depth molecular analysis of the consequences of both mutations on gene 
expression profiles. Therefore, in Chapter 7 of this thesis, we performed a first gene expression 
study in both transgenic mouse models to investigate whether the observed hyperexcitabiliy might 
be associated with changes in gene expression levels under basal (i.e., untriggered) conditions. To 
this end, the occipital cortex (i.e., the origin of the CSD) and the cerebellum (i.e., the origin of 
the ataxia) were investigated. Gene expression levels in the occipital cortex were notably similar 
in cortices of mutant and wildtype mice. However, gene expression in the cerebellum of S218L 
mice was somewhat different from that in wildtype and R192Q mice. Several of the differentially 
expressed genes in the cerebellum of S218L mice could be related to neurotransmission and more 
specifically to ataxia, which is a prominent feature in patients and mice with this mutation. As 
an example, the gene with the highest fold change, tyrosine hydroxylase (Th), which could be 
confirmed at the protein level, had already been implicated in ataxia of several natural mouse 
Cacna1a models (i.e. Rolling Nagoya108, Tottering109, and Leaner.110 Perhaps additional microarray 
experiments using migraine-relevant triggers are needed before gene expression profiles are more 
pronounced and can be combined with GWAS and/or exome-genome sequencing to prioritize findings.
8.10 Future perspectives
This thesis focused mainly on the identification and characterization of migraine gene mutations 
and pathways. Three FHM genes have been identified. The genetic spectrum of FHM mutations and 
their associated clinical features have been investigated in this thesis. Not all FHM families can be 
explained by mutations in known FHM genes, so additional FHM genes must exist. It is interesting 
to assess whether novel FHM genes will fit in the same pathway as the known FHM genes, or 
whether they will highlight additional pathways with relevance to migraine pathophysiology. 
With the availability of ‘Next Generation Sequencing’ technology, which allows high-throughput 
sequencing of either desired regions of the genome, all exons of the genome (the so-called exome), 
or the entire genome, these  FHM genes will probably soon be identified. First successes in gene 
identification for monogenic disorders using this exome strategy were published.111 
General Discussion 8
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For common migraine, clinical and genetic heterogeneity make the identification of susceptibility 
genes even more difficult than gene discovery in FHM. The diagnosis of migraine is mainly based 
on questionnaires and (sometimes) interviewing the patients. Unfortunately, a more objective 
method of diagnosing patients, such as biochemical testing in blood (or cerebrospinal fluid or 
urine) is currently not available. Systematic studies to identify such reliable biomarkers are dearly 
needed as they will help defining more homogeneous groups of patients for genetic studies. 
Ideally, biomarker information should somehow be combined with other endophenotyping 
approaches such as previously discussed LCA and TCA. Particularly TCA seems to reduce clinical 
heterogeneity. Endophenotyping likely will increase the power of the genetic analyses. Also 
because, as was shown for several other complex disorders such as Attention-Deficit/Hyperactivity 
Disorder (ADHD) and schizophrenia, the heritability of the individual traits may be higher than 
of the syndrome as a whole (i.e., combination of traits).112,113 One appealing strategy to decrease 
heterogeneity in migraine is to take co-morbidity with other diseases into account. A recent 
study in ERF indicated that migraine and depression may share, at least to some extent, genetic 
factors.77 By stratifying for depression, gene discovery in migraine may become (a little) easier. At 
the moment, most investments in migraine genetics go into GWAS. For many complex disorders, 
GWAS already led to successes.114-116 The coming two years will be very exciting as additional 
GWAS are currently being performed for migraine. Still, most gene variants identified with GWAS 
have a low relative risk (RR) of often 1.1 - 1.3 and seem to explain only a small proportion of 
disease heritability. Therefore, it is now being questioned whether GWAS will contribute much 
to understanding the majority of the genetic load. The question at hand is where the majority 
of the genetic burden is and how to increase our understanding in migraine mechanisms. Is it in 
epistasis or copy number variation? Can pathway analyses on GWA data increase our insight117,118? 
Or is most of the genetic load carried in large number of allelic variants that combine a very low 
allele frequency with a reasonably high relative risk? As this genetic variation (usually) is not 
captured in current GWAS, other approaches (i.e., large-scale deep sequencing) are needed. Also 
for this approach, the technology is available. The next few years will have to show what this 
new technology can bring for migraine. In conclusion, although the last decade has produced 
major advances in our knowledge of migraine pathophysiology, the best perhaps is yet to come. It 
will require a true multidisciplinary approach to harvest this knowledge and translate it to novel 
treatment options to help migraine patients. 
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The research in this thesis was aimed at identifying and characterizing novel migraine gene 
mutations and pathways. Several FHM and non-FHM genes were investigated in patients with 
monogenic familial hemiplegic migraine or other monogenic disorders in which migraine can be 
prevalent. Functional consequences of these mutations and the clinical phenotypes associated 
with them were investigated. Common migraine with a complex genetic background was studied 
using a genome-wide association analysis in an isolated population and with a meta-analysis 
study. Furthermore, FHM1 mice were used to study expression profiles in brain tissues that are 
relevant for the induction of cortical spreading depression – underlying the migraine aura - (i.e., 
the occipital cortex) and cerebellar ataxia (i.e., the cerebellum). These studies will further our 
insight in the molecular pathophysiology of migraine. 
Chapter 2 describes three novel mutations in FHM genes. In Chapter 2.1, a novel V1696F 
mutation was reported in the FHM1 CACNA1A gene in two monozygotic twin brothers that had 
clinical features overlapping with both FHM and alternating hemiplegia of childhood (AHC). 
Here it was shown for the first time that a mutation in the CACNA1A gene can lead to atypical 
AHC. Previously, only one ATP1A2 mutation had been identified in a family with atypical 
AHC. In Chapter 2.2, an FHM2 ATP1A2 mutation was described causing hemiplegic migraine 
associated with febrile seizures. This family demonstrates the further broadening of the clinical 
spectrum of FHM2 mutations. In Chapter 2.3, mutation scanning in the SCN1A (FHM3) gene was 
performed in ten FHM families that were found negative for mutations in FHM1 and FHM2. A 
novel L1649Q mutation was identified in a large FHM family of North American origin. Although 
electrophysiological investigations revealed that the L1649Q mutation had gain-of-function 
properties when introduced in a SCN5A cDNA, recent parallel electrophysiological investigations 
suggested that a loss-of-function effect was observed when the mutation was introduced in 
the proper SCN1A background. The study firmly established the role of neuronal NaV1.1 sodium 
channels in FHM.
In Chapter 3 a systematic analysis was performed to investigate the possible involvement of 
FHM genes in a large set of sporadic hemiplegic migraine (SHM) patients. In six out of the 39 
well characterized SHM patients, without associated neurological features, a causal mutation was 
identified. One SHM patient had a CACNA1A mutation, five patients had ATP1A2 mutations. A 
presumable SCN1A mutation in a seventh patient was shown to be a polymorphism. Functional 
assays were performed for all sequence variants and all six mutations were shown to have 
functional consequences. Our findings indicate that known FHM genes are involved in ~14% of 
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SHM patients, but that other genetic and non-genetic factors must be involved as well. In clinical 
practice, screening of the ATP1A2 gene offers the highest likelihood of success in cases of “pure” 
SHM not associated with other neurological symptoms. 
The excitatory amino acid transporter EAAT1, encoded by the SLC1A3 gene, is located in the 
same FHM pathway; affecting glutamate levels in the synaptic cleft. An EAAT1 mutation was 
recently described in a patient with severe episodic and progressive ataxia, seizures, alternating 
hemiplegia, and migraine headache. For Chapter 4, mutation scanning of the SLC1A3 gene was 
performed in 20 patients with episodic ataxia that were negative for CACNA1A mutations. A 
novel missense C186S mutation that segregated with EA in three family members was identified. 
Functional analysis revealed a modest, but significant, reduction of glutamate uptake into COS7 
cells for the mutant EAAT1. Our study is the first evidence that SLC1A3 mutations can cause 
EA without associated seizures or alternating hemiplegia. Moreover, it shows that the severity 
of clinical symptoms associated with EAAT1 mutations appeared correlated with the extent of 
glutamate transporter dysfunction 
Chapter 5 describes genetic and functional studies on the TREX1 gene the major mammalian 
3’-5’ exonuclease. In Chapter 5.1, the TREX1 gene is described as the causative gene for retinal 
vasculopathy with cerebral leukodystrophy (RVCL). RVCL is an autosomal dominant disorder 
characterized by progressive blindness due to vascular retinopathy that can be associated with 
a wide range of clinical symptoms, including migraine. Nine RVCL families were described, all 
having frameshift mutations leading to truncation of the C-terminal part of the TREX1 protein. 
Functional studies showed that these truncated proteins retained their exonuclease activity, 
but have abnormal perinuclear localization. TREX1 mutations can also be associated with other 
vascular and immune-related phenotypes, such as Aicardi-Goutieres syndrome (AGS) or systemic 
lupus erythematosis (SLE). Chapter 5.2 describes 60 neuropsychiatric SLE (NPSLE) patients with 
or without WHM and presents the first TREX1 mutation identified in NPSLE. The NPSLE patient 
with the mutation R128H also had extensive WMH, and other clinical features such as Raynaud’s 
phenomenon, lupus nephritis class IV, and severe migraine-like headaches. The mutation affects 
an arginine residue that is of extreme importance for the exonuclease activity of the TREX1 
protein. Our findings suggest a role for TREX1 in SLE with brain involvement.
Chapter 6 describes genome-wide association studies (GWAS) in common migraine. Common 
migraine can be subdivided in migraine with aura (MA) and migraine without aura (MO). Chapter 
6.1 describes the first clinic-based GWAS in a large cohort of 2,748 clinic-based MA patients. 
The most significantly associated SNP (rs1835740, P=5.12x10-9) is located on chromosome 8 and 
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was replicated in several independent MA and MO cohorts containing in total 3,202 migraine 
cases. The SNP is located between the astrocyte elevated gene 1 (MTDH/AEG-1) and the plasma 
glutamate carboxypeptidase (PGCP) gene. An eQTL analysis showed that the minor allele of SNP 
rs1835740 is associated with increased MTDG/AEG-1 expression levels, which pinpoints glutamate 
as a key molecule in migraine pathophysiology. In Chapter 6.2 the genetics of common migraine 
was investigated in the genetically isolated Erasmus Rucphen Family (ERF) population. Genetic 
studies in isolated populations are expected to benefit from the more homogeneous genetic 
and clinical background. None of the SNPs in the GWAS reached the threshold of genome-wide 
significance, but several SNPs showed (highly) suggestive associations. Subsequently, the GWA 
data of the ERF population was included in a large meta-analysis including multiple population-
based cohorts of the Dutch Icelandic (DICE) consortium, which revealed an interesting association 
for SNP rs9908234 (P=8.0x10-8) in the nerve growth factor receptor (NGFR) gene and migraine.
A different approach to identify migraine pathways and genes is to study gene expression 
changes in migraine knock-in mouse models that harbor pathogenic FHM1 mutations. These 
migraine mouse models were recently generated in our lab, and also highlight the importance 
of the cortical neurotransmitter glutatmate in migraine pathophysiology. Whereas FHM1 R192Q 
is associated with “pure” FHM, without additional symptoms, FHM1 S218L mutation leads to 
a particularly severe phenotype of FHM, cerebellar ataxia, seizures and delayed brain edema, 
resulting sometimes in fatal coma, after a mild head trauma. Studies revealed that the difference 
in severity of phenotype seen in patients can also be observed in the respective knock-in mice. 
Chapter 7 describes a study that investigated the gene expression profiles of these migraine mice 
in cortical and cerebellar tissue in an attempt to identify novel migraine pathways. Although 
neurotransmitter-related pathways were differentially expressed, the transcriptome in mutant 
mice was remarkably unchanged. Unlike in the cortex, a specific gene expression signature was 
identified in cerebellar tissue that highlighted molecular pathways underlying the cerebellar 
ataxia in S218L mice, and possibly patients with the same mutation. 
Chapter 8 provides a general discussion of the data from Chapter 2 to 7. The importance of 
the genetic factors and variants were identified in various migraine types and their relation 
to migraine pathways is discussed, as well as the information on migraine pathways that was 
obtained from the expression study. Ideas for future studies on migraine genetics, combining 
alternative phenotyping methods with genome-wide association studies are discussed. They may 
be a more successful strategy towards finding genetic factors for the common forms of migraine 




Het onderzoek beschreven in dit proefschrift heeft als doel het identificeren en karakteriseren 
van nieuwe migraine mutaties en biologische mechanismen. Verschillende FHM en niet-FHM 
genen zijn bestudeerd in patiënten met monogene familiaire hemiplegische migraine en in 
andere monogene aandoeningen waarbij migraine aanwezig kan zijn. De functionele gevolgen 
van deze mutaties en de klinische fenotypes geassocieerd met deze mutaties zijn onderzocht. 
De veel voorkomende vormen van migraine, welke een complex genetisch achtergrond hebben, 
zijn bestudeerd in een genoom-wijde associatie studie in een geïsoleerde populatie en ook in een 
meta-analyse studie. Verder zijn FHM1 muizen gebruikt om onderzoek te doen naar expressie 
profielen in hersenweefsels welke relevant zijn voor het initiëren van een corticale golf van 
neuronale depolarisatie – het onderliggende substraat van de migraine aura – (de occipitale 
cortex) en cerebellaire ataxie (het cerebellum). Deze studies zullen ons zullen ons inzicht in de 
moleculaire pathofysiologie van migraine vergroten.
Hoofdstuk 2 beschrijft drie nieuwe mutaties in FHM genen. In hoofdstuk 2.1, een nieuwe 
V1696F mutatie was beschreven in het FHM1 CACNA1A gen in twee monozygote tweeling broers 
met klinische symptomen welke opverlappend zijn met zowel FHM als alternerende hemiplegie op 
de kinderleeftijd (AHC). Hier laten we voor het eerst zien dat een mutatie in het CACNA1A gen kan 
leiden tot atypische AHC. In voorgaand onderzoek werd slechts een ATP1A2 mutatie geïdentificeerd 
in een familie met atypische AHC. In hoofdstuk 2.2 wordt een FHM2 ATP1A2 mutatie beschreven 
welke hemiplegische migraine geassocieerd met koorts convulsies veroorzaakt. Deze familie laat 
de verbreding van het klinische spectrum van FHM2 mutaties zien. In hoofdstuk 2.3 werd een 
mutatie scan in het SCN1A (FHM3) gen uitgevoerd in tien FHM families welke negatief waren 
voor mutaties in FHM1 en FHM2. Een nieuwe L1649Q mutatie werd geïdentificeerd in een grote 
FHM familie van Noord Amerikaanse afkomst. Hoewel elektrophysiologische studies lieten zien 
dat de L1649Q mutatie leidt tot verhoogde functie van het natrium kanaal wanneer de mutatie 
werd ingebracht in SCN5A cDNA, heeft recent parallel elektrophysiologisch onderzoek laten zien 
dat waarschijnlijk een verlies-van-functie effect aanwezig is waneer de mutatie in de juiste 
SCN1A achtergrond wordt ingebracht. Deze studie bevestigd de rol van neuronale NaV1.1 natrium 
kanalen in FHM.
In hoofdstuk 3 werd een systematische analyse uitgevoerd met als doel het onderzoeken van de 
mogelijke betrokkenheid van de FHM genen in een grote set sporadische hemiplegische migraine 
(SHM) patiënten. In zes van deze 39 goed gekarakteriseerde SHM patiënten, zonder bijkomende 
neurologische symptomen, werd een ziekte veroorzakende mutatie gevonden. Een SHM patiënt 
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had een CACNA1A mutatie en vijf patiënten hadden ATP1A2 mutaties. Een mogelijke SCN1A 
mutatie in een zevende patiënt bleek een polymorfisme te zijn. Functionele studies werden 
uitgevoerd voor alle sequentie varianten en alle zes mutaties lieten functionele consequenties 
zien. Onze bevindingen laten zien dat de bekende FHM genen een rol spelen in ongeveer 14% van 
de SHM patienten, maar dat andere genetische en niet-genetische factoren ook een rol moeten 
spelen. In de klinische praktijk zal het screenen van het ATP1A2 gen de meeste kans op succes 
bieden in patienten met ‘pure’ SHM, zonder bijkomende neurologische symptomen.
De excitatiore aminozuur transporter EAAT1, welke gecodeerd wordt door het SLC1A3 gene, 
bevindt zich in een zelfde FHM mechanisme en heeft een effect op de glutamaat concentratie 
in de synaptische spleet. Een EAAT1 mutatie was eerder beschreven in een patient met ernstige 
episodische en progressieve ataxie, convulsies, alternerende hemiplegie, en migraineuse hoofdpijn. 
Voor hoofdstuk 4 een mutatie scan van het SLC1A3 gen was uitgevoerd in 20 patiënten met 
episodische ataxie (EA) welke negatief waren voor mutaties in het CACNA1A gen. Een nieuwe 
missense C186S mutatie welke segregeert met EA in drie familieleden was geïdentificeerd. 
Functionele analyses lieten een geringe, maar significante, vermindering van glutamaat opname 
in COS7 cellen zien voor het mutante EAAT1. Onze studie laat het eerste bewijs zien dat SLC1A3 
mutaties EA zonder convulsies of alternerende hemiplegie kunnen veroorzaken. Ook laat deze 
studie zien dat de ernst van de klinische symptomen geassocieerd met EAAT1 mutaties lijkt te 
correleren met de ernst van de glutamaat transporter disfunctie.
Hoofdstuk 5 beschrijft genetische en functionele studies voor het TREX1 gen, een belangrijke 
3’-5’ exonuclease. In hoofdstuk 5.1, het TREX1 gen is beschreven als het ziekteveroorzakende 
gen voor retinale vasculopatie met cerebrale leukodystrofie (RVCL). RVCL is een autosomaal 
dominante aandoening welke gekenmerkt wordt door progressieve blindheid als gevolg van 
vasculaire retinopatie welke geassocieerd kan zijn met een wijde range aan klinische symptomen, 
inclusief migraine. Negen RVCL families werden beschreven, allemaal met een frameshift mutatie 
leidend tot een vervroegd einde van het TREX1 eiwit, waardoor het C-terminale gedeelte van het 
TREX1 eiwit ontbreekt. Functionele studies lieten zien deze verkorte eitwitten hun exonuclease 
activiteit behielden, maar een abnormale rondom de kern gelegen lokalisatie hadden. TREX1 
mutaties zijn ook gevonden in andere vasculaire en immuun-gerelateerde aandoeningen, zoals 
het Aicardi-Goutieres syndroom (AGS) of systemische lupus erythematosis (SLE). Hoofdstuk 5.2 
beschrijft 60 neuropsychiatrische SLE (NPSLE) patiënten met en zonder witte stof afwijkingen 
en presenteert de eerste TREX1 mutatie in een patiënt met NPSLE. De NPSLE patiënt met mutatie 
R128H heeft extensieve witte stof afwijkingen en andere klinische symptomen, zoals Raynaud’s 
fenomeen, lupus nephritis klasse IV, en ernstige op migraine-lijkende hoofdpijnen. De mutatie 
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veranderd een Arginine welke extreem belangrijk is voor de exonuclease activiteit van het TREX1 
eiwit. Onze bevindingen doen een rol vermoeden voor TREX1 in cerebrale SLE.
Hoofdstuk 6 beschrijft genoom-wijde associatie studies (GWAS) in de frequente vormen van 
migraine. De frequente vormen van migraine kunnen worden onderverdeeld in met aura (MA) en 
migraine zonder aura (MO). Hoofdstuke 6.1 beschrijft de eerste GWAS in een groot cohort van 
2,748 MA patiënten die verzameld zijn via hoofdpijn klinieken. De meest significant geassocieerde 
SNP (rs1835740, P=5.12x10-9) bevindt zich op chromosoom 8 en kon gerepliceerd worden in 
verschillende onafhankelijke MA en MO cohorten welke in totaal 3,202 migraine patiënten 
bevatten. Deze SNP bevindt zicht tussen het astrocyt verhoogde gen 1 (MTDH/AEG-1) gen and het 
plasma glutamaat carboxypeptidase (PGCP) gen. Een kwantitatieve expressie (eQTL) studie kon 
laten zien dat het zeldzame allel van deze SNP associeert met verhoogde MTDG/AEG-1 expressie 
niveaus. Dit identificeert glutamaat als essentieel molecuul in migraine pathofysiologie.
In hoofdstuk 6.2 wordt de genetica van de frequente vormen van migraine onderzocht in 
de genetisch geïsoleerde Erasmus Rucphen Family (ERF) populatie. Naar verwachting heeft de 
meer homogene genetische en klinische achtergrond van deze populatie een positief effect op 
genetische studies voor migraine. Geen van de SNPs uit de GWA studie haalde de drempel van 
genoom-wijde significantie, maar verschillende SNPs lieten wel (hoog) suggestieve associaties 
zien. Vervolgens, werd de GWA data van de ERF populatie toegevoegd aan een grote meta-
analyse welke verschillende via de populatie geselecteerde migraine cohorten van het Nederlands 
IJslandse (DICE) consortium bevatte. Deze studie leidde tot een interessante associatie voor SNP 
rs9908234 (P=8.0x10-8) in het zenuw groeifactor receptor (NGFR) gen met migraine.
Een andere benadering voor het identificeren van migraine mechanismen en genen is het 
bestuderen van gen expressie veranderingen in transgene migraine muizen. Deze muismodellen 
voor migraine zijn recent gegenereerd in ons lab, en benadrukken de functie van de corticale 
neurotransmitter glutamaat in de pathofysiologie van migraine. Hoewel FHM R192Q geassocieerd 
is met ‘pure’ FHM, zonder bijkomende symptomen, leidt FHM1 S218L mutatie tot een bijzonder 
ernstig FHM fenotype met cerebellaire ataxie, convulsies, en hersen oedeem, welke soms zelfs 
tot fatale coma kan leiden na een mild hoofdtrauma. Studies hebben aangetoond dat het verschil 
in ernst van het fenotype gezien in patiënten overeenkomt met respectievelijke transgene 
muizen. Hoofdstuk 7 beschrijft een studie die de gen expressie profielen van deze migraine 
muizen bestudeerd met als doel het identificeren van nieuwe migraine mechanismen. Hoewel 
neurotransmitter-gerelateerde systemen differentieel tot expressie kwamen, is het transcriptoom 
van de mutante muizen opvallend gelijk aan dat van niet-mutante muizen. Voor het cerebellaire 
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weefsel was een specifieke signatuur geïdentificeerd welke moleculaire mechanismen liet zien 
specifiek voor cerebellaire ataxie in de S218L muis, en waarschijnlijk ook voor patiënten met 
deze mutatie.
Hoofdstuk 8 geeft de algemene discussie over de data van hoofdstuk 2 tot en met 7 weer. 
Het belang van de genetische factoren en varianten die geïdentificeerd zijn in de verschillende 
migraine typen en de relatie tot migraine mechanismen is besproken, evenals de informatie 
over migraine mechanismen die verkregen was uit de expressie studie. Ideeen voor toekomstige 
migraine genetica studies, waarin alternatieve fenotyperings methoden in combinatie met 
genoom-wijde associatie studies worden ook besproken. Deze studies zijn mogelijk succesvolle 
strategieën voor het vinden van genetische factoren voor de meer voorkomende vormen van 




AHC  alternating hemiplegie of childhood
AGS Aicardi-Goutiere syndrome
ATP adenosine tri-phosphate
cDNA copy deoxyribonucleic acid
CMH Cochran-Mantel-Haenszel
CNS central nervous system
CSD cortical spreading depression
CVR cerebroretinal vasculopathy
DNA deoxyribonucleic acid
EAAT1 excitatory amino acid transporter
EA episodic ataxia
eQTL expression quantitative trait locus
ERF Erasmus Rucphen Family (study)
FHM familial hemiplegic migraine
FP fluorescent protein
GEFS+  generalised epilepsy with febrile seizures
GWAS genome-wide association study 
HERNS  hereditary endotheliopathy, retinopathy, nepropathy and stroke
HVR hereditary vascular retinopathy
IHS international headache society
KI knock-in
LCA latent class analysis
LCL lymphoblastoid cell lines
LD linkage disequilibrium
LOD logarithm of odds
MAF minor allele frequency
MO migraine without aura
MA migraine with aura
MRI magnetic resonance imaging
NPSLE  neuro psychiatric systemic lupus erythematosus
OR odds ratio
PCR polymerase chain reaction
qPCR  quantitative polymerase chain reaction
RNA ribonucleic acid
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RVCL  retinal vasculopathy with cerebral leukodystrophy
SHM sporadic hemiplegic migraine
SLE systemic lupus erythematosus
SNP single nucleotide polymorphism
SMEI severe myoclonic epilepsy of infancy
TCA trait component analysis
TGVS trigeminovascular system
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